CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
NOVEL OXAZOLIDINONE DERIVATIVES AND PROCESS FOR THE
PREPARATION THEREOF
TECHNICAL FIELD
The present invention relates to novel o~azolidinone
derivatives of formula 1 with antibacterial activity, their
pharmaceutically acceptable salts, and pharmaceutical
compositions comprising the same. Also, the present invention
is concerned with a method for the preparation thereof.
Formula 1
O,,
- O
R2 ~ ~ N~IVHAc
R
1
BACKGROUND OF THE INVENTION
Used as orally administrable antibacterial . agents,
oxazolidinone compounds are not products of fermentation, but
artificially synthesized ones, and various structures of
their derivatives are known. For instance, 3-phenyl-2-
oxazolidinone derivatives having one or two substituents are
stated in US Pat. Nos. 4,948,801, 4,461,773, 4,340,606,
4,476,136, 4,250,318 and 4,128,654. 3-
((Monosubstituted)phenyl]-2-oxazolidinone derivatives of
1
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
formula 2 are disclosed in EP 0312000, J. Med. Chem. 32,
1673(1989), and J. Med. Chem. 33, 2569 (1990), Tetrahedron,
45, 123(1989).
Formula 2
\ - ~O
/ N~/~.NHAc
Pharmcia & Upjohn developed oxazolidinone derivatives
of formula 3 and 4 (WO 93/23384, WO 95/14684 and WO
95/07271). Having succeeded in gaining the approval of the
FDA (Food and Drug Administration) of U. S. A., the
oxazolidinone derivatives of formula 3 are going to come into
the market. However, these conventional synthetic
oxazolidinone compounds was found to suffer from the
disadvantage of showing antibacterial activity against a
narrow spectrum of bacteria, being toxic to humans, and being
poor in therapeutic activity in vivo.
Formula 3
0
/'~ /
O~j ~ ~ N~NHAc
'' ~F
Formula 4
2
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
O
O ~ ~0
NO~N~-/ ~ ~ N~NHAc
F
WO 93/09103 discloses oxazolidinone. derivatives of
formula l, substituted with heterocyclics such as thiazole,
indole, oxazole, and quinole as well as pyridine, at position
4 of the phenyl ring. However, these oxazolidinone
derivatives do not provide sufficient medicinal effects
because the heterocyclics bear simple substituents such as
alkyl or amino groups.
SUMMARY OF THE INVENTION
Leading to the present invention, the intensive and
thorough research on oxazolidinone derivatives, conducted by
the present inventors aiming to overcome the above problems
encountered in prior arts, resulted in the finding that
oxazolidinone derivatives substituted with pyridine or
pyrimidine derivatives at the 4 position of the phenyl ring
have potent antibacterial activity against a broad spectrum
of bacteria and their antibacterial activity is maintained
high in vivo.
Therefore, it is an object of the present invention to
provide oxazolidinone derivatives of formula l,.which potent
3
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
in inhibitory activity against a broad spectrum of bacteria,
and pharmaceutically acceptable salts thereof.
It is another object of the present invention to
provide a process for preparing such an oxazolidinone
derivative of formula 1, or its pharmaceutically acceptable
salt.
It is a further object of the present invention to
provide a pharmaceutical composition comprising such an
oxazolidinone derivative of formula 1, or its
pharmaceutically acceptable salt as a therapeutically
effective ingredient.
DETAILED DESCRIPTION OF THE INVENTION
In accordance with an aspect of the present invention,
there is provided an oxazolidinone derivative of formula 1:
Formula 1
O~O
R2 ~ ~ N~NHAc
R~
1
Wherein,
R1 is H, F, Cl or CF3;
4
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
~4
R2 is t~ or N ,
where R3 is
1) H,
2) C1-C4 alkoxy, or piperazinyl optionally substituted
with R5,
where RS is:
(a) H;
(b) Triphenylmethyl;
(c) substituted. or unsubstituted acetyl, provided
that the substituted acetyl is selected from
the group consisting of benzyloxyacetyl,
acetoxyacetyl, hydroxy acetyl, C1-C3
alkylaminoacetoxyacetyl,. acetyl substituted
with halogen, morpholi-4-nylaCetyl, imidazol-
l-ylcarbonyloxy acetyl, C1-C3
alkoxycarbonylmethylaminoacetyl, C1-C3
alkoxyacetyl, t-butyl acetyl, phenyl acetyl
optionally substituted with C1-C3 alkoxy, and
C1-C3 alkoxyoxoacetyl;
(d) substituted or unsubstituted benzoyl,
provided that the substituted benzoyl is
selected from the group consisting of C1-C4
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
selected from the group consisting of Cl-C4
alkoxybenzoyl, trihalomethylbenzoyl and
nitrobenzoyl;
(e) substituted or unsubstituted carbonyl,
provided that the substituted carbonyl is
selected from the group consisting of C1-C4
haloalkylcarbonyl, phenoxycarbony, and
benzyloxycarbonyl;
( f ) C1-C3 alkoxyphenyl of ;
(g) acryloyl optionally substituted with Cz - C3
alkyl;
(h) nicotinoyl;
(i) pivaloyl;
(j) crotonyl, or
( k ) n-valeryl ,
R4 is : H; azido; - ( C=O ) 1-R6; -NR~RB; - ( CHI )m-R9; or -ORlo.
wherein R6 is: H; C1-C3 alkoxy; amino; C1-C3
alkylamino; or C1-C3 hydroxyalkylamino,
l is an integer of 1 or 2,
R~ and R8, which may be the same or different,
represent,
(a) H;
6
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
(b) Cz-C4 alkyl optionally substituted with one
or more phenyl groups, or C1-C4 alkenyl
substituted with C1-C3 alkylamino;
(c) substituted or unsubstituted acetyl, provided
that the substituted acetyl is selected from
the group consisting of acetoxyacetyl,
hydroxyacetyl, C1-C3 alkylaminoacetoxyacetyl,
C1-C3 alkoxyacetyl, aminoacetyl, azidoacetyl,
acetylaminoacetyl, C1-C3 alkylaminoacetyl,
aminopropionyl, and hydroxylpropionyl; or
(d) nicotinoyl,
Rg is: H; azido; hydroxy; C1-C3
alkylaminoacetoxy; acetylthio, mercapto,
cyano, a halogen atom, or a 5- or 6-membered
heterocycle,
m is an integer of 1-4,
Rlo is: H; C1-C3 alkyl; acetyl; alkoxyalkyl;
methanesulfonyl; or Heterocylic rings
selected from the group consisting of .
a) 5- or 6-membered heteroring containing
one or more N or O, as ring members,
preferably represented by the following
formula:
7
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
R~ 2 .
R~2 ~~~ "~.i'~~'-'~R'12 ~r'''\,--~/R~1
_~ ~.vN ~--wN °~,s
~--N Rii, Ro , R» , Or Ri2,
b) a 5-membered heterocyclic ring containing
at least one nitrogen or oxygen atom or both
of them, as ring members, in which any one
carbon atom is saturated with two hydrogen
atoms or forms a double bond with oxygen.
(ketone), nitrogen (imino) or sulfur
(thioketone), preferably of the following
formula:
E E E
D~B D~B D~B
A--~ , A=/ , O r A
wherein A, B, and D, which may be the
same or different, each represents a
carbon, an oxygen or a nitrogen atom,
and E represents two hydrogen atoms,
an oxygen, a sulfur, or a nitrogen
atom, and more preferably of the
following formula:
8
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
0 II t~ SII
~''~N~N ~ N~N ~'N~N
~IJ~Rtt ~ ~ '~J~Rtt ~-' Rtt
Rt2 Rtt, Rtz , Rtz , Rt2 ,
~~'''N~_R,z ~J''N\~/N ~N\~/N ..
'~R,t , Rt~Rtz, Or Rt~Rtz . .
c) 5- or 6-membered hetero aromatic ring
containing C, N, 0 or S as ring members and
preferably one or two N or O, or at least
one nitrogen and at least one oxygen atom
together, as ring members of the following
formula:
R11 12 Rt1 Rtt O
~N,~ ~ ~ ~ ,~~~0.
R R ~~~ ~
J ~L hj
~ ~ R
~ ~
12 ~ -I- I_
77 11
N
N~
~
N , N R12 , R1iR12)
, R12 , RtE,
"r~~~0. ~~.r~'~ 0.~R11 ~R12)~S ~N
R12\ 'S\N ' \\
\
N (N-N) X11 ~R N
~NJ~R11 ~R72) u~~ R
11 ~
12)
, , ~ ,
Rn~R,z)
~~''"\Sw ,:~'~~S. R11~R12) ~S~R11 N N
N R12~Q ~
~ '~
~ ~
,~ _ L _N ,~
~ I
G /~ /,,
~
R11 ~R12) , N-N , Ri 1 N R1 z
~ ,
'N
~
-R"~R,z)
~
, Or N=N
wherein R11 the
and R1~, which same
are or
different, eachrepresents:
(i) H, F, C1, r or I;
B
9
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
(ii) C1-C4 alkyl substituted optionally with at
least one substituent, provided that the
substituted alkyl is selected from the group
consisting of hydroxyalkyl,
alkoxycarbonylalkyl, trihaloalkyl,
acetoxyalkyl, alkylaminoalkyl, alkoxyalkyl,
and methanesulfonyloxyalkyl;
(iii) substituted or unsubstituted acetyl,
provided that the substituted acetyl is
selected from the group consisting of
acetoxyacetyl, hydroxyacetyl, C1-C3 alkylamino
acetoxyacetyl, C1-C3 alkoxyacetyl,
aminoacetyl, azidoacetyl, acetylaminoacetyl,
C1-C3 alkylaminoacetyl, aminopropionyl, and
hydroxypropionyl;
(iv) azido, hydroxy, mercapto, cyano, ketone, or
amino;
(v) substituted or unsubstituted imino, provided
that the substituted imino is selected from
the group consisting of hydroxyimino,
alkylimino, alkoxyimino or
methanesulfonyloxyimino;
l0
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
(vi) hydrozino optionally substituted with
alkoxycarbonyl;
(vii) -OR13, where R13 is H, C1-C3 alkyl, acetyl,
alkoxyalkyl, hydroxyacetyl or
methanesulfonyl;
(viii) -NRl4Ris. wherein R14 and R15 represent
independently H, C1-C3 alkyl, acetyl,
alkoxylalkyl, hydroxyacetyl or
methansulfonyl;
(1x) -(C=O)-(Rl6jnW
wherein R16 is
1j C1-C6 alkyl, or alkenyl optionally
substituted with C1-C3 alkyl;
2) alkoxycarbonyl;
3) acetoxymethyl, benzyloxymethyl,.
hydroxymethyl, C1-C3 alkylacetoxymethyl,
halomethyl, C1-C3 alkoxymethyl,
morpholinylmethyl, Ci-C3
alkoxycarbonylmethyl aminomethyl, C1-C3.
methanesulfonyloxymethyl, alkoxyoxomethyl,
CI-Cs nicotinoyloxymethyl,
alkoxyphenylmethyl, benzyl, or
trihalomethyl;
11
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
4) Cl-C3 alkoxy, phenyloxy, allyloxy, Cl-C3
haloalkyloxy, benzyloxy optionally
substituted with nitoro, or 9-
fluorenylmethyloxy;
5) Nicotinoylmethyl; or
6) a 5- or 6-membered heterocyclic ring
Preferable, concrete examples of the compounds of
formula 1 include:
1) (S)-[N-3-(4-pyrimidin-5-yl)-3-fluorophenyl]-2-oxo-5-
oxazolidinyl]methyl acetamide (compound of Example 1)
2) (S)-[N-3-(4-(2-methoxypyrimidin-5-yl)-3-fluorophenyl)-
2-oxo-5-oxazolidinyl]methyl acetamide (compound of
Example 2)
3) (S)-[N-3-(4-(2-aminopyrimidin-5-yl)-3-fluorophenyl)-2-
oxo-5-oxazolidinyl]methyl acetamide (compound of
Example 3)
4) (S)-[N-3-(4-(2-(4-triphenylmethylpiperazin-1-yl)
pyrimidin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]
methyl acetamide (compound of Example 4)
5) (S)-[N-3-(4-(2-piperazin-1-ylpyrimidin-5-yl)-3-
fluorophenyl)-2-oxo-5-oxazolidinyl]methyl acetamide
(compound of Example 5)
12
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
6) (S)-[N-3-(4-(2-(4-acetylpiperazin-1-yl)pyrimidin-5-yl)
-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl acetamide
(compound of Example 6)
7) (S)-[N-3-(4-(2-(4-benzyloxyacetylpiperazin-1-yl)
pyrimidin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]
methyl acetamide (compound of Example 7)
8) (S)-[N-3-(4-(2-(4-acetoxyacetylpiperazin-1-yl)
pyrimidin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]
methyl acetamide (compound of Example 8)
9) (S)-[N-3-(4-(2-(4-hydroxyacetylpiperazin-1-yl)
pyrimidin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]
methyl acetamide (compound of Example 9)
10) (S)-[N-3-(4-(2-(4-dimethylaminoacetoxyacetylpiperazin-
1- yl)pyrimidin-5-yl)-3-fluorophenyl)-2-oxo-5-
oxazolidinyl]methyl acetamide (compound of Example 10)
11) (S)-[N-3-(4-(2-(4-bromoacetylpiperazin-1-yl)pyrimidin-
5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetamide (compound of Example 11)
12) (S)-[N-3-(4-(2-(4-morpholin-4-ylacetylpiperazin-1-yl)
pyrimidin-5-yl)-3-fluorophenyl)-2-oxo-5-
oxazolidinyl]methyl acetamide (compound of Example 12)
13
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
13) (S)-[N-3-(4-(2-(4-imidazol-1-ylcarbonyloxyacetyl
piperazin-1-yl)pyrimidin-5-yl)-3-fluorophenyl)-2-oxo-5-
oxazolidinyl]methyl acetamide (compound of Example 13)
14) (S)-[N-3-(4-(2-(4-chloroacetylpiperazin-1-yl)
pyrimidin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]
methyl acetamide (compound of Example 14)
15) (S)-[N-3-(4-(2-(4-methoxycarbonylmethylaminoacetyl
piperazin-1-yl)pyrimidin-5-yl)-3-fluorophenyl)-2-oxo-5-
oxazolidiyl]methyl acetamide (compound of Example 15)
16) (S)-[N-3-(4-(2-(4-(4-methoxyphenylpiperazin-4-yl)
acetylpiperazin-1-yl)pyrimidin-5-yl)-3-fluorophenyl)-2-
oxo-5-oxazolidinyl]methyl acetamide (compound of
Example 16)
17) (S)-[N-3-(4-(2-(4-methoxyacetylpiperazin-1-yl)
pyrimidin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]
methyl acetamide (compound of Example 17)
18) (S)-[N-3-(4-(2-(4-acryloylpiperazin-1-yl)pyrimidin-5-
yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetamide (compound of Example 18)
19) (S)-[N-3-(4-(2-(4-ethoxyoxoacetylpiperazin-1-yl)
pyrimidin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]
methyl acetamide (compound of Example 19)
20) _ (S)-[N-3-(4-(2-(4-nicotinoylpiperazin-1-yl)pyrimidin-
14
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetamide (compound of Example 20)
2l) (S)-[N-3-(4-(2-(4-pivaloylpiperazin-1-yl)pyrimidin-5-
yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetamide (compound of Example 21)
22) (S)-[N-3-(4-(2-(4-t-butylacetylpiperazin-1-yl)
pyrimidin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]
methyl acetamide (compound of Example 22).
23) (S)-[N-3-(4-(2-(4-(2,5-dimethoxyphenyl)acetylpipera
tine-1-yl)pyrimidin-5-yl)-3-fluorophenyl)-2-oxo-5-
oxazolidinyl]methyl acetamide (compound of Example 23)
24) (S)-[N-3-(4-(2-(4-(3,3-dimethylacryloyl)piperazin-1-
yl)pyrimidin-5-yl)-3-fluorophenyl)-2-oxo-5-
oxazolidinyl]methyl acetamide (compound of Example 24)
25) (S)-[N-3-(4-(2-(4-(2,6-dimethoxybenzoyl)pipe.razin-1-
yl)pyrimidin-5-yl)-3-fluorophenyl)-2-oxo-5-
oxazolidinyl]methyl acetamide (compound of Example 25)
26) (S)-[N-3-(4-(2-(4-(2-trifluoromethylbenzoyl)piperazin-
1-y1)pyrimidin-5-yl)-3-fluorophenyl)-2-oxo-5-
oxazolidinyl]methyl acetamide (compound of Example 26)
27) (S)-[N-3-(4-(2-(4-(4-trifluoromethylbenzoyl) ~piperazin-
1-yl)pyrimidin-5-yl)-3-fluorophenyl)-2-oxo-5-
oxazolidinyl]methyl acetamide (compound of Example 27)
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
28) (S)-[N-3-(4-(2-(4-phenylacetylpiperazin-1-yl)pyrimidin
-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetamide (compound of Example 28)
29) (S)-[N-3-(4-(2-(4-(3,5-dinitrobenzoyl)piperazin-1-yl)
pyrimidin-5-yl)-3-fluorophenyl)-2-oxo-5-
oxazolidinyl]methyl acetamide (compound of Example 29)
30) (S)-[N-3-(4-(2-(4-crotonylpiperazin-1-yl)pyrimidin-5-
yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetamide (compound of Example 30)
31) (S)-[N-3-(4-(2-(4-trichloroacetylpiperazin-1-y1)pyri
midin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]
methyl acetamide (compound of Example 31)
32) (S)-[N-3-(4-(2-(4-n-valerylpiperazin-1-yl)pyrimidin-5-
yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetamide (compound of Example 32)
33) (S)-[N-3-(4-(2-(4-(1-bromoethylcarbonyl)piperazin-1-
yl)pyrimidin-5-yl)-3-fluorophenyl)-2-oxo-5-
oxazolidinyl]methyl acetamide (compound of Example 33)
34) (S)-[N-3-(4-(2-(4-phenoxycarbonylpiperazin-1-yl)pyri
midin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]
methyl acetamide (compound of Example 34)
16
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
35) (S)-[N-3-(4-(2-(4-benzyloxycarbonylpiperazin-1-yl)
pyrimidin-5-yl)-3-fluorophenyl)-2-oxo-5-
oxazolidinyl]methyl acetamide (compound of Example 35)
36) (S)-[N-3-(4-pyridin-2-yl)-3-fluorophenyl]-2-oxo-5-oxa
zolidinyl]methyl acetamide (compound of Example 36)
37) (S)-[N-3-(4-(2-aminopyridin-5-yl)-3-fluorophenyl)-2-
oxo-5-oxazolidinyl]methyl acetamide (compound of
Example 37)
38) (S)-[N-3-(4-(3-methoxycarbonylpyridin-5-yl)-3-fluoro
phenyl)-2-oxo-5-oxazolidinyl]methyl acetamide
(compound of Example 38)
39) (S)-[N-3-(4-(2-acetylaminopyridin-5-yl)-3-fluorophen
yl)-2-oxo-5-oxazolidinyl]methyl acetamide (compound of
Example 39)
40) (S)-[N-3-(4-(2-acetoxyacetylaminopyridin-5-yl)-3-fluo
rophenyl)-2-oxo-5-oxazolidinyl]methyl acetamide
(compound of Example 40)
41) (S)-[N-3-(4-(2-hydroxyacetylaminopyridin-5-yl)-3-fluo
rophenyl)-2-oxo-5-oxazolidinyl]methyl acetamide
(compound of Example 41)
42) (S)-[N-3-(4-(2-imidazol-1-yl-pyridin-5-yl)-3-fluoro
phenyl)-2-oxo-5-oxazolidinyl]methyl acetamide
(compound of Example 42)
17
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
43) (S)-[N-3-(4-(2-morpholin-4-yl-pyridin-5-yl)-3-fluoro
phenyl)-2-oxo-5-oxazolidinyl]methyl acetamide
(compound of Example 43)
44) (S)-[N-3-(4-(2-triphenylmethylaminopyridin-5-yl)-3-flu
orophenyl)-2-oxo-5-oxazolidinyl]methyl acetamide
(compound of Example 44)
45) (S)-[N-3-(4-(2-methoxypyridin-5-yl)-3-fluorophenyl)-2-
oxo-5-oxazolidinyl]methyl acetamide (compound of
Example 45)
46) (S)-[N-3-(4-(2-methoxyacetylaminopyridin-5-yl)-3-fluo
rophenyl)-2-oxo-5-oxazolidinyl]methyl acetamide
(compound of Example 46)
47) (S)-[N-3-(4-(2-(4-triphenylmethylpiperazin-1-yl)pyr
idin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetamide (compound of Example 47)
48) (S)-[N-3-(4-(2-triphenylmethylaminopyridin-5-yl)-3-fl
uorophenyl)-2-oxo-5-oxazolidinyl]methyl acetamide
(compound of Example 48)
49) (S)-[N-3-(4-(2-azidopyridin-5-yl)-3-fluorophenyl)-2-
oxo-5-oxazolidinyl]methyl acetamide (compound of
Example 49)
18
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
50) (S)-[N-3-(4-(2-hydroxymethylpyridin-4-yl)-3-fluoro
phenyl)-2-oxo-5-oxazolidinyl]methyl acetamide (compound
of Example 50)
51) (S)-[N-3-(4-(2-methoxycarbonylpyridin-4-yl)-3-fluoro
phenyl)-2-oxo-5-oxazolidinyl]methyl acetamide (compound
of Example 51)
52) (S)-[N-3-(4-(2-dimethylaminocarbonylpyridin-4-yl)-3-
fluorophenyl)-2-oxo-5-oxazolidinyl]methyl acetamide
(compound of Example 52)
53) (S)-[N-3-(4-(2-hydroxypyridin-5-yl)-3-fluorophenyl)-2-
oxo-5-oxazolidinyl]methyl acetamide (compound of
Example 53)
54) (S)-[N-3-(4-(N-2-dimethylaminoacetoxyacetylamino
pyridin-4-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]
methyl acetamide (compound of Example 54)
55) (S)-[N-3-(4-(2-methylaminopyridin-4-yl)-3-fluoro.
phenyl)-2-oxo-5-oxazolidinyl]methyl acetamide
(compound of Example 55)
56) (S)-[N-3-(4-(2-dimethylaminopyridin-4-yl)-3-fluoro
phenyl)-2-oxo-5-oxazolidinyl]methyl acetamide
(compound of Example 56)
57) (S)-[N-3-(4-(2-hydroxyacetylaminopyridin-5-yl)-3-fluo
rophenyl)-2-oxo-5-oxazolidinyl]methyl acetamide
19
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
(compound of Example 57)
58) (S)-[N-3-(4-(2-hydroxyacetylaminopyridin-5-yl)-3-fluo
rophenyl)-2-oxo-5-oxazolidinyl]methyl acetamide hydroxy
propylmethyl cellulose (HPMC,
hydroxypropylmethylcellulose) (compound of Example 58)
59) (S)-[N-3-(4-(2-acetoxypyridin-5-yl)-3-fluorophenyl)-2-
oxo-5-oxazolidinyl]methyl acetamide (compound of
Example 59)
60) (S)-[N-3-(4-(2-methoxymethyloxypyridin-5-yl)-3-fluoro
phenyl)-2-oxo-5-oxazolidinyl]methyl acetamide
(compound of Example 60)
61) (S)-[N-3-(4-(2-methanesulfonyloxypyridin-5-yl)-3-fluo
rophenyl)-2-oxo-5-oxazolidinyl]methyl acetamide
(compound of Example 61)
62) (S)-[N-3-(4-(2-aminocarbonylpyridin-4-yl)-3-fluoro
phenyl)-2-oxo-5-oxazolidinyl]methyl acetamide
(compound of Example 62)
63) (S)-[N-3-(4-(2-dimethylaminoacetoxymethylpyridin-4-yl)-
3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl acetamide
(compound of Example 63)
64) (S)-[N-3-(4-(2-(2-hydroxyethyl)aminocarbonylpyridin-4-
yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetamide (compound of Example 64)
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
65) (S)-[N-3-(4-(2-N,N-di(2-hydroxyethyl)aminocarbonyl.
pyridin-4-yl)-3-fluorophenyl)-2-oxo-5~oxazolidinyl]
methyl acetamide (compound of Example 65)
66) (S)-[N-3-(4-(2-piperazin-1-ylpyridin-5-yl)-3-fluoro
phenyl)-2-oxo-5-oxazolidinyl]methyl acetamide
(compound of Example 66)
67) (S)-[N-3-(4-(2-(4-acetoxyacetylpiperazin-1-yl)pyridin-
5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetamide (compound of Example 67)
68) (S)-[N-3-(4-(2-(4-benzyloxyacetylpiperazin-1-y1)pyri
din-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetamide (compound of Example 68)
69) (S)-[N-3-(4-(2-(4-hydroxyacetylpiperazin-1-yl)pyridin-
5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetamide (compound of Example 69)
70) (S)-[N-3-(4-(2-(4-dimethylaminoacetoxyacetylpiperazin-
1-yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-
oxazolidinyl]methyl acetamide (compound of Example 70)
71) (S)-[N-3-(4-(2-(4-chloroacetylpiperazin-1-yl)pyridin-5-
yl)-3-fluorophenyl)-2-oxo-5-oxasolidinyl]methyl
acetamide (compound of Example 71)
21
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
72) (S)-[N-3-(4-(2-(4-acetylpiperazin-1-yl)pyridin-5-yl)-3-
fluorophenyl)-2-oxo-5-oxazolidinyl]methyl acetamide
(compound of Example 72)
73) (S)-[N-3-(4-(2-(4-methoxyacetylpiperazin-1-yl)pyridin-
5-y1)-3-fluorophenyl)-2-oxo-5-oxazol.idinyl]methyl
acetamide (compound of Example 73)
74) (S)-[N-3-(4-(2-(4-morpholinylacetylpiperazin-1-yl)pyri
din-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetamide (compound of Example 74)
75) (S)-[N-3-(4-(2-(4-methoxycarbonylmethylaminoacetyl
piperazin-1-yl)pyridin-5-yl)-.3-fluorophenyl)-2-oxo-5-
oxazolidinyl]methyl acetamide (compound of Example 75)
76) (S)-[N-3-(4-(2-(4-ethoxycarbonylpi.peridin-1-yl)pyridin
-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetamide (compound of Example 76)
77) (S)-[N-3-(4-(2-azidomethylpyridin-4-yl)-3-fluoro
phenyl)-2-oxo-5-oxazolidinyl]methyl acetamide
(compound of Example 77)
78) (S)-[N-3-(4-(2-imidazol-1-yl)methylpyridin-4-yl)-3-flu
orophenyl]-2-oxo-5-oxazolidinyl]methyl acetamide
(compound of Example 78)
22
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
79) (S)-[N-3-(4-(2-morpholin-4-yl)methylpyridin-4-yl)-3-
fluorophenyl)-2-oxo-5-oxazolidinyl]methyl acetamide
(compound of Example 79)
80) (S)-[N-3-(4-(2-acetylthiomethylpyridin-4-yl)-3-fluoro
phenyl)-2-oxo-5-oxazolidihyl]methyl acetamide
(compound of Example 80)
81) (S)-[N-3-(4-(2-mercaptomethylpyridin-4-yl)-3-fluoro
phenyl)-2-oxo-5-oxazolidinyl]methyl acetamide
(compound of Example 81),
82) (S)-[N-3-(4-(2-(4-methanesulfonyloxyacetylpiperazin-1-
yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-
oxazolidinyl]methyl acetamide (compound of Example 82)
83) (S)-[N-3-(4-(2-(4-acryloylpiperazin-1-yl)pyridin-5-yl)-
3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl acetamide
(compound of Example 83)
84) (S)-[N-3-(4-(2-(4-ethoxyoxoacetylpiperazin-1-yl)pyri
din-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetamide (compound of Example 84)
85) (S)-[N-3-(4-(2-(4-nicotinoylpiperazin-1-y1)pyridin-5-
yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetamide (compound of Example 85)
23
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
86) (S)-[N-3-(4-(2-(4-pivaloylpiperazin-1-yl)pyridin-5-yl)
-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl acetamide
(compound of Example 86)
87) (S)-[N-3-(4-(2-(4-tetrabutylacetylpiperazin-Z-yl)pyri
din-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetamide (compound of Example 87)
88) (S)-[N-3-(4-(2-(4-nicotinoyloxyacetylpiperazin-1-yl)
pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]
methyl acetamide (compound of Example 88)
89) (S)-[N-3-(4-(2-(4-(2,5-dimethoxyphenylacetyl)piperazin
-1-yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-
oxazolidinyl]methyl acetamide (compound of Example 89)
90) (S)-[N-3-(4-(2-(4-(3,3-dimethylacryloyl)piperazin-2-
yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]
methyl acetamide (compound of Example 90)
91) (S)-[N-3-(4-(2-(4-(2,6-dimethoxybenzoyl)piperazin-1-
yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-
oxazolidinyl]methyl acetamide (compound of Example 91)
92) (S)-[N-3-(4-(2-(4-(2-trifluoromethyl)benzoyl)pipera
zin-1-yl)pyridin-5-yl)-3-fluorophenyl]-2-oxo-5-
oxazolidinyl]methyl acetamide (compound of Example 92)
24
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
93) (S)-[N-3-(4-(2-(4-(4-trifluoromethyl)benzoyl)piperazin
-1-yl)pyridin-5-yl)-3-fluorophenyl]-2-oxo-5-
oxazolidinyl]methyl acetamide (compound of Example 93)
94) (S)-[N-3-(4-(2-(4-benzylcarbonylpiperazin-1-yl)pyridin
-5-y1)-3-fluorophenyl)=2-oxo-5-oxazolidinyl]methyl
acetamide (compound of Example 94)
95) (S)-[N-3-(4-(2-(4-crotonylpiperazin-1-yl)pyridin-5-yl)
-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl acetamide
(compound of Example 95)
96) (S)-[N-3-(4-(2-(4-trifluoromethylcarbonylpiperazin-1-
yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-
oxazolidinyl]methyl acetamide (compound of Example 96)
97) (S)-[N-3-(4-(2-(4-n-valerylpiperazin-1-yl)pyridin-5-
yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetamide (compound of Example 97)
98) (S)=[N-3-(4-(2-(4-phenyloxycarbonylpiperazin-1-yl)pyri
din-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetamide (compound of Example 98)
99) (S)-[N-3-(4-(2-(4-allyloxycarbonylpiperazin-1-yl)
pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]
methyl acetamide (compound of Example 99)
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
100) (S)-[N-3-(4-(2-(4-(1-chloroethyl)oxycarbonylpiperazin-
1-yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-
oxazolidinyl]methyl acetamide (compound of Example 100)
101) (S)-[N-3-(4-(2-(4-(4-nitrobenzyl)oxycarbonylpiperazin-
1-yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-
oxazolidinyl]methyl acetamide (compound of Example 101)
102) (S)-[N-3-(4-(2-(4-benzyloxycarbonylpiperazin-1-yl)pyri
din-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetamide (compound of Example 102)
103) (S)-[N-3-(4-(2-(4-(9-fluorenylmethyloxycarbonyl)pipe
razin-1-yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-
oxazoldin yl]methyl acetamide (compound of Example 103)
104) (S)-[N-3-(4-(2-(4-(2-pyrimidinyl)piperazin-1-yl)pyrid
in-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetami de (compound of Example 104)
105) (S)-[N-3-(4-(2-(4-methoxycarbonylmethylpiperazin-1-
yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]
methyl acetamide (compound of Example 105)
106) (S)-[N-3-(4-(2-fluoromethylpyridin-4-yl)-3-fluoro
phenyl)-2-oxo-5-oxazolidinyl]methyl acetamide
(compound of Example 106)
26
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
1,07) (S)-[N-3-(4-(2-cyanomethylpyridin-4-yl)-3-fluorophen
yl)-2-oxo-5-oxazolidinyl]methyl acetamide (compound of
Example 107)
108) (S)-[N-3-(4-(2-methylpyridin-4-yl)-3-fluorophenyl)-2-
oxo-5-oxazolidinyl]methyl acetamide (compound of
Example 108)
109) (S)-[N-3-(4-(2-(4-(2-hydroxy)ethylpiperazin-1-yl)pyrid
in-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetamide (compound of Example 109)
110) (S)-[N-3-(4-(2-(4-(2-acetoxy)ethylpiperazin-1-yl)pyri
din-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetamide (compound of Example 110)
111) (S)-[N-3-(4-(2-(4-methoxycarbonylpiperazin-1-y1)pyrid
in-5-yl)-3-fluorophenyl)-2-oxo-5-oXazolidinyl]
methylacetamide(compound of Example 111)
112) (S)-[N-3-(4-(2-(4-(2-methanesulfonyloxy)ethyl
piperazin-1-yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-
oxazolidinyl]methyl acetamide (compound of Example 112)
113) (S)-[N-3-(4-(2-(4-hydroxymethyl)imidazol-1-yl)pyridin-
5-y1)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetamide (compound of Example 113)
114) (S)-[N-3-(4-(2-aminoacetylaminopyridin-5-yl)-3-fluoro
phenyl)-2-oxo-5-oxazolidinyl]methyl acetamide
27
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
(compound of Example 114)
115) (S)-[N-3-(4-(2-(4-cyanopiperazin-1-yl)pyridin-5-yl)-3-
fluorophenyl)-2-oxo-5-oxazolidinyl]methyl acetamide
(compound of Example 115)
116) (S)-[N-3-(4-(2-(4-carboxamideoximpiperazin-1-yl)pyri
din-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetamide (compound of Example 116)
117) (S)-[N-3-(4-(2-(4-oxopiperidin-1-yl)pyridin-5--yl)-3-
fluorophenyl)-2-oxo-5-oxazolidinyl]methyl acetamide
(compound of Example 117)
118) (S)-[N-3-(4-(2-azidoacetylaminopyridin-5-yl)-3-fluoro
phenyl)-2-oxo-5-oxazolidinyl]methyl acetamide
(compound of Example 118)
119) (S)-[N-3-(4-(2-(1,2,3,4,6,7-hexahydro-5-oxo-1,4-diaze
pan-1-yl)-pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-
oxazolidinyl]methyl acetamide (compound of Example 119)
120) (S)-[N-3-(4-(2-N-(dimethylaminomethylene) aminopyridin
-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetamide (compound of Example 120)
121) (S)-[N-3-(4-(2-(4-hydroxyiminopiperidin-1-yl)pyridin-5-
yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetamide (compound of Example 121)
28
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
122) (S)-[N-3-(4-(2-(4-methanesulfonyloxyiminopiperidin-1-
yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]
methyl acetamide (compound of Example 122)
123) (S)-[N-3-(4-(2-(4-methyliminopiperidin-1-yl)pyridin-5-
yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetamide (compound of Example 123)
124) (S)-[N-3-(4-(2-(4-methoxycarbonylhydrazino piperidin-1-
yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-
oxazolidinyl]methyl acetamide (compound of Example 124)
125) (S)-[N-3-(4-(2-N-(L-alanyl)aminopyridin-5-yl)-3-fluoro
phenyl)-2-oxo-5-oxazolidinyl]methyl acetamide
(compound of Example 125)
126) (S)-[N-3-(4-(2-acetylaminoacetylaminopyridin-5-yl)-3-
fluorophenyl)-2-oxo-5-oxazolidinyl]methyl acetamide
(compound of Example 126)
127) (S)-[N-3-(4-(2-dimethylaminoacetylaminopyridin-5-yl)-3-
fluorophenyl)-2-oxo-5-oxazolidinyl]methyl acetamide
(compound of Example 127)
128) (S)-[N-3-(4-(2-nicotinoylaminopyridin-5-yl)-3-fluoro
phenyl)-2-oxo-5-oxazolidinyl]methyl acetamide
(compound of Example 128)
29
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
129) (S)-[N-3-(4-(2-(1,2,4-triazol-1-yl)pyridin-5-yl)-3-
fluorophenyl)-2-oxo-5-oxazolidinyl]methyl acetamide
(compound of Example 129)
130) (S)-[N-3-(4-(2-(4-hydroxypiperidin-1-yl)pyridin-5-yl)-
3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl acetamide
(compound of Example 130)
131) (S)-[N-3-(4-(2-N,N-(hydroxyacetyl)methylaminopyridin-5-
yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetamide (compound of.Example 131)
132) (S)-[N-3-(4-(2-(4-methylimidazol-1-yl)pyridin-5-yl)-3-
fluorophenyl)-2-oxo-5-oxazolidinyl]methyl acetamide
(compound of Example 132)
133) (S)-[N-3-(4-(2-(2-hydroxypropionyl)aminopyridin-5-yl)-
3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl acetamide
(compound of Example 133)
134) (S)-[N-3-(4-(2-(3-amino-1,2,4-triazol-1-yl)pyridin-5-
yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl)methyl
acetamide (compound of Example 134)
135) (S)-[N-3-(4-(2-(4-ethoxycarbonylimidazol-1-yl)pyridin-
5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetamide (compound of Example 135)
136) (S)-(N-3-(4-(2-(1-tetrazolyl)-pyridin-5-yl)-3-fluoro
phenyl)-2-oxo-5-oxazolidinyl)methyl acetamide
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
(compound of Example 136)
137) (S)-[N-3-(4-(2-(5-methyl-(1,3,4)-oxadiazol-2-yl)-pyrid
in-5-yl)-3-fluorophenylj-2-oxo-5-oxazolidinyl]methyl
acetamide (compound of Example 137)
138) (S)-[N-3-(4-(2-(5-methyl-(1,2,4)-oxadiazol=3-yl)pyrid
in-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetamide (compound of Example 138)
139) (S)-[N-3-(4-(2-(1-methyl-5-tetrazolyl)-pyridin-5-yl)-3-
fluorophenyl)-2-oxo-5-oxazolidinyl]methyl acetamide
(compound of Example 139)
140) (S)-[N-3-(4-(2-(2-methyl-5-tetrazolyl)-pyridin-5-yl)-3-
fluorophenyl)-2-oxo-5-oxazolidinyl]methyl acetamide
(compound of Example 140)
141) (S)-[N-3-(4-(2-(4-ethoxycarbonyl-(1,2,3)-triazol-1-yl)
-5-pyridinyl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]
methyl acetamide (compound of Example 141)
142) (S)-[N-3-(4-(2-(3-pyrrolynyl)-5-pyridinyl)-3-fluoro
phenyl)-2-oxo-5-oxazolidinyl]methyl acetamide
(compound of Example 142)
143) (S)-[N-3-(4-(2-(2-oxo-(1,3)-oxazolidin-3-yl)-pyridin-5-
yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetamide (compound of Example 143)
31
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
144) (S)-[N-3-(4-(2-((1,3)-oxazol-5-y1)-pyridin-5-yl)-3-
fluorophenyl)-2-oxo-5-oxazolidinyl]methyl acetamide
(compound of Example 144)
145) (S)-[N-3-(4-(2-((1,2,4)-o~adiazol-3-yl)-pyridin-5-yl)-
3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl acetamide
(compound of Example 145)
146) (S)-[N-3-(4-(2-((1,2,3)-triazol-1-yl)-pyridin-5-yl)-3-
fluorophenyl)-2-oxo-5-oxazolidinyl]methyl acetamide
(compound of Example 146)
147) (S)-[N-3-(4-(2-(3-methyl-2-oxo-2,3-dihydro-(1,3,4)-tri
azol-1-yl)-5-pyridinyl)-3-fluorophenyl)-2-oxo-5-
oxazolidinyl]methyl acetamide (compound of Example 147)
148) (S)-[N-3-(4-(2-(2-oxo-(1,3)-imidazolidin-1-yl)-pyridin
-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetamide (compound of Example 148)
149) (S)-[N-3-(4-(2-(4-hydroxy-piperidin-1-yl)-5-pyridinyl)
-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl acetamide
(compound of Example 149)
150) (S)-[N-3-(4-(2-(2-oxo-(2,3)-dihydro-(1,3,4)-triazol-1-
yl)-5-pyridinyl)-3-fluorophenyl)-2-oxo-5-oxazol~idinyl]
methyl acetamide (compound of Example 150)
151) (S)-[N-3-(4-(2-(5-hydroxymethyl-(1,2,4)-oxadiazol-3-
yl)-5-pyridinyl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]
32
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
methyl acetamide (compound of Example 151)
152) (S)-[N-3-(4-(2-(5-tetrazolyl)-5-pyridinyl)-3-fluoro
phenyl)-2-oxo-5-oxazolidinyl]methyl acetamide
(compound of Example 152)
153) (S)-[N-3-(4-(2-(5-methoxymethyl-(1,2,4)-oxadiazol-3-
yl)-5-pyridinyl)-3-fluorophenyl)-2=oxo-5-oxazolidinyl]
methyl acetamide (compound of Example 153)
154) (S)-[N-3-(4-(2-(5-trichloromethyl-(1,2,4)-oxadiazol-3-
yl)-5-pyridinyl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]
methyl acetamide (compound of Example 154)
l55) (S)-[N-3-(4-(2-(5-dimethylamino-(1,2,4)-oxadiazol-3-
yl)-5-pyridinyl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]
methyl acetamide (compound of Example 155)
156) (S)-[N-3-(4-(2-(5-amino-(1,2,4)-oxadiazol-3-yl)-pyri
din-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetamide (compound of Example 156)
157) (S)-[N-3-(4-(2-(4-acetylamino-1-piperidinyl)-py~idin=5-
yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetamide (compound of Example 157)
158) (S)-[N-3-(4-(2-(4-acetyloxymethylcarbonylamino-piperid
in-1-yl)-pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-
oxazolidinyl]methyl acetamide (compound of Example 158)
33
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
159)' (S)-[N-3-(4-(2-(4-hydroxymethylcarbonylamino-piperidin
-1-yl)-pyridin-5-y1)-3-fluorophenyl)-2-oxo-5-
oxazolidinyl]methyl acetamide (compound of Example 159)
160) (S)-[N-3-(4-(2-(3,4-dihydroxy-pyrrolidin-1-yl)-pyridin
-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetamide (compound of Example 160).
More preferable examples of the compounds of formula 1
include;
1) (S)-[N-3-(4-(2-(1,2,4-triazol-1-yl)pyridin-5-yl)-3-flu
orophenyl)-2-oxo-5-oxazolidinyl]methyl acetamide
(compound of Example 129),
2) (S)-[N-3-(4-(2-(5-methyl-(1,3,4)-oxadiazol-2-yl)-
pyridin-5-yl)3-fluorophenyl)-2-oxo-5-
oxazolidinyl]methyl acetamide (compound of Example
137),
3) (S)-[N-3-(4-(2-(5-methyl-1,2,4-oxadiazol-3-yl)-pyridin-
5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetamide (compound of Example 138),
4) (S)-[N-3-(4-(2-(1-methyl-5-tetrazolyl)-pyridin-5-yl)-3-
fluorophenyl)-2-oxo-5-oxazolidinyl]methyl acetamide
(compound of Example 139), and
34
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
5) (S)-[N-3-(4-(2-oxo-(1,3)-oxazolidin-3-yl)-pyridin-5-
yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl acetaur
fide (compound of Example 143).
As for the pharmaceutically acceptable salt, it is
preferably an acid addition salt prepared by use of a
pharmaceutically acceptable free acid. Whether it is
inorganic or organic, a free acid can be used if it is
pharmaceutically acceptable. Examples of the inorganic free
acid include hydrochloric acid, bromic acid, sulfuric acid,
and phosphoric acid. Available organic free acids. are
exemplified by citric acid, acetic acid, lactic acid,
tartaric acid, malefic acid, fumaric acid, gluconic acid,
methane sulfonic acid, glyconic acid, succinic acid, 4-
toluenesulfonic acid, galuturonic acid, embonic acid,
glutamic acid, and aspartic acid.
In addition, the pharmaceutically acceptable salt of
the compound of formula 1 can be prepared using a base.
Available is pharmaceutically acceptable metals, especially
alkaline metal. Examples of useful metal include sodium and
potassium.
In accordance with another aspect of the present
invention, there is provided a method for preparing an
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
oxazolidinone derivative of formula 1. As seen in the
following Scheme 1, the preparation of the oxazolidinone
derivative is achieved by reacting, a trimethylstanyl
oxazolidinone derivative 2 with a pyridine derivative 3 in
the presence of a palladium catalyst.
Scheme 1
Me3Sn O~~ + R2 X Pd RZ O/ z'
~NHAc ~ ~ ~NHAc
R~ R~
g 1
(wherein Rl, R2 and X are each as defined above).
A detailed reaction route for the preparation of the
oxazolidinone derivative of the present invention is
illustrated in the following Scheme 2. ~ As shown, the
oxazolidinone derivative is prepared by:
a) aminating a hydroxymethyloxazolidinone derivative 4
at its hydroxy group to give an amine compound 5 (step 1),
b) acetylating the amine compound 5 by use of acetic
anhydride to produce an acetyl compound 6 (step 2),
c) halogenating the acetyl compound 6 at its phenyl
ring to produce a halogen compound 7 (step 3);'
36
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
d) stannylating the halogen compound 7 in the presence
of a palladium catalyst to give a trimethylstannyl
oxazolidinone derivative 2 (step 4), and
e) substituting the trimetylstannyl group of the
oxazolidinone derivative 2 with a pyridine or pyrimidine ,
moiety in the presence of a palladium catalyst to yield a
compound 1 (step 5).
Scheme 2
o~o ~ o~o
~OH ~ ~ ~NH2 ~ / ~NHAc
Ri R1 R1
4 5 6
O O
(Me3Sn)2, Pd - ~O
X ~ ~ N~NHAc Me3Sn ~ ~ N~NHAc
R~ ~' ~ Ri
2
O
R2-X Pd O
R2 ~ ~ N~NHAc
3 R,
1
wherein Rz and RZ are as defined .above, and X is a
halogen atom.
37
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
Below, a detail description will be stepwise given of
the method for preparing oxazolidinone derivatives of the
present invention
The hydroxymethyl oxazolidinone derivative of formula
4 , used as the starting material in Scheme 4 , can be readily
synthesized by well-known processes. For example, a
benzyloxycarbonyl group is introduced into the amine group of
aniline and then reacted with glyCidylbutyrate in the
presence of a strong base to obtain the starting material.
Examples of the strong base suitable for use in this
synthesis include n-butyl lithium, sec-butyl lithium and
tert-butyl lithium with preference for n-butyl lithium. The
synthesis is preferably carried out at -78 °C.
In the step 1, the hydroxy group of the
hydroxymethyloxazolidinone derivative 4 is converted into an
amine group. In this regard, a leaving group is first
attached to the hydroxy group for the introduction of an
azide group which is then reduced into an amine group.
Suitable as the leaving group are methane sulfonyl,
para-toluene sulfonyl, and halogen. Preferably, the
attachment of the leaving group, is conducted at 0 °C.
38
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
Because azide is a good nucleophile, the leaving group,
such as methane sulfonyl, para-toluene sulfonyl or halogen,
can be readily substituted by azide through nucleophilic
displacement. For this reaction, sodium azide is=used in an
amount of about 1 to 3 equivalents relative to the
methyloxazolidinone derivative reactant. The nucleophilic
displacement is preferably carried out 80 to 110 °C for 1 to 2
hours in a solvent, which is exemplified. by
dimethylformamide, dimethylsulfoxide and 1,4-dioxane.
Next, reduction of the resulting azide provides the
primary amine of formula 5. This reduction is achieved by
catalytic hydrogenation or by use of triphenyl phosphine. As
for the catalytic hydrogenation, it is preferably carried aut
at room temperature under a hydrogen atmosphere using
palladium in a solvent selected from the group consisting of
tetrahydrofuran, methanol and mixtures thereof. When using
triphenyl phosphine, the azide compound is refluxed in a
tetrahydrofuran solution added with a small amount of water
for 2 hours to produce the primary amine.
In the step 2; the amine compound of the formula 5,
obtained in the step 1, is reacted with acetic anhydride in
the presence of a base to give the corresponding compound of
39
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
formula 6. Suitable base for use in this acetylation are
triethyl amine, pyridine, and diisopropylethyl amine.
In the step.3, the compound of formula 6 is halogenated
on position 4 of its phenyl ring to produce the corresponding
compound of formula 7.
Preferable halide with which the phenyl ring is
substituted is iodide. The iodination is preferably conducted
by reacting the compound of formula 6 with iodine
monochloride (ICl) alone, or iodine in the presence of silver
trifluoroacetate (CF3COOAg) at room temperature.
In the step 4, the halide group on position 4 of the
phenyl ring is displaced with trimethyl stannyl by reaction
with hexametylditin in the presence of a palladium catalyst
to give the trimethylstannyl oxazolidinone derivative of
formula 2. Dichlorobistriphenylphosphine palladium (II), or
tetrakistriphenylphosphine palladium (0) is useful as the
palladium catalyst.
This displacement is preferably carried out at 90 to
120 °C in a solvent, such as 1,4-dioxane, dimethylformamide,
or tetrahydrofuran.
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
In the step 5, the trimethylstannyl oxa'~olidinone
derivative of formula 2 is reacted with the pyridine or
pyrimidine derivative of formula 3 in the presence of a
palladium (0) or a palladium (II) catalyst to prepare the
oxa~olidinone compound of the present invention.
Preferably, this reaction is conducted at 60 to 150 °C
for about 30 min to 12 hours. As a solvent for the reaction,
dimethylformamide, 1,4-dioxane, and tetrahydrofuran may be
used alone or in combination.
For use in the present invention, the pyridine halide
of formula 3 can be prepared from, for example,
dibromopyridine and pyridine, as illustrated in Scheme 3.
Such preparation is reported in the literature (J. Medicinal
Chem. V41, 2399(1998), Chem. Pharm. Bull, 314(1996), J. Med.
Chem. 957(2000), J. Med. Chem. 1230(2000), J. Med. Chem.
1086(1991), J. Med. Chem. 2837(1997), J. Med. Chem.
2019(1998)).
Scheme 3
X~~~/,X + R2H ~ R2 X
8 g 3
Wherein, R2 and X are as defined above.
41
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
When R2' is piperazinylpyrimidine, the synthesis of the
compound of formula 1 progress by way of the intermediates of
Scheme 4
Scheme 4
O ~--~ N
O TrNVN~N~Br~ or CI ~ O
Me3Sn N ~ TrN -
~NHAc ~ N- ~ ~ ~rNHAc
R~ Ri
1O
O
HCI ~"~ ~O RaX ~ / ~ G
1 R3 N~~ ~ ~ N~NHAc
-' HN~ N ~ ~ N~NHA ~/ '' ~c
NGI R Ri
1
11 12
wherein, R1 and R3 are each as defined above, and X is a
halogen atom.
As illustrated in Scheme 4, the trimetyl stannly group
of the compound of formula 2 is displaced with
triphenylmethyl-protected piperazine pyrimidine, followed by
the removal of the protecting group by use of a hydrochloric
acid solution. The resulting deprotected compound of formula
11 is substituted on the amine group of the piperidine moiety
to synthesize the compound of formula 12.
When R2 is pyridine, the synthesis of the compound of formula
1 progress by way of the intermediates of Scheme 5
42
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
Scheme 5
O" NC~ ~X O
Me3Sn ~ ~ N~~NHAc ~ NC ~ \ ~ ~ N -~NHAc.
'' ~ N '''' ~v-
R~ R~
2 13 5
O
HN ~ ~ R ~L R4yr ~ ~O
HOHN N- ~ ~ N~NHAc N- ~ ~ N~NHAc
R RT
14 ' 1
Wherein R1, R2, R6 and X are each as defined above, and
L is a typical leaving group and preferably halogen or
methylcarbonyl oxy group.
As illustrated in Scheme 5, the trimethylstannyl.
oxazolidinone derivative of formula 2 is reacted with a
cyanopyridine derivative to synthesize an intermediate of
formula 13, whose cyano group is then subjected to imination
using hydroxylamine to form the corresponding compound of
formula 14. It is cyclized to 'the desired compound as a
result of reaction with a carboxylic acid derivative.
As for the synthesis of the intermediate of formula 13,
it is performed by refluxing the reactants at 100 to 120°C
for 4 to 10 hours in an organic solvent, such as N-
methylpyrrolidine or tetrahydrofuran.
43
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
In the presence of sodium hydrogen carbonate and
hydroxylamine hydrochloride, the compound of formula l3 is
iminated at a reflux temperature for 2 to 5 hours. Alcohols
can be used as solvents with preference for ethanol, methanol
or isopropanol.
Reaction of the compound of formula 14 ~ with an
activated carboxylic acid derivative provides the
oxazolidinone derivative of, formula 1. The activated
carboxylic acid derivative is acyl chloride in which R6 is
substituted, or acetic anhydride. The cyclization is
conducted at a reflux temperature for 4 to 8 hours in a
solvent such as pyridine, tetrahydrofuran or acetone.
In accordance with a further aspect of, the present
invention, there is provided a pharmaceutical composition
comprising the compound of formula 1 as an effective
ingredient conferring antibacterial activity.
For formulating a pharmaceutical composition, at least
one species of the compound of formula 1 is admixed with at
least one pharmaceutically acceptable expedient, which is
nontoxic to humans and inactive.
44
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
Administrable via oral or parenteral routes, the
compounds of formula 1 may be used with ordinary medicine
forms.
That is, the compounds of formula 1 can be formulated
into various dosage forms for oral or parenteral
administration. For formulation, pharmaceutically acceptable
diluents, expedients and/or carriers may be used, including
fillers, thickeners, binders, wetting agents, disintegrants,
surfactants, etc. Solid dosage forms for oral administration
are exemplified by tablets, pills, powders, granules, and
capsules. These solid forms are prepared by admixing at least
one compound of formula 1 with at least one expedient, such
as starch, calcium carbonate, sucrose, lactose, gelatine,
etc. In addition to expedients, a lubricant such as magnesium
styrate may be added.
Exemplified by suspensions, internal solutions,
emulsions, syrups, etc., liquid dosage forms for oral
administration may comprise simple diluents, such as water
and liquid paraffin, as well as wetting agents, sweeteners,
aromatics, and/or perspectives.
Dosage forms for parenteral administration include
sterile aqueous solutions, non-aqueous solvents, suspensions,
emulsions, freeze-dried agents, suppositories, etc. For
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
formulation of non-aqueous solvents and suspensions,
vegetable oils, such as propylene glycol and polyethylene
glycol, or injectable esters such as ethyl oleate, may be
used. As bases for suppositories, Witepsol, macrogol, Tween
61, cocoa oil, laurinic acid, and glycerogelatine are useful.
In general, the compound of formula 1 may be
administered in a total dose of 1.2 g to adults in 2 or 3
installments a day. However, the dose may vary depending on
the conditions of the subject, including, for example,
physical constitutions and weights of patients, kinds and
severity of diseases, administration routes and intervals,
etc.
It is found that not only does the compound of formula
Z show inhibitory activity against a broad spectrum of
bacteria, but its antibacterial activity is excellent in
vivo. For example, the compound of the present invention can
exert potent antibacterial activity versus various human and
animal pathogens, including Gram-positive bacteria such as
Staphylococi, Enterococci and Streptococi, anaerobic
microorganisms such as Bacteroides and Clostridia, and acid-
resistant microorganisms such as Mycobacterium tuberculosis
and Mycobacterium avium.
46
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
A better understanding of the present invention may be
obtained in light of the following examples which are set
forth to illustrate, but are not to be construed to limit the
present invention.
<PREPARATION EXAMPLE 1>
Preparation of N-Carbobenzoxy-3-fluoroaniline
In l L of tetrahydrofuran (THF) was dissolved 100 g
(0.90 moles) of 3-fluoroaniline and the solution was added
with 150 g (1.8 moles) of sodium hydrogen carbonate. After
being cooled to 0 °C, the solution was slowly added with 154
ml (1.08 moles) of N-carbobenzyloxy chloride (CbzCl) for
reaction. While the temperature was maintained at 0 °C, the
reaction mixture was let to react for 2 hours with stirring.
Afterwards, the reaction was extracted with 0.5 L of ethyl
acetate. The organic layer, after being separated, was washed
with brine, dried over anhydrous MgS04, and concentrated in
vacuo. The residue was washed twice with n-hexane to afford
the title compound as a white crystal. 132 g. Yield 85 %.
<PREPARATTON EXAMPLE 2>
(R)-[N-3-(3-Fluorophenyl)-2-oxo-5-oxazolidinyl]methanol
47
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
In 1 . 3 L of THF was dissolved 133 g ( 0 . 54 moles ) of N-
carbobenzoxy-3-fluoroaniline prepared in Preparation Example
1 and the solution was cooled to -78 °C. To the solution, 370
ml of n-butyl. lithium .(n-BuLi, 1.6 M/n-hexane, 0.59 moles)
was slowly added in a nitrogen atmosphere,. followed by
stirring for 10 min. Following cautious introduction of 84 ml
(1.1 moles) of (R)-(-)-glycidylbutyrate, the reaction mixture
was stirred for 2 hours at the same temperature and allowed
to stand for 24 hours at room temperature for reaction. After
completion of the reaction, the solution was added with an
ammonium chloride (NH4C1) solution and extracted with 0.5 L of
ethyl acetate at room temperature. The organic layer, thus
separated, was washed with brine, dried over anhydrous
magnesium sulfate, and concentrated in vacuo. The residue was
dissolved in 100 ml of ethyl acetate and washed with n-hexane
to give white crystals, which were purified to the title
compound. 80 g. Yield 70 %.
1H NMR(DMSO-d6) 57.85(t,lH), 7.58(dd,lH), 7.23(dd,lH),
4.69(m,lH), 4.02(t,lH), 3.80(dd,lH), 3.60(br dd,2H)
<Preparation Example 3>
Preparation of (R)-[N-3-(3-Fluorophenyl)-2-oxo-5- .
oxazolidinyl]methylmethane sulfonate
48
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
In 300 ml of methylene chloride was dissolved 55.1 g
(0.26 mol) of.(R)-[N-3-(3-fluorophenyl)-2-oxo-5-oxa~olidinyl]
ethanol, and 54.4 ml (0.39 moles) of triethylamine and 24 ml
(Ø312 moles) of methanesulfonyl chloride were slowly added
to the solution at 0 °C. After being stirred at 0 °C for
about 40 min, the solution was added with water, extracted
with chloroform, dried over anhydrous magnesium sulfate,
concentrated under vacuum, and dried to give the title
compound. 78.3 g.
<reparation Example 4>
Preparation of (R)-[N-3-(3-Fluorophenyl)-2-oxo-5-
oxazolidinyl]methyl azide
In 800 ml of dimethylformamide was dissolved 78 g (0.27
moles) of (R)-[N-3-(3-fluorophenyl)-2-oxo-5-oxa2olidinyl]
ethyl methane sulfonate and the solution was added with 26.3
g (0.41 moles) of sodium azide and stirred at 100 °C for 2
hours. The solution was separated into layers by adding
water, followed by extraction with ethyl acetate. The ethyl
acetate layer was dehydrated, concentrated und.er~vacuum, and
dried to obtain the title compound. 70 g.
<Preparation Example 5>
49
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
Preparation of (S)-[N-3-(3-Fluorophenyl)-2-oxo-5-
oxazolidinyl]methyl amine
In a mixture of tetrahydrofuran (400 ml) and methanol
(80 ml) was dissolved 70 g of (R)-[N-3-(3-fluorophenyl)-2-
oxo-5-oxazolidinyl]methyl azide, and the azide compound was
reduced at room temperature for 24 hours under a hydrogen
atmosphere in the presence of 8 g of palladium on carbon
(Pd/C) with stirring, followed by filtration and
concentration in vacuo to obtain the tile compound. 54:6 g.
<Preparation Example 6>
Preparation of (S)-[N-3-(3-Fluorophenyl)-2-oxo-5-
oxazolidinyl]methyl acetamide
In 500 ml of methylene, chloride was dissolved 54.6 g
(0.26 moles) of (S)-[N-3-(3-fluorophenyl)-2-oxo-5-
oxazolidinyl]methyl amine and the solution was reacted with
36.8 ml (0.39 moles) of acetic anhydride at 0 °C for 1 hour in
the presence of 72.4 ml (0.52 moles) of triethyl amine with
stirring. Afterwards, the reaction mixture was added with
water, and extracted with chloroform. The organic layer thus
obtained was washed with brine, dried, and concentrated in
vacuo to give ivory powder which was then three times washed
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
with n-hexane to obtain the title compound. 49.6 g. Yield
76 0.
<Preparation Example 7>
Preparation of (S)-[N-3-(4-Iodo-3-~luorophenyl)-2-oxo-5-
oxazolidinyl]methyl acetamide
In a mixture of acetic acid (2.5 L) and trifluoroacetic
acid (700 ml) was dissolved 54.5 g (0.22 moles) of (S)-[N-3-
(3-fluorophenyl)-2-oxo-5-oxazolidinyl] ethyl acetamide. which
was then slowly added at room temperature with a solution of
455.7 g (2.8 moles) of iodine monochloride (ICl) in 300 ml of
acetic acid. Iodination was carried out for 15 hours at room
temperature with stirring, followed by the addition of
diethyl ether to give precipitates. They, after being
filtered, were dissolved in a mixture of chloroform and
methanol, washed with sodium thiosulfate and sodium hydrogen
carbonate (NaHC03), and dehydrated. The residue was
concentrated under vacuum and dried to obtain the title
compound. 59.5 g. Yield 80.4%
1H NMR(DMSO-d6) s8.23(t,lH), 7.82(dd,lH), 7.56(dd,lH),
7.18(dd,lH). 4.74(m,lH), 4.10(t,lH), 3.73(dd,lH), 3.40(br
dd,2H), 1.83(s,3H)
51
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
<Preparation Example 8>
Preparation of (S)-[N-3-(4-Trimethylstannyl-3-fluorophenyl)-
2-oxo-5-oxazolidinyl]methyl acetamide
In &60 ml of 1,4-dioxane was dissolved 50 g of (S)-[N-
3-(4-iodo-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetamide which was then reacted for 2 hours with 52 g of
hexamethylditin in the presence of 9..3 g of
dichlorobistriphenylphosphine palladium (II) with refluxing.
The reaction solution was filtered by use of cellite and the
filtrate was concentrated under vacuum. From the residue, the
title compound was separated through column chromatography.
45 g.
<Preparation Example 9>
Preparation of 2-Piperazin-1-yl-5-iodopyrimidine
In a mixture of acetic acid (5 ml), water (1 ml) and
sulfuric acid (0.15 ml) was dissolved 2 g of 1-(2-
pyrimidyl)piperazine which was then reacted with 0.86 g of
iodine in the presence of 0.38 g of periodic acid at 100 °C
for 6 hours with stirring. Chloroform was added to the
reaction mixture, followed by washing with sodium hydrogen
carbonate and brine. The organic layer thus obtained was
dehydrated, filtered and concentrated under vacuum.
52
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
Purification with column chromatography provided the title
compound. 600 mg.
1H-NMR (CDC13) 58.16(s,2H), 3.87(m,4H), 3.01(m,4H)
<Preparation Examp1e.10>
Preparation of 2-(4-Triphenylmethylpiperazin-1-yl)-5-
iodopyrimidine
In 100 ml of methylene chloride was dissolved 13 g of
2-piperazin-1-yl-5-iodopyrimidine which was then reacted with
15 g of triphenylmethyl chloride at room temperature for 1
hour in the presence of 16 ml of triethylamine with stirring.
The reaction mixture was added with methylene chloride, after
which the organic layer was washed with water and brine,
dehydrated,' filtered and concentrated under vacuum. The
residue was purified by use of ethyl acetate and a small
quantity of methanol to obtain the title compound. 10 g.
~H-NMR (CDC13) s 8.13(s,2H), 7.49(m,5H), 7.23(m,lOH),
3.86(m,4H), 2.33(m,4H)
<Preparation Example 11>
Preparation of 2-Acetylamino-5-bromopyridine
In 29 ml of pyridine was dissolved 1 g of 2-amino-5-
bromopyridine which was then acetylated through reaction with
0.61 ml of acetyl chloride at room temperature for 15 hours
53
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
with stirring. Following the addition of water, the reaction
mixture was extracted with ethyl .acetate, and the organic
layer thus obtained was washed with brine. Dehydration,
filtration and concentration under vacuum of the organic
layer provided a solid which was then recrystallized in
ethanol and hexane to obtain the title compound. 1.06 g.
Yield 850.
1H-NMR(CDC13) s8.60(s,lH), 8.34(d,lH), 8.18(d,lH),
7.79(dd,lH), 2.18(s,3H)
<Preparation Example 12>
Preparation of 2-Acetoxyacetylamino-5-bromopyridine
In 29 ml of methylene chloride was dissolved 1 g of 2-
amino-5-bromopyridine which was then reacted with 0.93 ml of
acetoxyacetyl chloride in the presence of 1.61 ml of triethyl
amine at room temperature for 1 hour with stirring. Water was
added to the reaction mixture before extraction with
methylene chloride. The organic layer thus obtained was
washed with brine, dehydrated, filtered and concentrated in
vacuo. Recrystalli~ation of the concentrate in ethyl ether
gave the title compound. 615 mg.
1H-NMR(CDC13) s 8.57(s,lH), 8.32(d,lH), 8.15(d,lH),
7.82(dd,lH), 4.73(s,2H), 2.21(s,3H)
54
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
<Preparation Example 13>
Preparation of 2-(1-Tetrazolyl)-5-bromopyridine
In 10 ml of 1-methyl-2-pyrrolidone was dissolved 1.0 g
of 2,5-dibromopyridine and the solution was added with 0.5 g
of 1,2,3,4-tetrazole, along with 1.75 g of potassium
carbonate. The reaction mixture was reacted at 100 °C for 3
hours with stirring. After completion of the reaction, the
reaction mixture was added with water and extracted with
ethyl acetate. The organic layer thus obtained was
dehydrated, filtered and concentrated and the concentrate was
subjected to column chromatography to give the title
compound. 0.8 g.
1H-NMR(DMSO-d6) 510.17(s.lH), 8.80(d,lH), 8.40(dd,lH),
8.00(d,lH)
<Preparation Example 14>
Preparation of 2-[5-Methyl-(1,3,4)-oxadiazol-2-yl]-5-
bromopyridine
In 10 ml of acetic anhydride was dissolved 1 g of 2-(5-
tetrazolyl)-5-bromopyridine, followed by refluxing for 2
hours. After completion of the reaction, the same post-
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
treatment as in Preparation Example 13 was conducted to give
the title compound. 0.6 g.
~H-NMR(CDC13) s8.79(d.lH), 8.09(dd,lH), 7.97(dd,lH),
2.64(s,3H)
<Preparation Example 15>
Preparation of 2-[5-Methyl-(1,2,4)-oxadiazol-3-yl]-5-
bromopyridine.
In 250 ml of acetic anhydride was dissolved 8.6 g of 2-
(imino-N-hydroxyaminomethyl)-5-bromopyridine and the solution
was refluxed for one day. After completion of the reaction,
the same post-treatment as in Preparation Example 13 was
conducted to give the title compound. 2.8 g.
1H-NMR(CDC13) 68.80(dd.lH), 7.96(dd,2H), 2.67(s,3H)
<preparation Example 16>
Preparation of 2-(1-Methyl-5-tetrazolyl)-5-bromopyridine and
2-(2-Methyl-5-tetrazolyl)-5-bromopyridine
In 5 ml of dimethylformamide was dissolved 400 mg of 2-
(5-tetrazolyl)-5-bromopyridine and the solution was reacted
with 502 mg of iodomethane in the presence of 300 mg of
potassium hydroxide at room temperature for 1 hour with
stirring. After completion of the reaction, a post-treatment
similar to that of Preparation Example 3 ,was conducted to
56
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
obtain 110 mg of 2-(1-methyl-5-tetrazolyl)-5-bromopyridine
(thin layer chromatography eluting with a mixture of 1:4
ethyl acetate:hexane, Rf: 0.3) and 220 mg of 2-(2-methyl-5-
tetrazolyl)-5-bromopyridine (thin layer chromatography
eluting with a mixture of 1:4 ethyl acetate . hexane, Rf:
0.5).
NMR data of 2-(1-methyl-5-tetrazolyl)-5-bromopyridine
1H-NMR(CDC13) 58.80(d,lH), 8.11(d,lH), 7.96(dd,lH),
4.43(s,3H)
<Preparation Example 17>
Preparation of 2-[4-Carboxyethoxy-(1,2,3)=triazol-1-yl]-5-
bromopyridine
In 1 ml of dimethylformamide was dissolved 100 mg of 2-
azide-5-bromopyridine, followed by the addition of 10 mg of
ethyl propiolate at room temperature. Temperature elevation
of the reaction mixture to 120 °C made a reaction progress
faster. After completion of the reaction, the same post-
treatment as in Preparation .Example- 13 was conducted to
obtain the title compound. 100 mg.
1H-NMR(DMSO-d6) s8.85(d.lH), 8.74(dd,lH), 8.34(dd,lH) ,
8.06(t,lH), 4.38(q,2H), 2.03(s.lH), 1.23(t,3H)
57
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
<Preparation Example 18>
Preparation of 2-(3-Pyrrolin-1-yl)-5-bromopyridine
In l00 ml of 1-methyl-2-pyrrolidone was dissolved 10 g
of 2,5-dibromopyridine which was then added with 3.5 ml of 3-
pyrrolidine, along with 8.7 g of potassium carbonate at room
temperature, followed by reacting them at 100 °C for 24 hours.
After completion of the reaction, the same post-treatment was
carried out as in Preparation Example 3 to obtain the title
compound. 8 g.
1H-NMR(CDC13) cS7.48(d.lH), 7.39(dd,lH), 6.21(d,lH),
5.89(s,2H), 4.15(s,4H)
<Preparation Example 19>
Preparation of 2-[2-Oxo-(1,3)-oxazolidin-1-yl]-5-
bromopyridine
In 20 ml of 1-methyl-2-pyrrolidone was dissolved 1.2 g
of 2-oxazolidone which was then added with 3.92 g of 2,5-
dibromopyridine, along with 3.81 g of potassium carbonate at
room temperature. Reaction was conducted at 120 °C for 4
hours with stirring. After completion of the reaction, the
same post-treatment as in Preparation Example 13 was carried
out to obtain the title compound. 50 mg.
58
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
1H-NMR(DMSO-d6) 88.33(d.lH), 8.12(dd,lH), 7.79(dd,lH),
4.47(m,2H), 4.22(m,2H)
<Preparation Example 20>
Preparation of 2-[(1,2,4)-Oxadiazol-3-yl]-5-bromopyridine
In 10 ml of triethyloxoformate was dissolved 1.0 g of
2-(imino-N-hydroxyaminomethyl)-5-bromopyridine, after which
2-3 drops of trifluoroboronetherate (BF3etherate) were added
to the solution which was then reacted for 3 hours with
refluxing. After completion of the reaction, the same post-
treatment as in Preparation Example 3 was carried out to
obtain the title compound. 0.7 g.
1H-NMR(CDC13) 58.77(brs.2H), 8.00(m,2H)
<Preparation Example 21>
Preparation of 2 -[(1,2,3)-Triazol-1-yl]-5-bromopyridine
In 20 ml of 1-methyl-2-pyrrolidone was dissolved 1.72 g
of 2,5-dibromopyridine, followed by the addition of 500 mg of
1H-(1,2,3)-triazole and 3 g of potassium carbonate at room
temperature. Reaction was conducted at 100 °C for 24 hours.
After completion of the reaction, the same post-treatment as
in Preparation Example 3 was carried out to obtain the title
compound. 120 mg.
59
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
1H-NMR(DMSO-d6) s 8.85(d.lH), 8.75(dd,lH), 8.34(dd,lH),
8.06(t,lH); 8.00(s;lH)
<Preparation Example 22>
Preparation of 2-[3-Methyl-2-oxo-(2,3)-di.hydro-(1,3,4)-
triazol-1-yl]-5-bromopyridine
In dimethylformamide was dissolved 311 mg of 2-[2-oxo-
(2,3)-dihydro-(1,3,4)-triazol-1-yl]-5-bromopyridine and the
solution was added with 217 mg of potassium hydroxide and
then dropwise with 366 ml of iodomethane at 0 °C. Reaction
was conducted at room temperature for 4 hours and led to
completion. After the reaction was completed, the same post-
treatment as in Preparation Example 13 was carried out to
obtain the title compound. 290 mg.
1H-NMR(DMSO-d6) 58.62(d.lH), 8.61(s,lH), 8.27(dd,lH),
8.13(d,lH), 3.39(s,3H)
<Preparation Example 23>
Preparation of 2-[3-t-Butoxycarbonyl-2-oxo-(2,3)-dihydro-
(1,3,4)-triazol-1-yl]-5-bromopyridine
In 20 ml of methylenechloride was dissolved 1.6 g of 2-
[2-oxo-(2,3)-dihydro-(1,3,4)-triazol-1-yl]-5-bromopyridine
which was added with 1.11 ml of triethyl amine and 3.4 g of
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
di-tert-butylcarbonate. Reaction was conducted at room
temperature for 1 hour with the catalytic aid of a small
amount of dimethylaminopyrrolidine with stirring. After the
reaction was terminated, the same post-treatment as in
Preparation Example 13 was carried out to obtain the title
compound. 2.84 g.
1H-NMR(CDC13) s 8.47(s.lH), 8.45(dd,lH), 8.13(d,lH),
7.91(dd,lH), 1.16-1.20(m,9H)
<Preparation Example 24>
Preparation of 2-[2-Oxo-(1,3)-imidazolidin-1-yl]-5-
bromopyridine
In 50 ml of 1-methyl-2-pyrrolidone was dissolved 15.14
g of 2,5-dibromopyridine and the solution was added with 5.0
g of 2-oxo-1,3-imidazolidine(2-imidazolidone, 2-
imidazolidione) and 16.05 g of potassium carbonate at room
temperature. The reactants were reacted at 100 °C for 24
hours with stirring. After completion of the reaction, the
same post-treatment as in Preparation Example 13 was carried
out to obtain the title compound. 2.0 g.
1H-NMR(CDC13) S 8.55(d.lH), 8.45(s,lH), 8..34(d,lH),
8.15(dd,lH)
61
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
<Preparation Example 25>
Preparation of 2-[(1,3)-Oxazol-5-yl]-5-bromopyridine
In 5.4 ml of methanol was dissolved 200 mg of 5-bromo-
2-formyl pyridine (5-bromo-2-pyridinyl aldehyde) which was
then reacted with 231 mg of tosylmethylisocyanide for 3 hours
in the presence of 178 mg of potassium carbonate under
reflux. After completion of the reaction, the same post-
treatment as in Preparation Example 13 was carried out to
obtain the title compound. 204 mg.
1H-NMR(CDC13) 6 8.65(d.lH), 7.95(s,lH), 7.89(dd,lH),
7.68(s,lH) , 7.56(d,lH)
<Preparation Example 26>
Preparation of 2-(4-Hydroxy-piperidin-1-yl-5-bromopyridine
In 100 ml of 1-methyl-2-pyrrolidone was dissolved 10 g
of 2 , 5-dibromopyridine which was then added with 5 . 2 g of 4-
hydroxypiperidine, along with 17.5 g of potassium carbonate
at room temperature. Reaction was conducted at 100 °C for 3
hours with stirring. After completion of the reaction, the
same post-treatment as in Preparation Example 13 was carried
out to obtain the title compound. 9 g.
1H-NMR(CDC13) &7.43(d.lH), 7.38(dd,lH), 6.21(d,lH),
4.69(m,lH) , 3.72(m,2H), 3.12(m,2H), 1.75(m,2H), 1.34(m,2H)
62
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
<Preparation Example 27>
Preparation of 2-[3-t-Butoxycarbonyl-2-oxo-(1,3)-
imidazolidin-1-yl]-5-bromopyridine
In 2 ml of tetrahydrofuran was dissolved 200 mg of 2-.
(2-oxo-1,3-imidazolidin-1-y1)-5-bromopyridine, followed by
reaction with 216 mg of di-tert-butyldicarbonate at room
temperature for 4 hours in the presence of 300 ml of triethyl
amine. After completion of the reaction, the same post-
treatment as in Preparation Example 13 was carried out to
obtain the title compound. 310 mg.
1H-NMR(CDC13) s 8.31(d.lH), 8,21(d,lH), 7.72(dd,lH),
3.99(m,2H) , 3.87(m,2H), 1.54(s,9H)
<EXAMPLE 1>
Preparation of (S)-[N-3-(4-Pyrimidin-5-yl)-3-fluorophenyl)-2-
oxo-5-oxazolidinyl]methyl acetamide.
In 4 ml of dimethylformamide was dissolved 322 mg of
(S)-[N-3-(4-trimethylstannyl-3-fluorophenyl)-2-oxo-5-oxazoli
dirsyl]methyl acetamide and the solution was added with 400 mg
of 5-iodopyrimidine, 0.27 ml of triethyl amine, and 0.22 g of
dichlorobistriphenylphosphine palladium (II) at room
temperature. Subsequently, reaction was conducted for 4 hours-
63
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
at 100 °C with stirring. Water was added to the reaction
mixture which was then extracted with ethyl acetate. The
organic layer thus separated was washed with brine,
dehydrated, filtered and concentrated in vacuo. Through
column chromatography, the concentrate was purified to the
title compound. 100 mg..
1H-NMR (CDC13) s 9.16(s,lH), 8.87(s,2H), 7.62(dd,lH),,
7.43(t,lH), 7.33(dd,lH), 6.37(bt,lH), 4.82(m,lH), 4.08(t,lH),
3.84(dd,lH), 3.67(m,2H), 2.00(s,3H)
<EXAMPLE 2>
Preparation of (S)-[N-3-(4-(2-Methoxypyrimidin-5-yl)-3-
fluorophenyl)-2-oxo-5-oxazolidinyl]methyl acetamide
The title compound was prepared in a manner similar to
that of Example 1, except that, 2-methoxy-5-iodopyrimidine,
instead of 5-iodopyrimidine, was used as a starting material.
<EXAMPLE 3>
Preparation of (S)-[N-3-.(4-(2-Aminopyrimidin-5 -yl)-3-
fluorophenyl)-2-oxo-5-oxazolidinyl]methyl acetamide
The same procedure as in Example 1 was conducted,
except for using, instead of 5-iodopyrimidine, 2-amino-5-
64
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
bromopyrimidine as a starting material, to prepare the title
compound. 45 mg.
'~H-NMR (DMSO-d6) 8.42(s,lH), 8.30(s,lH), 8.26(t,lH),
7.53(m,4H),. 6.67(s,lH), 4.75(m,lH), 4.16(m,lH), 3.77(m,lH),
3.42(m,2H), 1.83(s,3H)
<EXAMPLE 4>
Preparation of (S)-[N-3-(4-(2-(4-Triphenylmethylpiperazin-1-
yl)pyrimidin-5-yl)-3-fluorophenyl)-2-oxo-5-
oxazolidinyl]methyl acetamide
In 5.6 ml of dimethylformamide was dissolved 400 mg of
(S)-[N-3-(4-trimethylstannyl-3-fluorophenyl)-2-oxo-5-
oxazolidinyl]methyl acetamide which was then reacted with 770
mg of 2-(4-triphenylmethylpiperazin-1-yl)-5-iodopyrimi dine
at 80 °C for 1 hour in the presence of.48 mg of copper
chloride. Water was added to the reaction mixture, followed
by extraction with ethyl acetate. The organic layer thus
obtained was washed with brine, dehydrated, filtered and
concentrated in vacuo. The concentrate was purified by column
chromatography to give the title compound. 300 mg.
1H-NMR (DMSO-d6) 8.48(s,2H), 8.25(t,lH), 7.40(m,lSH),
7.17(m,2H), 6.95(m,lH), 4.72(m,lH), 4.11(m,lH), 3.73(m;lH),
3.40(t,2H), 1.81(s,3H)
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
<EXAMPLE 5>
Preparation of (S)-[N-3-(4-(2-piperazin-1-yl-pyrimidin-5-yl)-
3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl acetamide
hydrochloride
To a solution of 200 mg of (S)-[N-3-(4-(2-(4-
triphenylmethylpiperazin-1-yl)pyrimidin-5-yl)-3-fluorophen
yl)-2-oxo-5-oxazolidinyl]methyl acetami.de in tetrahydrofuran
was added 1 m1 of a 6 N hydrochloride solution at room
temperature, followed by stirring for 24 hours. The solid
thus formed was purified and washed with tetrahydrofuran and
ethyl ether to obtain the title compound. 110 mg.
~H-NMR (DMSO-d6) 9.49(bs,lH), 8.63(s,2H), 8.33(t,lH),
7.49(m,4H), 4.74(m;lH), 4.13(t,lH), 4.02(m,4H), 3.78(dd,lH),
3.41(t,2H), 3.16(m,4H), 1.81(s,3H)
<EXAMPLE 6>
Preparation of (S)-[N-3-(4-(2-(4-Acetylpiperazin-Z-yl)pyrimi
din-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl aceta
mide
A solution of 30 mg of (S)-[N-3-(4-(2-piperazin-1-
ylpyrimidin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetamide hydrochloride in tetrahydrofuran were added with 10
66
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
~u,l of acetyl chloride and 30.3 ~,l of triethyl amine at room
temperature and let to react for 30 min with stirring. After
completion of the acetylation, chloroform was added to the
reaction mixture which was then washed with water and brine..
The organic layer thus obtained was dehydrated, filtered and
concentrated in vacuo. The concentrate was subjected to
column chromatography to give the title compound. 30 mg.
iH-NMR (CDC13) 8.47(s,2H), 7.53(dd,lH), 7.29(m,2H),
6.30(t,lH), 4.79(m,lH), 3.86(m,5H), 3.66(m,4H), 3.51(m,2H),
2.14(s,3H), 2.01(s,3H)
<EXAMPLE 7>
Preparation of (S)-[N-3-(4-(2-(4-Benzyloxyacetylpiperazin-1-
yl)pyrimidin-5-yl)-3-fluorophenyl)-2-oxo-5-
oxazolidinyl]methyl acetamide
The same procedure as in Example 6 'was conducted,
except for using, instead of acetyl chloride, 26.6 ~,l of
benzyloxyacetyl chloride as a starting material, to prepare
the title compound. 30 mg.
zH-NMR (CDC13) s8.48(s,2H), 7.52(dd,lH),~ 7.27(m,7H),
6.15(t,lH), 4.79(m,lH), 4.60(s,2H), 4.21(s,2H), 4.05(t,lH),
3.83(m,SH), 3.65(m,6H), 2.01(s,3H)
67
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
<EXAMPLE 8>
Preparation of (S)-[N-3-(4-(2-(4-Acetoxyacetylpiperazin-1-
yl)pyrimidin-5-yl)-3-fluorophenyl)-2-oxo-5-
oxazolidinyl]methyl acetamide
The same procedure as in Example 6 was conducted,
except for using, instead of acetyl chloride, 16 ~,l of
acetoxyacetyl chloride as a starting material, to prepare the
title compound. 23 mg.
1H-NMR(CDC13) s8.49(d,2H), 7.56(dd,lH), 7.35(m,2H),
6.04(t,lH), 4.80(m,lH), 4.77(s,2H), 4.06(t,lH), 3.95(m,4H),
3.70(m,5H), 3.50(m,2H), 2.21(s,3H), 2.01(s,3H).
<EXAMPLE 9>
Preparation of (S)-[N-3-(4-(2-(4-Hydroxyacetylpiperazin-1-
yl)pyrimidin-5-yl)-3-fluorophenyl)-2-oxo-5-
oxazolidinyl]methyl acetamide
In methanol was dissolved 220 mg of the title compound
of Example 8 which was then hydroxylated with 1 ml of a 1 N
KOH solution at room temperature for 1 hour with stirring.
Following the removal of excess alcohol by concentration
under vacuum, the residue was added with water and extracted
with chloroform. The organic layer was dehydrated, filtered
68
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
and concentrated in vacuo. Purification through column
chromatography provided the title compound. I89 mg.
1H-NMR (CDC13) s8.48(s,2H), 7.54(dd,lH), 7.34(t,lH),
7.26(dd,lH), 4.79(m,lH), 4.21(s,2H), 4..05(t,lH), 3.88(m,4H),
3.77(m,4H), 3.65(m,lH), 3.34(m,2H), 2.00(s,3H).
<EXAMPLE 10>
Preparation of (S)-[N-3-(4-(2-(4-Dimethylaminoacetoxyacetyl
piperazin-1-yl)pyrimidin-5-yl)-3-fluorophenyl)-2-oxo-5-
oxazolidinyl]methyl acetamide
In 2.5 ml of pyridine was dissolved 50 mg of (S)-[N-3-
(4-(2-(4-hydroxyacetylpiperazin-1-yl)pyrimidin-5-yl)-3-floor
ophenyl)-2-oxo-5-oxa2olidinyl]methyl acetamide and the
solution was dropwise added with 43.7 mg of N,N-
dimethylglycine, 84 mg of 1-(3-dimethylaminopropyl)-3-
ethylcarbodiimide hydrochloride, and 20 mg of 4-
dimethylaminopyridine and stirred at room temperature for 15
hours. The reaction mixture was added with water and
extracted with ethyl acetate. The organic layer thus
obtained, after being washed with brine, was dehydrated,
filtered and concentrated in vacuo. The concentrate was
purified by column chromatography to obtain the title
compound. 22 mg.
69
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
1H-NMR (CDC13) s8.49(s,2H), 7.56(dd,lH), 7.34(t,lH),
7.27(dd,lH), 6.01(t,lH), 4.83(s,2H), 4.79(m,lH);. 4.06(t,lH),
3.89(m,4H), 3.78(m,4H), 3.32(s,2H), 2.40(s,6H), 2.01(s,3H)
<EXAMPLE 11>
Preparation of (S)-[N-3-(4-(2-(4-Bromoacetylpiperazin-1-
yl)pyrimidin-5-yl)-3-fluorophenyl)-2-oxo-5-
oxazolidinyl]methyl acetamide
The same procedure as in Example 6 was conducted,
except for using, instead of acetyl chloride, 63.06 ~,1 of
bromoacetyl, to prepare the title compound. 49 mg.
1H-NMR (CDC13) 58.49(s,2H), 7.56(dd,lH), 7.34(t,lH),
7.26(dd,lH), 6.01(t,lH), 4.80(m,lH), 4.06(t,lH), 3.95(m,4H),
3.87(s), 3.77(m,4H), 3.65(m,lH), 3.34(m,2H), 2.00(s,3H)
<EXAMPLE 12>
Preparation of (S)-[N-3-(4-(2-(Morpholin-4-yl)-methylcar
bonlypiperazin-1-yl)pyrimidin-5-yl)-3-fluorophenyl]-2-oxo-5-
oxazolidinyl]methyl acetamide
In tetrahydrofuran, 25 mg of (S)-[N-3-(4-(2-(4-
bromoacetylpiperazin-1-yl)pyrimidin-5-yl)-3-fluorophenyl)-2-
oxo-5-oxazolidinyl]methyl acetamide was reacted with 8 ~,1 of
morpholine at room temperature for 2 hours in the presence of
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
19.3 ~,l of triethyl amine. The reaction mixture was
concentrated in vacuo, followed by purification through
column chromatography to give the title compound. 25 mg.
1H-NMR(CDC13) s8.50(d,2H), 7.56(dd,lH), 7.35(m,2H)~,
5.99(t,lH), 4.79(m,lH), 4.06(t,lH), 3.89(m,5H), 3.73(m,lOH),
2.55(m,4H), 2.01(s,3H).
<EXAMPLE 13>
Preparation of (S)-[N-3-(4-(2-(4-(Imidazol-1-yh-carbonyl-
oxymethyl carbonyl piperazin-1-yl)pyrimidin-5-yl)-3-
fluorophenyl)-2-oxo-5-oxazolidinyl)methyl acetamide
In tetrahydrofuran, 30 mg of (S)-[N-3-(4-(2-(4-
hydroxyacetylpiperazin-1-yl)pyrimidin-5-yl)-3-fluorophenyl)-
2-oxo-5-oxazolidinyl]methyl acetamide was reacted with 34 mg
of 1,1-carbonyldiimidazole at room temperature for 1 hour
with stirring. The reaction mixture was added with chloroform
and washed with sodium hydrogen carbonate. The organic layer
thus obtained was dehydrated, filtered and concentrated in
vacuo. Column chromatography with the concentrate provided
the title compound. 28 mg.
1H-NMR(CDC13) s8.50(d,2H), 8.19(s,lH), 7.56(dd,lH),~
7.50(s,lH), 7.35(m,2H), 7.07(s,lHj, 6.06(t;lH), 5.06(s,2H),
71
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
4.79(m,lH), 4.06(t,lH), 3.95(m,4H), 3.75(m,5H); 3.48(m,2H),
2.01(s,3H).
<EXAMPLE 14>
Preparation of (S)-[N-3-(4-(2-(4-Chloroacetylpiperazin-1-
yl)pyrimidin-5-yl)-3-fluorophenyl)-2-oxo-5-
oxazolidinyl]methyl acetamide
The same procedure as in Example 6 was conducted,
except for using, instead of acetyl chloride, 54.5 ~ul of
chloroacetyl chloride as a starting material, to prepare the
title compound.. 102 mg.
zH-NMR (CDC13) 58.49(s,2H), 7.56(dd,lH), 7.39(t,lH),
7.27(dd,lH), 6.01(t,lH), 4.78(m,lH), 4.11(s,2H), 4.05(t,lH),
3.88(m,4H), 3.77(m,4H), 3.65(m,6H), 2.01(s,3H)
<EXAMPLE 15>
Preparation of (S)-[N-3-(4-(2-(4-Methoxycarbonylmethyl
aminoacetylpiperazin-1-yl)pyrimidin-5-yl)-3-fluorophenyl)-2-
oxo-5-oxazolidinyl]methyl acetamide
In methanol was dissolved 50 mg of the title compound
of Example 14 and the solution was added with 181 ~,l of
triethyl amine and 32 mg of glycine methylester and refluxed
for 4 hours. Following removal of excess methanol, the
72
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
residue was added with water and extracted with chloroform.
The organic layer thus separated was dehydrated, filtered and
concentrated .zn vacuo. Through column chromatography, the
concentrate was purified to the title compound. 20 mg.
<EXAMPLE 16>
Preparation of (S)-[N-3-(4-(2-(4-(4-Methoxyphenylpiperazin-4-
yl)acetylpiperazin-1-yl)pyrimidin-5-yl)-3-fluorophenyl)-2-
oxo-5-oxazolidinyl]methyl acetamide
Except for starting with 18 mg of
methoxyphenylpiperazine instead of glycinemethylester
hydrochloride, the same procedure as. in Example 15 was
conducted to prepare the title compound. 32 mg.
~H-NMR(CDC13) s8.49(d,2H), 7.56(dd,lH), 7.35(m,2H),
6.86(q,4H), 6.04(t,lH), 4.79(m,lH), 4.06(t,lH), 3.88(m,5H),
3.74(s,3H), 3.70(m,8H), 2.01(s,3H)
<EXAMPLE 17>
Preparation of (S)-[N-3-(4-(2-(4-Methoxyacetylpiperazin-1-
yl)pyrimidin-5-yl)-3-fluorophenyl)-2-oxo-5-
oxazolidinyl]methyl acetamide
73
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
Except for starting with 13 ,u1 of methoxyacetyl
chloride instead of acetyl chloride, the same procedure as in
Example 6 was conducted to prepare the title compound. 32 mg.
1H-NMR(CDC13) 8.48(d,2H), 7.56(dd,lH), 7.35(m,2H),
6.35(t,lH), 4.79(m,lH), 4.14(s;2H), 4.06(t,lH), 3.87(m,SH),
3.65(m,4H), 3.58(m,2H), 3.42(s,3H), 2.01(s,3H)
<EXAMPLE 18>
Preparation of (S)-[N-3-(4-(2-(4-Acryloylpiperazin-1-
yl)pyrimidin-5-yl)-3-fluorophenyl)-2-oxo-5-
oxazolidinyl]methyl acetamide
Except for starting with 14 ~,l of acryloyl chloride
instead of acetyl chloride, the same procedure as in Example
6 was conducted to prepare the the title compound. 28 mg.
1H-NMR(CDC13) s8.49(d,2H), 7.56(dd,lH), 7.35(m,2H),
6.62(dd,lH), 6.36(dd,lH), 6.09(t,lH), 5:75(dd,lH),
4.80(m,lH), 4.06(t,lH), 3.97(m,4H), 3.85(m,3H),. 3.68(m,4H),
2.01(s,3H)
<EXAMPLE 19>
Preparation of (S)-[N-3-(4-(2-(4-Ethoxyoxoacetylpiperazin-l-
yl)pyrimidin-5-yl) -3-fluorophenyl)-2-oxo-5-
oxazolidinyl]methyl acetamide
74
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
Except for starting with 16 ~,l of ethylchlorooxoacetate
instead of acetyl chloride, the same procedure as in Example
6 was conducted to prepare the title compound. 30 mg.
1H-NMR(CDC13) s8.50(d,2H), 7.56(dd,lH), 7.35(m,2H),
7.13(m,3H), 6.03(t,lH), 4.79(m,lH), 4.37(q,2H), 4.06(t,lH),
3.95(m,4H), 3.75(m,5H), 3.51(m,2H), 2.01(s,3H), 1.37(t,3H)
<EXAMPLE 20>
Preparation of (S)-[N-3-(4-(2-(4-Nicotinoylpiperazin-1-
yl)pyrimidin-5-yl)-3-fluorophenyl)-2-oxo-5-
oxazolidinyl]methyl acetamide
Except for starting with 26 mg of nicotinoyl chloride
instead of acetyl chloride, the same procedure as in Example
6 was conducted to prepare the title compound. 22 mg.
1H-NMR(CDC13) 8.70(s,2H); 8.50(s,2H), 7.82(d,lH),
7.56(dd,lH), 7.35(m,2H), 5.99(t,lH), 4.80(m,lH), 4.06(t,lH),
3.95(m,4H), 3.75(m,7H), 2.01(s,3H)
<EXAMPLE 21>
Preparation of (S)-[N-3-(4-(2-(4-Pivaloylpiperazin-1-
yl)pyrimidin-5-yl)-3-fluorophenyl)-2-oxo-5-
oxazolidinyl]methyl acetamide.
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
Except for starting with 17.4 ~,l of pivaloylchloride .
instead of acetylchloride, the title compound was prepared in
a manner similar to that of Example 6. 30 mg..
1H-NMR(CDC13) 58.49(d,2H), 7.56(dd,lH), 7.35(m,2H),
6.05(t,lH), 4.79(m,lH), 4.06(t,lH), 3.88(m,4H), 3.65(m,7H),
2.01(s,3H), 1.30(s,9H)
<EXAMPLE 22>
Preparation of (S)-[N-3-(4-(2-(4-t-Butylacetylpiperazin-1-
yl)pyrimidin-5-yl)-3-fluorophenyl)-2-oxo-5-
oxazolidinyl]methyl acetamide
Except for starting with 20 ~,l of t-butylacetyl
chloride instead of acetylchloride, the title compound was
prepared in a manner similar to that of Example 6. 20 mg.
1H-NMR(CDC13) 8.48(d,2H), 7.56(dd,lH), 7.35(m,2H),
6.27(t,lH), 4.79(m,lH), 4:05(t,lH), 3.87(m,4H), 3.69(m,4H),
3.58(m,3H), 2.01(s,3H), 1.05(s,9H)
<EXAMPLE 23>
Preparation of (S)-[N-3-(4-(2-(4-(2,5-Dimethoxyphenyl)acetyl
piperazin-1-yl)pyrimidin-5-yl)-3-fluorophenyl)-2-oxo-5-
oxazolidinyl]methyl acetamide
76
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
Except for starting with 30 mg of 2,5-
dimethoxyphenylacetyl chloride instead of acetylchloride, the
title compound was prepared in a manner similar to that of
Example 6. 36 mg.
1H-NMR(CDC13) 58.48(d,2H), 7.55(dd,lH), 7.33(m,2H),
6.84(m,lH), 6.76(m,2H), 6.03(t,lH), 4.79(m,lH), 4.06(t,lH),
3.78(s,3H), 3.72(s,3H), 2.00(s,3H).
<EXAMPLE 24>
Preparation of (S)-[N-3-(4-(2-(4-(3,3-Dimethylacryloyl)
piperazine-1-yl)pyrimidin-5-yl)-3-fluorophenyl)-2-oxo-5-
oxazolidinyl]methyl acetamide
Except for starting with 16 ~,l of 3,3-dimethylacryloyl
chloride instead of acetylchloride, the title compound was
prepared in a manner similar to that of Example 6. 20 mg.
1H-NMR(CDC13) s8.49.(d,2H); 7.56(dd,lH), 7.34(m,2H),
6.04(t,lH), 5.81(s,lH), 4.79(m,lH), 4.06(t,lH), 3.85(m,5H),
3.70(m,5H), 3.62(m,2H), 2.01(s,3H)
<EXAMPLE 25>
Preparation of (S)-[N-3-(4-(2-(4-(2,6-Dimethoxybenzoyl)
piperazine-1-yl)pyrimidin-5-yl)-3-fluorophenyl)-2-oxo-5-
oxazolidinyl]methyl acetamide
77
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
Except for starting with 29 mg of 2,6-dimethoxybenzoyl
chloride instead of acetylchloride, the title compound was
prepared in a manner similar to that of Example 6. 27 mg.
1H-NMR(CDC13) 8.48(d,2H), 7.56(dd,lH), 7.35(m,3H),
6.58(d,2H), 6.04(t,lH), 4.79(m,lH), 4.06(t,lH), 3.95(m,4H),
3.75(m,5H), 3.31(m,2H), 2.01(s,3H)
<EXAMPLE 26>
Preparation of (S)-[N-3-(4-(2-(4-(2-Trifluoromethylbenzoyl)
piperazin-1-yl)pyrimidin-5-yl)-3-fluorophenyl)-2-oxo-5-
oxazolidinyl]methyl acetamide
Except for starting with 29 ~,1 of 2-
trifluoromethylbenzoyl chloride instead of acetylchloride,
the title compound was. prepared. in a manner similar to that
of Example 6. 36 mg.
1H-NMR(CDC13) 8.47(d,2H), 7.74(d,l.H), 7.57(m,3H),
7.38(m,2H), 7.34(m,lH), 6.07(t,lH), 4.79(m,13), 4.06(t,lH),
3.95(m,6H), 3.64(m,2H) 3.25(m,2H), 2.01(s,3H)
<EXAMPLE 27>
Preparation of (S)-[N-3-(4-(2-(4-(4-Trifluoromethylbenzoyl)
piperazin-1-yl)pyrimidin-5-yl)-3-fluorophenyl)-2-oxo-5-
oxazolidinyl]methyl acetamide
78
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
Except for starting with 40 ~,l of 4-
trifluoromethylbenzoyl chloride instead of acetylchloride,
the title compound was prepared in a manner similar to that
of Example 6. 35 mg.
1H-NMR(CDC13) s8.50(d,2H), 7.72(d,2H), 7.57(m,3H),
7.35(m,2H), 6.01(t,lH), 4.79(m,lH), 4.09(t,lH), 3.95(m,4H),
3.75(m,7H), 2.01(s,3H)
<EXAMPLE 28>
Preparation of (S)-[N-3-(4-(2-(4-Phenylacetylpiperazin-1-
yl)pyrimidin-5-yl)-3-fluorophenyl)-2-oxo-5-
oxazolidinyl]methyl acetamide
Except for starting with 20 ~,1 of phenylacetyl chloride
instead of acetylchloride, the title compound was prepared in
a manner similar to that of Example 6. 23 mg.
<EXAMPLE 29>
Preparation of (S)-[N-3-(4-(2-(4-(3,5-Dinitrobenzoyl)piper
azin-1-yl)pyrimidin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidin
yl]methyl acetamide
Except for starting with 20 u1 of 3,5-dinitrobenzoyl
chloride instead of acetylchloride, the title compound was
prepared in a manner similar to that of Example 6. 20 mg.
79
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
1H-NMR(CDC13) 58.50(d,2H), 8.30(d,lH), 7.62(d,lH),,
7.56(dd,lH), 7.35(m,lH), 7.27(dd,lH), 6.02(t,lH), 4.79(m,lH),
4.06(t,lH), 2.01(s,3H)
<EXAMPLE 30>
Preparation of (S)-[N-3-(4-(2-(4-Crotonylpiperazin-1-yl)pyri
midin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl acet
amide
Except for starting with 14 ~,1 of crotonyl chloride
instead of acetylchloride, the title compound was prepared in
a manner similar to that of Example 6.25 mg.
1H-NMR(CDC13) s8.49(d,2H), 7.56(dd,lH), 7.35(m,2H),
6.69(m,lH), 6.28(dd,lH), 6.01(t,lH), 4.79(m,lH), 4.06(t,lH),
3.95(m,4H), 3.75(m,7H), 2.01(s,3H), 1.90(dd,3H)
<EXAMPLE 31>
Preparation, of (S)-[N-3-(4-(2-(4-Trichloroacetylpiperazin-1-
yl)pyrimidin-5-yl)-3-fluorophenyl)-2-oxo-5-
oxazolidinyl]methyl acetamide
Except for starting with' 32 ~l of trichloroacetyl
chloride instead of acetylchloride, the title compound was
prepared in a manner similar to that of Example 6. 25 mg.
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
1H=NMR(CDC13) 88.50(d,2H), 7.56(dd,lH), 7.37(m,2H),
6.03(t,lH), 4.80(m,lH), 4.06(t,lH), 3.95(m,4H), 3.75(m,7H),
2.01(s,3H).
<EXAMPLE 32>
Preparation of (S)-[N-3-(4-(2-(4-n-Valerylpiperazin-Z-yl)py
rimidin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetamide
Except for starting with 25 ~,l of valeryl chloride
instead of acetylchloride, the title compound was prepared in
a manner similar to that of Example 6.35 mg.
<EXAMPLE 33>
Preparation of (S)-[N-3-(4-(2-(4-(1-Bromoethylcarbonyl) pipe
razin-1-yl)pyrimidin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazol
idinyl]methyl acetamide
Except for starting with 12 ~,1 of bromoethylcarbonyl
chloride instead of acetylchloride, the title compound was
prepared in a manner similar to that of Example 6. 10 mg.
<EXAMPLE 34>
81
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
Preparation of (S)-[N-3-(4-(2-(4-Phenoxycarbonylpiperazin-1-
yl)pyrimidin-5-yl)-3-fluorophenyl)-2-oxo-5-
oxazolidinyl]methyl acetamide
Except for starting with 18 ~,l of phenylchloroformate
instead of acetylchloride, the title compound was prepared in
a manner similar to that of Example 6.15 mg.
1H-NMR(CDC13) s8.50(d,2H), 7.56(dd,lH), 7.35(m,4H),
7.13(m,3H), 6.00(t,lH), 4.79(m,lH), 4.06(t,lH), 3.95(m,4H),
3.75(m,7H), 2.01(s,3H)
<EXAMPLE 35>
Preparation of (S)-[N-3-(4-(2-(4-Benzyloxycarbonylbenzyloxy
aarbonylpiperazin-1-yl)pyrimidin-5-yl)-3-fluorophenyl)-2-oxo
-5-oxazolidinyl]methyl acetamide
Except for starting with 17 ~,l of benzylcarbonyl
chloride instead of acetylchloride, the title compound was
prepared in a manner similar to that of Example 6. 22 mg.
1H-NMR(CDC13) s8.47(d,2H), 7.55(dd,lH), 6.00(t,lH),
5.15(s,lH), 4.79(m,lH), 4.06(t,lH), 3.85(m,4H), 3.78(dd,lH),
3.58(m,4H), 2.00(s,3H)
<EXAMPLE 36>
82
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
Preparation of (S)-[N-3-(4-Pyridin-2-yl)-3-fluorophenyh]-2-
oxo-5-oxazolidinyl]methyl acetamide
In 4 ml of dimethylformamide was dissolved 300 mg of
(S)-[N-3-(4-trimethylstannyl-3-fluorophenyl)-2-oxo-5-
oxazolidinyl]methyl acetamide which was then reacted with
0.14 ml of 2-bromopyridine in the presence of 0.25 ml of
triethylamine with the catalytic aid of 0.2 g of
dichlorobistriphenylphosphine palladium (II) at 100 °C with
stirring after their addition at room temperature. ~ After
completion of the reaction, the reaction. mixture was added
with water and extracted with ethyl acetate. The organic
layer thus separated was washed with brine, dehydrated,
filtered and concentrated in vacuo. Through column
chromatography, the concentrate was purified to the title
compound. 50 mg.
<EXAMPLE 37>
Preparation of (S)-[N-3-(4-(2-Aminopyridin-5-yl)-3-
fluorophenyl)-2-oxo-5-oxazolidinyl]methyl acetamide
With the exception of adding, instead of 2-
bromopyridine, 5.0 g of 2-amino-5-iodopyridine2-bromopyridine
as a starting material, the same procedure as in Example 36
was conducted to give the title compound. 15 g. Yield 45 0.
83
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
1H-NMR(DMSO-d6) 88.26(t,lH), 8.08(s,lH), 7.52(m,3H),
7.32(dd,lH), 8.51(d,lH), 6.14(s,2H), 4.74(m,lH), 4.14(t,.lH),
3.75(dd,lH), 3.41(m,2H), 1.85(s,3H)
<EXAMPLE 38>
Preparation of (S)-[N-3-(4-(3-Methoxycarbonylpyridin-5-yl)-3-
fluorophenyl)-2-oxo-5-oxazolidinyl]methyl acetamide
In 2.4 ml of dimethylformamide was dissolved 200 mg of
(S)-[N-3-(4-trimethylstannyl-3-fluorophenyl)-2-oxo-5-oxazol
idinyl]methyl acetamide 200 mg which was then reacted with
260.3 mg of methyl 5-bromopyridine-3-carboxylate in the
presence of 0.17 ml of triethylamine with the catalytic aid
of 135 mg of dichlorobistriphenylphosphine palladium (II) at
100 °C for 3 hours with stirring after their addition at room
temperature. Water was then added to the reaction mixture,
followed by the extraction with ethyl acetate. The organic
layer was washed with brine, dehydrated, filtered and
concentrated in vacuo. Purification of the concentrate
through column chromatography provided the title compound. 60
mg.
1H-NMR(CDC13) s9.16(d,lH), 8.90(t,lH),. 8.42(m,lH),
7.60(dd,lH), 7.45(t,lH), 7~.30(dd,lH), 6.16(bt,lH),
84
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
4.81(m,lH), 4.10(t,lH), 3.96(s,3H), 3.81(dd,lH), 3.70(m,2H),
2.02(s,3H)
<EXAMPLE 39>
Preparation of (S)-[N-3-(4-(2-Acetylaminopyridin-5-yl)-3-
fluorophenyl)-2-oxo-5-oxazolidinyl]methyl acetamide.
With the exception of using 260 mg of 2-amino-5-
iodopyridine-2-bromopyridine as a starting material,. the same
procedure as in Example 38 was conducted to give the title.
compound. 45 mg.
1H-NMR(DMSO-d6) 58.48(s,lH), 8.28(t,lH), 8.15(d,lH),
7.98(d,lH), 7.64(m,lH), 7.43(m,lH), 4.76(m,lH), 4.18(t,lH),
3.79(t,lH), 3.42(t,2H), 2.10(s,3H), 1.82(s,3H)
<EXAMPLE 40>
Preparation of (S)-[N-3-(4-(2-Acetoxyacetylaminopyridin-5-
yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl acetamide
In 5.6 ml of dimethylformamide was dissolved 467 mg of
(S)-[N-3-(4-trimethylstannyl-3-fluorophenyl)-2-oxo-5-
oxazolidinyl]methyl acetamide which was then reacted with 615
mg of 2-acetoxyacetylamino-5-bromopyridine in the presence of
0.39 ml of triethyl amine with the catalytic aid of 237 ml of
dichlorobistriphenylphosphine palladium (II) at 100 °C for 4
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
hours with stirring after their addition at room temperature.
Water was added to the reaction mixture, followed by
extraction with ethyl acetate. The organic layer was washed
with brine, dehydrated, filtered, and concentrated in vacuo.
The concentrate was purified through column chromatography to
give the title compound. 218 mg.
1H-NMR(DMSO-d6) 88.50(s,lH), 8.28(t,lH), 8.12(d,lH),
8.00(d,lH), 7.64(m,2H), 7.39(m,lH), 4.76(m,4H), 4.15(t,lH),
3.78(dd,lH), 3.42(t,2H), 2.10(s,3H), 1.82(s,3H)
<EXAMPLE 41>
Preparation of (S)-[N-3-(4-(2-Hydroxyacetylaminopyridin-5-
yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl aaetamide
In a mixture of methanol (1 ml) and chloroform (1 ml)
was dissolved 100 mg of . (S)-[N-3-(4-(2-acetoxyacetyl
aminopyridin-5-yl)-3-fluorophenyl)-2-oxo-5-
oxazolidinyl]methyl acetamide, following dropwise addition of
a 1 N KOH solution at room temperature. Reaction was
performed at room temperature for 1 hour with stirring. After
being added with water, the reaction mixture was extracted
with ethyl acetate. The organic layer thus separated. was
washed with brine, dehydrated, filtered.. and concentrated
under vacuum to give a solid. It was recrystallized in
86
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
methylenechloride and hexane to provide the-title compound.
50 mg.
~H-NMR(DMSO-d6) s8.50(s,lH), 8.28(d,lH), 8.17(d,lH),
7.99(d,lH), 7.64(m,2H), 7.42(dd,lH), 5.75(t,lHO, 4.76(m,lH),
4:13(t,lH), 4.05(d,2H), 3.79(dd,lH), 3.42(t,2H), 1.83(s,3H).
<EXAMPLE 42>
Preparation of (S)-[N-3-(4-(2-Imidazol-1-ylpyridin-5-yl)-3-
fluorophenyl)-2-oxo-5-oxazolidinyl]methyl acetamide
With the exception of starting with 2-imidazolyl-5-
bromopyridine, the same procedure as in Example 38 was
carried out to give the title compound.
1H-NMR(CDC13) s8.61(s,lH), 8.39(s,lH), 8.00(dd,lH),
7.87(s,lH), 7.61(dd,lH), 7.49(m,2H), 7.32(dd,lH), 7.21(s,lH),
6.13(t,lH), 4.80(m,lH), 4.08(t,lH), 3.81(dd,lH), 3.61(m,2H),
2.02(s,3H)
<EXAMPLE 43>
Preparation of (S)-[N-3-(4-(2-(4-Morpholinyl)-pyridin-5-yl)-
3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl acetamide
With the exception of starting with 2-(4-morpholinyl)-
5-bromopyridine, the same procedure as in Example 38 was
carried out to give the title compound.
87
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
1H-NMR{CDC13) s8.31(s,lH), 7.87(dd,lH), 7.50(dd,lH),
7,.38(t,lH), 7.20(dd,lH), 6.65(d,lH), 6.55(t,lH), 4.79(m,lH),
4.04(t,lH), 3.81(m,5H), 3.62(m,2H), 3.52{m;4H), 2.00(s,3H)
<EXAMPLE 44>
Preparation of (S)-[N-3-(4-(2-Triphenylmethylaminopyridin-5-
yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl acetamide
With the exception of starting ~ with 2-
triphenylmethylamino-5-bromopyridine, the same procedure as
in Example 38 was carried out to give the title compound.
<EXAMPLE 45>
Preparation of (S)-[N-3-(4-(2-Methoxypyridin-5-yl)-3-
fluorophenyl)-2-oxo-5-oxazolidinyl]methyl acetamide
In 5 ml of dimethylformamide was dissolved 430 mg of
(S)-[N-3-(4-trimethylstannyl-3-fluorophenyl)-2-oxo-5-
oxazolidinyl]methyl acetamide which was then reacted with 610
mg of 2-methoxy-5-iodopyridine in the presence of 0.36 ml of
triethyl amine with the catalytic aid of 292 mg of
dichlorobistriphenylphosphine palladium {II) at 100 °C for 2
hours after the addition of the reactants at room
temperature. Water was then added to the reaction mixture,
followed by extraction with ethyl acetate. The organic layer
88
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
was washed with brine, dehydrated, filtered and concentrated
in vacuo. The concentrate was purified by column
chromatography to give the title compound. 200 mg.
~H-NMR(CDC13) 68.25(s,lH), 7.70(m,lH), 7.51(dd,lH),.
7.38(t,lH), 7.22(m,lH), 6.78(d,lH), 6.65(t,lH), 4~80(m,lH),
4.08(t,lH), 3.97(s,3H), 3.81(dd;lH), 3.65(m,2H), 2.00(s,3H)
<EXAMPLE 46>
Preparation of (S)-[N-3-(4-(2-Methoxyacetylaminopyridin-5-
yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl aaetamide
In 2.5 ml of dimethylformamide was dissolved 200 mg of
(S)-[N-3-(4-trimethylstannyl-3-fluorophenyl)-2-oxo-5-
oxazolidinyl]methyl acetamide and the solution was added with
295 mg of methoxyacetylamino-5-bromopyridine, . 0.17 ml of
triethyl amine, and 135 mg of dichlorobistri phenylphosphine
palladium (II). Reaction was carried out at 100.°C for 2
hours with stirring. Water was added to the reaction mixture,
followed by extraction with ethyl acetate. The organic layer
thus separated was washed with brine, dehydrated, filtered,
and concentrated under vacuum. Column chromatography of the
concentrate provided the title compound. 47 mg.
89
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
IH-NMR(DMSO-d6) s8.50(s,lH), 8.20(t,lH), 8.15(d,lH),
7.97(d,lH), 7.64(m,2H), 7.42(m,lH), 4.78(m,lH), 4.16(t,lH),
4.09(s,3H), 3.79(dd,lH), 3.42(t,2H), 3.37(s,3H), 1.83(s,3H)
<EXAMPLE 47>
Preparation of (S)-[N-3-(4-(2-(4-Triphenylmethylpiperazin-1-
yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetamide
With the exception of starting with 2-(4-
triphenylmethylpiperazin-1-yl)-5-bromopyridine, the title
compound was prepared in a manner similar to that of Example
38.
<EXAMPLE 48>
Preparation of (S)-[N-3-(4-(2-Triphenylmethylaminopyridin-5-
yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl acetamide
Hydrochloride
With the exception of starting with 2-
triphenylmethylamino-5-bromopyridine, the title compound was
prepared in a manner similar to that of Example 38.
<EXAMPLE 49>
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
Preparation of (S)-[N-3-(4-(2-Azidopyridin-5-yl)-3-
fluorophenyl)-2-oxo-5-oxazolidinyl]methyl acetamide
With the exception of starting with 2-azido-5-
bromopyridine, the title compound was prepared in a manner
similar to that of Example 38.
<EXAMPLE 50>
Preparation of (S)-[N-3'-(4-(2--HydroXymethylpyridin-4-yl)-3-
fluorophenyl)-2-oxo-5-oxazolidinyl]methyl acetamide
In a mixture of ethanol (3 ml) and tetrahydrofuran (1.3
ml) was dissolved 100 mg of (S)-[N-3-(4-(2-
methoxycarbonylpyridin-4-yl)-3-fluorophenyl)-2-oxo-5-
oxazolidinyl]methyl acetamide and the solution was added with
29.3 mg of sodium borohydride and 32.8 mg of lithium chloride
at room temperature. After being reacted at room temperature
for 2 hours with stirring, the reaction mixture was added
with ethyl acetate. The organic layer thus separated was
washed with sodium hydrogen carbonate (NaHC03) and brine,
dried, filtered, and concentrated in vacuo. Purification of
the concentrate in ethyl acetate provided the title compound.
35 mg.
91
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
iH-NMR(DMSO-d6) s8.54(d,lH), 8.28(t,lH), 7.70(m,3H),
7.45(m,2H), 5.52(t,lH), 4.76(m,lH), 4.62(d,2H), 4.17(t,lH),
3.79(dd,lH), 3.42(t,2H), 1.83(s,3H)
<EXAMPLE 51>
Preparation of (S)-[N-3-(4-(2-Methoxycarbonylpyridin-4-
yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl acetamide
In 9.5 ml of dimethylformamide was dissolved 790 mg of
(S)-[N-3-(4-trimethylstannyl-3-fluorophenyl)-2-oxo-5-
oxazolidinyl]methyl acetamide which was then reacted with 1 g
of methyl 4-iodopyridin-2-Carboxylate in the presence of 0.67
ml of triethyl amine with the catalytic aid of 533 mg of
dichlorobistriphenylphosphine palladium (II) at 100 °C for 3
hours after the addition of the reactants at room
temperature.
1H-NMR(DMSO-d6) 58.78(d,lH), 8.27(m,2H), 7.70(m,3H),
7.47(dd,2H), 4.76(m,lH), 4.20(t,lH), 4.18(s,3H), 3.90(dd,lH),
3.43(t,2H), 1.83(s,3H)
<EXAMPLE 52>
Preparation of (S)-[N-3-(4-(2-Dimethylaminocarbonylpyridin-4-
yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl aaetamide
92
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
In 5 ml of dimethylformamide was dissolved 380 mg of
(S)-[N-3-(4-trimethylstannyl-3-fluorophenyl)-2-oxo-5-
oxazolidinyl]methyl acetamide and the solution was added with
300 mg of N,N-2-dimethylaminocarbonyl-4-iodopyridine, 0.32 mg
of triethyl amine and 255 mg of dichlorobistriphenylphosphine
at room temperature. Reaction was carried out at 100 °C for 2
hours with stirring. Water was added to the reaction mixture,
followed by extraction with ethyl acetate. The organic layer
thus separated was washed with brine, dehydrated, filtered
and concentrated in vacuo. Purification of the concentrate
through column chromatography gave the title compound. 91 mg.
1H-NMR(DMSO-d6) 58.63(d,lH), 8.27(t,lH), 7.70(m,4H),
7.45(dd,lH), 4.76(m,lH), 4.17(t,lH), 3.79(dd,lH), 3.42(t,2H),
3.01(s,3H), 2.96(s,3H), 1.83(s,3H)
<EXAMPLE 53>
Preparation of (S)-[N-3-(4-(2-Hydroxypyridin=5--yl)-3-
fluorophenyl)-2-oxo-5-oxazolidinyl]methyl acetamide
The title compound was prepared in a manner similar to
that of Example 38, with the exception of using 2-hydroxy-5-
bromopyridine as a starting material.
93
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
<EXAMPLE 54>
Preparation of (S)-[N-3-(4-(N-2-Dimethylaminoaaetoxyacetyl
aminopyridin-4-yl)-3-fluorophenyl)-2-oxo-5-
oxazolidinyl]methyl acetamide
In 2.5 ml of pyridine was dissolved 200 mg of (S)-[N-3-
(4-(N-2-hydroxyacetylaminopyridin-4-yl)-3-fluorophenyl)-2-
oxo-5-oxazolidinyl]methyl acetamide and the solution was
added with 205 mg of N,N-dimethylglycine, 381 mg of 1-(3-
dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride 91 mg
of 4-dimethylaminopyridine at room temperature. Reaction was
carried out at room temperature for 15 hours with stirring.
Water was added to the reaction mixture, followed by
extraction with ethylacetate. The organic layer thus
separated was washed with brine, dehydrated, filtered, and
concentrated under vacuum. The concentrate was purified
through column chromatography to obtain the title compound.
110 mg.
<EXAMPLE 55>
Preparation of (S)-[N-3-(4-(2-Methylaminopyridin-5-yl)-3-
fluorophenyl)-2-oxo-5-oxazolidinyl]methyl acetamide
In 6 ml of tetrahydrofuran was dissolved 500 mg of (S)-
[N-3-(4-trimethylstannyl-3-fluorophenyl)-2-oxo-5-
94
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
oxazolidinyl]methyl acetamide which was then reacted with 564
mg of 2-methylamino-5-iodopyridine in the presence of 153 mg
of lithium chloride 153 mg with the catalytic aid of 278 mg
of tetrakistriphenylphosphine palladium (II) for 48 hours
under reflux. Water was added to the reaction mixture which
was then extracted with ethyl acetate. The organic layer thus
separated was washed with brine, dehydrated, filtered, and
concentrated under vacuum. The concentrate was purified by
column chromatography to give the title compound. 181 mg.
1H-NMR(DMSO-d6) s8.26(t,lH), 8.16(s,lH), 7.58(m,2H),
7.35(dd,lH), 6.70(dd,lH), 6.50(d,lH), 4.74(m,lH), 4.17(t,lH),
3.79(dd,lH), 3.43(t,2H), 2.78(d,3H), 1.82(s,3H)
<EXAMPLE 56>
Preparation of (S)-[N-3-(4-(2-Dimethylaminopyridin-5-yl)-3-
fluorophenyl)-2-oxo-5-oxazolidinyl]methyl acetamide~
The title compound was prepared in a manner similar to
that of Example 55, with the exception of using 2-
dimethylamino-5-iodopyridine.
1H-NMR(DMSO-d6) &8.31(m,2H), 7.71(dd,lH), 7.60(m,3H),
7.34(dd,lH), 6.73(d,lH), 4.73(m,lH), 4.14(t,lH), 3.76(dd,lH),
3.42(t,2H), 3.05(s,6H), 1.82(s,3H)
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
<EXAMPLE 57>
Preparation of (S)-[N-3-(4-(2-Hydroxyacetylaminopyridin-5-
yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl acetamide
Hydrochloride
In a mixture of methanol and chloroform was dissolved
500 mg of (S)-[N-3-(4-(2-hydroxyacetylaminopyridin-5-yl)-3-
fluorophenyl)-2-oxo-5-oxazolidinyl]methyl acetamide which was
then reacted with 0.5 m1 of hydrochloride at room temperature
for 1 hour with stirring. The reaction mixture was
concentrated under vacuum and the concentrate was purified
many times with ethyl ether to give the title compound. 520
mg.
1H-NMR(DMSO-d6) 810.01(s,lH), 8.53(s,lH), 4.75(m,lH),
4.18(t,lH), 4.08(s,2H), 3.78(dd,lH), 3.42(t,2H), 1.83(s,3H)
<EXAMPLE 58>
Preparation of (S)-[N-3-(4-(2-Hydroxyacetylaminopyridin-5-
yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl acetamide
Hydroxypropylmethylcellulose Multiploid?
In a solvent mixture of ethanol and methylene chloride,
a mixture of (S)-[N-3-(4-(2-hydroxyacetylaminopyridin-5-yl)-
3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl acetamide and
hydroxypropylmethyl cellulose (HPMC) in a weight proportion
96
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
of 2:1 was slowly dissolved. After 2 hours of stirring, the
solvent was evaporized by use of spray drying to give the
title compound.
<EXAMPLE 59>
Preparation of (S)-[N-3-(4-(2-Acetoxypyridin-5-yl)-3-
fluorophenyl)-2-oxo-5-oxazolidinyl]methyl acetamide
The title compound was prepared in a manner similar to
that of Example 38, with the exception of using 2-acetoxy-5=
bromopyridine as a starting material.
<EXAMPLE 60>
Preparation of (S)-[N-3-(4-(2-Methoxymethyloxypyridin-5-yl)-
3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl acetamide
The title compound was prepared in a manner similar to
that of Example 38, with the exception of using 2-methoxyoxy-
5-bromopyridine as a starting material.
<EXAMPLE 61>
Preparation of (S)-[N-3-(4-(2-Methanesulfonyloxy
pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetamide
97
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
The title compound was prepared in a manner similar to
that of 38, with the exception of using methylsulfonyloxy-5-
bromopyridine as a starting material.
<EXAMPLE 62>
Preparation of (S)-[N-3-(4-(2-Aminocarbonylpyridin-4-yl)-3-
fluorophenyl)-2-oxo-5-oxazolidinyl]methyl acetamide
The title compound was prepared in a manner similar to
that of Example 38, with the exception of using 2-
aminocarbonyl-4-bromopyridine as a starting material.
<EXAMPLE 63>
Preparation of (S)-[N-3-(4-(2-Dimethylaminoacetoxymethyl
pyridin-4-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetamide
In 2 ml of pyridine was dissolved 155 mg of (S)-[N-3-
(4-(2-hydroxymethylpyridin-4-yl)-3-fluorophenyl)-2-oxo-5-
oxazolidinyl]methyl acetamide and the solution was dropwise
added with 318 mg of N,N-dimethylglycine, 662 mg of 1-(3-
dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride 158 mg
of 4-dimethylaminopyridine individually and stirred for 15
hours at room temperature. Water was then added to the
reaction mixture, followed by extraction with ethyl acetate..
98
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
The organic layer was washed with brine, dehydrated, filtered
and concentrated in vacuo. The concentrate was subjected to
column chromatography to give the title compound. 113 mg.
1H-NMR(CDC13) 88.48 (d,lH), 5.18(s,2H), 4.75(ni,lH),
4.00(t,lH), 3.76(dd,lH), 3.60(bs;2H), 3.19(s,2H), 2.25(s,6H),
1.93(s,3H)
<EXAMPLE 64>
Preparation of (S)-[N-3-(4-(2-(2-Hydroxyethyl)aminocarbonyl
pyridin-4-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetamide
In 3 m1 of dimethylformamide was dissolved 245 mg of
(S)-[N-3-(4-trimethylstannyl-3-fluorophenyl)-2-oxo-5-oxazol
idinyl]methyl acetamide 245 mg which was then reacted with
345 mg of 2(2-hydroxyethyl)aminocarbonyl-4-iodopyridine in
the presence of 0.21 ml of triethyl amine with the catalytic
aid of 166 mg of dichlorobistriphenylphosphine palladium (II)
at 100 °C for 3 hours . after the addition of the reactants at
room temperature. Water was then added to the reaction
mixture, followed by extraction with ethyl acetate. ~ The
organic layer thus separated was washed with brine,
dehydrated, filtered, and concentrated under vacuum. Through
99
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
column chromatography, the concentrate was purrfled to the
title compound. 60 mg.
~H-NMR(DMSO-d6) s8.69(d,lH), 8.27(t,lH), 8.19(s,lH),
7.81(m,lH), 7.70(m,lH), 7.45(dd,2H), 4.79(m,lH), 4.17(t,lH),
3.79(dd,lH), 3.51(t,2H), 3.43(m,4H), 1.83(s;3H)
<EXAMPLE 65>
Preparation of (S)-[N-3-(4-(2-N,N-di(2-Hydroxyethyl)amino
carbonylpyridin-4-yl)-3-fluorophenyl)-2-oxo-5-
oxazolidinyl]methyl acetamide
Starting with N,N-di(2-hydroxyethyl)aminocarbonyl-4-
iodopyridine, the title compound was prepared in a manner
similar to that of Example 64.
1H-NMR(DMSO-d6) 88.60(d,lH), 8.26(t,lH), 7.64(m,4H),
7.45(m,lH), 4.80(m,3H), 4.17(t,lH), 3.79(dd,lH), 3.54(m,lOH),
1.83(s,3H)
<EXAMPLE 66>
Preparation of (S)-[N-3-(4-(2-Piperazin-1-ylpyridin-5-yl)-3-
fluorophenyl)-2-oxo-5-oxazolidinyl]methyl acetamide
Hydrochloride
In tetrahydrofuran, 200 mg of (S)-[N-3-(4-(2-(4-
triphenylmethylpiperazin-1-yl)pyridin-5-yl)-3-fluorophenyl)-
100
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
2-oxo-5-oxazolidinyl]methyl acetamide was reacted with 1 ml
of a 1N HC1 solution at room temperature for one day with
stirring to give a solid which was then filtered. Washing the
filtrate with tetrahydrofuran and ether provided the title
compound. 110 mg. Yield 88%.
<EXAMPLE 67>
Preparation of (S)-[N-3-(4-(2-(4-Acetoxyacetylpiperazin-1-
yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetamide
In tetrahydrofuran was dissolved 30 mg of (S)-[N-3-(4-
(2-piperazin-1-ylpyridin-5-yl)-3-fluorophenyl)-2-oxo-5-
oxazolidinyl]methyl acetamide which was then acetylated with
16 ~,1 of acetoxyacetyl chloride in the presence of 30 ~,l of
triethyl amine at room temperature for 20 min with stirring....
Water was then added to the reaction mixture, followed by
extraction with chloroform. The organic layer thus separated
was washed with brine, dehydrated, filtered, and concentrated
in' vacuo. The concentrate was purified through column
chromatography to provide the title compound. 23 mg.
<EXAMPLE 68>
101
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
Preparation of (S)-[N-3-(4-(2-(4-Benzyloxyacetylpiperazin-1-
yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetamide
Starting with benzyloxyacetylpiperazinyl-5-bromo
pyridine, the title compound was prepared in a manner similar
to that of Example 38.
<EXAMPLE 69>
Preparation of (S)-[N-3-(4-(2-(4-Hydroxyacetylpiperazin-1-
yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetamide
In methanol, 220 mg of the compound prepared in Example
68 was reacted with 1 ml of a 1 N KOH solution at room
temperature with stirring. After removal of excess methanol
by vacuum concentration, water was added to the residue,
followed by extraction with~chloroform. The organic. layer
thus separated was dehydrated, filtered, and concentrated
under vacuum. The concentrate was subjected to column
chromatography to provide the title compound. 189 mg.
1H-NMR(CDC13) 88.35(s,lH)~, 7.70(d,lH), 7.50(dd,lH),
7.37(t,lH), 7.27(dd,lH), 6.70(d,lH), 4.74(m,lH), 4.21(d,2H),
4.06(t,lH), 3.80(m,3H), 3.62(m,6H), 3.39(m,2H), 2.01(s,3H)
102
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
<EXAMPLE 70>
Preparation of (S)-[N-3-(4-(2-(4-Dimethylaminoacetoxyacetyl
piperazin-1-yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazol
idinyl]methyl acetamide
Starting with (S)-[N-3-(4-(2-(4-hydroxyacetylpiper
azin-1-yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolid
inyl]methyl acetamide, the title compound was prepared in a
manner similar to that of Example 63.
1H-NMR(DMSO-d6) 58.34(s,lH), 7.53(m,lH), 7.37(dd,lH),
7.33(t,lH), 7.26(dd,lH), 6.72(d,lH), 5.80(t,lH), 4.83(m,3H),
3.79(m,,7H), 3.54(t,4H), 3.33(d,2H), 2.40(s,6H), 2.01(s,3H)
<EXAMPLE 71>
Preparation of (S)-[N-3-(4-(2-(4-Chloroacetylpiperazin-1-
yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetamide
Starting with chloroacetyl chloride, the title compound
was prepared in a manner similar to that of Example 67.
1H-NMR(CDC13) 58.35(s,lH), 7.72(m,lH), 7.50(dd,lH),
7.41(t,2H), 6.74(d,lH), 6.16(t,lH), 4.79(m;lH), 3.79(m,l3H),
2.02(s,3H)
<EXAMPLE 72>
103
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
Preparation of (S)-[N-3-(4-(2-(4-Acetylpiperazin-1-
yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetamide
Starting with acetyl chloride, the title. compound was
prepared in a manner similar to that of Example 67:
<EXAMPLE 73>
Preparation of (S)-[N-3-(4-(2-(4-Methoxyacetylpiperazin:-1-
yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetamide
Starting with methoxyacetyl chloride, the title
compound was prepared in a manner similar to that of Example
67.
<EXAMPLE 74>
Preparation of (S)-[N-3-(4-(2-(4-Morpholinylacetylpiperazin-
1-yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-
oxazolidinyl]methyl aaetamide
In tetrahydrofuran was dissolved 30 mg of the compound
prepared in Example 72, which was then reacted with 10.4 ~,1
of morpholine in the presence of 25 ~,l of triethyl amine at
room temperature for 2 hours with stirring. The reaction
mixture was concentrated in vacuo, and purification of the
104
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
concentrate through column chromatography provided the title
compound. 30 mg.
<EXAMPLE 75>
Preparation of (S)-[N-3-(4-(2-(4-Methoxycarbonylmethylamino
acetylpiperazin-1-yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-
oxazolidinyl]methyl acetamide
With the exception of using ethoxycarbonylmethylamino
hydrochloride as a starting material, the same procedure as
in Example 74 was conducted to give the title compound.
1H-NMR(CDC13) 58.34(s,lH), 7.70(dd,lH), 7.54(dd,lH),
7.37(t,lH), 7.27(dd,lH), 6.68(d,lH), 5.98(m,lH), 4.76(m,lH),
4.06(t,lH), 3.90(m,lH), 3.782(m,8H), 3.63(m,3H), 3.52(m,5H)
3.39(m,lH), 2.01(s,3H)
<EXAMPLE 76>
Preparation of (S)-[N-3-(4-(2-(4-Ethoxycarbonylpiperidin-1-
yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetamide
With the exception of using (4-ethoxycarbonylpiperidin-
1-yl)-5-bromopyridine as a starting material, the same
procedure as in Example 38 was conducted to give the title
compound.
105
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
<EXAMPLE 77>
Preparation of (S)-[N-3-(4-(2-Azidomethylpyridin-4-yl)-3-
fluorophenyl)-2-oxo-5-oxazolidinyl]methyl acetamide
With the exception of using , 2-aaidoinethyl-4-
bromopyridine as a starting material, the same procedure as
in Example 38 was conducted to give the title compound.
1H-NMR(DMSO-d6) s8.67(d,lH), 8.27(t,lH), 7.72(d,lH),
7.68(dd,lH), 7.62(s,lH), 7.57(d,lH), 7.44(dd,lH),. 4.76(m,lH),
4.56(s,3H), 4.17(t,lH), 3.79(dd,lH), 3.42(t,2H), 1.82(s,3H)
<EXAMPLE 78>
Preparation of (S)-[N-3-(4-(2-Imidazole-1-yl)methylpyridin-4-
yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl acetamide
With the exception of using 2-imidazolylmethyl-4-
bromopyridine as a starting material, the same procedure as
in Example 38 was conducted to give the title compound.
1H-NMR(DMSO-d6) 58.55(d,lH), 8.18(t,lH), 7.68(s,lH),
7.58(m,2H), 7.40(m,2H), 7.28(s,lH), 7.16(s,lH), 6.81(s,lH),
5.22(s,2H), 4.68(m,lH), 4.16(t,lH), 3.69(dd,lH), 3.38(t,2H),
1.73(s,3H)
<EXAMPLE 79>
106
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
Preparation of (S)-[N-3-(4-(2-Morpholin-4-yl)methylpyridin-4-
yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl acetamide
TnTith the exception of using morpholinylmethyl-4-
bromopyridine as a starting material, the same procedure as
in Example 38 was conducted to give the title compound.
1H-NMR(DMSO-d6) &8.56(d,lH), 8.28(t,lH), 7.60(m;3H),
7.45(m,2H), 4.78(m,lH), 4.17(t,LH), 3.77(dd,lH), 3.57(m,4H),
3.42(m,2H), 2.43(m,4H), 1.82(s,3H)
<EXAMPLE 80>
Preparation of (S)-[N-3-(4-(2-Acetylthiomethylpyridin-4-yl)-
3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl acetamide
With the exception of using acetylthiomethyl-4-
bromopyridine as a starting material, the same procedure as.
in Example 38 was conducted to give the title compound.
1H-NMR(CDC13) 58.56(d,lH), 7.58(dd,lH), 7.49(m;2H),
7.32(m,2H), 6.03(t,lH), 4.81(m,lH), 4.28(s,2H), 4.09(t,lH),
3.81(dd,lH), 3.69(m,2H), 2.35(s,3H), 2.01(s,3H)
<EXAMPLE 81>
Preparation of (S)-[N-3-(4-(2-Mercaptomethylpyridin-4-yl)-3-
fluorophenyl)-2-oxo-5-oxazolidinyl]methyl acetamide
107
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
In methanol, 58 mg of the compound prepared in Example
82 was reacted with a 1 N NaOH solution at room temperature
for 5 min with stirring. Water was added to the reaction
mixture, followed by extraction with ethyl acetate. The
organic layer thus separated was dehydrated, filtered, and
concentrated under vacuum. Through column chromatography, the
concentrate was purified to provide the title compound. 15
mg.
zH-NMR(CDC13) 58.54(d,lH), 6.18(t,lH), 4.81(m,lH),
4.10(t,lH), 3.85(d,2H), 3.65(dd,2H), 2.01(s,3H)
<EXAMPLE 82>
Preparation of (S)-[N-3-(4-(2-(4-Methansulfonyloxyacetyl
piperazin-1-yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazol
idinyl]methyl acetamide
In tetrahydrofuran, 30 mg of the compound prepared in
Example 70 was reacted with 15 ~,l of methanesulfonylchloride
in the presence of 30 ~,l of triethylamine at room temperature
for 1 hour with stirring. Water was added to the reaction
mixture, followed by extraction with ethyl acetate. The
organic layer thus separated was dehydrated, filtered, and
concentrated under vacuum. Through column chromatography, the
108
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
concentrate was purified to provide the title compound. 20
mg.
lH-NMR(CDC13) s8.34(s,lH), 7.42(dd,lH), 7.52(dd,lH),
7.38(t,lH), 7.27(dd,lH), 6.72(d,lH), 6.17(t,lH), 4.94(s,lH),
4.81(m,lH), 4.10(t,lH), 3.75(m,l3H), 3.24(s,3H), 2.O1(s,3H)
<EXAMPLE 83>
Preparation of (S)-[N-3-(4-(2-(4-Acryloylpiperazin-1-yl)
pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetamide
With the exception of using acryloylchloride as a
starting material, the same procedure as in Example 68 was
carried out to provide the title compound.
<EXAMPLE 84>
Preparation of (S)-[N-3-(4-(2-(4-Ethoxyoxoacetylpiperazin-1-
yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetamide
With the exception of using ethoxyacetyl chloride as a
starting material, the same procedure as in Example 67 was
carried out to provide the title compound.
<EXAMPLE 85>
109
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
Preparation of (S)-[N-3-(4-(2-(4-Nicotinoylpiperazin-1-
yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazol~idinyl]methyl
acetamide
With the exception of using nicotinoyl chloride as a
starting material, the same procedure as in Example .67 was
carried out to provide the title compound.
<EXAMPLE 86>
Preparation of (S)-[N-3-(4-(2-(4-Pivaloylpiperazin-1-
yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetamide
With the exception of using pivaloylchloride as a
starting material, the same procedure as in Example 67 was
carried out to provide the title compound.
<EXAMPLE 87>
Preparation of (S)-[N-3-(4-(2-(4-Tetrabutylacetylpiperazin-1-
yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetamide
With the exception of using tetrabutylacetylchloride as
a starting material, the same procedure as in Example 67 was
carried out to provide the title compound.
110
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
<EXAMPLE 88>
Preparation of (S)-[N-3-(4-(2-(4-Nicotinoyloxyacetyl
piperazin-1-yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazol
idinyl]methyl acetamide ,
With the exception of using nicotinoylacetylchloride as
a starting material, the same procedure as in Example 67 was
carried out to provide the title compound.
<EXAMPLE 89>
Preparation of (S)-[N-3-(4-(2-(4-(2,5-Dimethoxyphenylacetyl)
piperazin-1-yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazol
idinyl]methyl acetamide
With the exception of using 2,5-dimethoxyacetylchloride
as a starting material, the same procedure as in Example 67
was carried out to provide the title compound.
<EXAMPLE 90>
Preparation of (S)-[N-3-(4-(2-(4-(3,3-Dimethylacryloyl)
piperazine-1-yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazol
idinyl]methyl acetamide
With the exception of using 2,3-
dimethylacryloylchloride as a starting material, the same
111
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
procedure as in Example 67 was carried out to provide the
title compound.
<EXAMPLE 91>
Preparation of (S)-[N-3-(4-(2-(4-(2,6-Dimethoxybenzoyl)
piperazin-1-yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazol
idinyl]methyl acetamide
With the exception of using 2,6-
dimethoxybenzoylchloride as a starting material, the same
procedure as in Example 67 was carried out to provide the
title compound.
<EXAMPLE 92>
Preparation of (S)-[N-3-(4-(2-(4-(2-
Trifluoromethyl)benzoyl)piperazin-1-yl)pyridin-5-yl)-3-
fluorophenyl]-2-oxo-5-oxazolidinyl]methyl acetamide
With the exception of using 2-trifluoromethylbenzoyl
chloride as a starting material, the same procedure as in
Example 67 was carried out to provide the title compound.
<EXAMPLE 93>
112
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
Preparation of (S)-[N-3-(4-(2-(4-(4-Trifluoromethyl)benzoyl)
piperazin-1-yl)pyridin-5-yl)-3-fluorophenyl]-2-oxo-5-
oxazolidinyl]methyl acetamide
With the exception of using 4-trifluoromethylbenaoyl
chloride as a starting material, the same procedure as in
Example 67 was carried out to provide the title compound.
<EXAMPLE 94>
Preparation of (S)-[N-3-(4-(2-(4-Benzylcarbonylpiperazin-1-
yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetamide
With the exception of using phenyl acetyl chloride as a
starting material, the same procedure as in Example 67 was
carried out to provide the title compound.
<EX.AMPLE 95>
Preparation of (S)-[N-3-(4-(2-(4-Crotonylpiperazin-1-
yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetamide
With the exception of using crotonylchloride as a
starting material, the same procedure as in Example 67 was
carried out to provide the title compound.
113
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
<EXAMPLE 96>
Preparation of (S)-[N-3-(4-(2-(4-Trifluoromethylcarbonyl
piperazin-1-yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-
oxazolidinyl]methyl acetamide
With the exception of using trifluoroacetyl chloride as
a starting material, the same procedure as in Example 67 was
carried out to provide the title compound.
<EXAMPLE 97>
Preparation of (S)-[N-3-(4-(2-(4-n-Valerylpiperazin-1-yl)
pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetamide
With the exception of using valeryl chloride as a
starting .material, the same procedure .as in Example 67 was
carried out to provide the title compound.
<EXAMPLE 98>
Preparation of (S)-[N-3-(4-(2-(4-Phenyloxycarbonylpiperazin-
1-yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-
oxazolidinyl]methyl acetamide
With the exception of using phenylCarbonyl Chloride as
a starting material, the same procedure as in Example 67 was
carried out to provide the title compound.
114
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
<EXAMPLE 99>
Preparation of (S)-[N-3-(4-(2-(4-Allyloxycarbonylpiperazin-1-
yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetamide
With the -exception of using allyloxycarbonyl chloride
as a star ing material, the same procedure as in Example 67
was carried out to provide the title compound.
<EXAMPLE 100>
Preparation of (S)-[N-3-(4-(2-(4-(1-Chloroethyl)oxycarbonyl
piperazin-1-yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazol
idinyl]methyl acetamide
With the exception of using 1-chloroethyloxycarbonyl
chloride as a starting material, the same' procedure as in
Example 67 was carried out to provide the title compound.
<EXAMPLE 101>
Preparation of (S)-[N-3-(4-(2-(4-(4-Nitrobenzyl)oxycarbonyl
piperazin-1-yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazol
idinyl]methyl acetamide
115
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
With the exception of using 4-nitrobenzyloxycarbonyl
chloride as a starting material, the same procedure as in
Example 67 was carried out to provide the title compound.
<EXAMPLE 102>
Preparation of (S)-[N-3-(4-(2-(4-Benzyloxycarbonylpiperazin-
l-yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-
oxazolidinyl]methyl acetamide
With the exception of using benzyloxycarbonyl,chloride
as a starting material, the same procedure as in Example 67
was carried out to provide the title compound.
<EXAMPLE 103>
Preparation of (S)-[N-3-(4-(2-(4-(9-Fluorenylmethyloxy
carbonyl)piperazin-1-yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-
5-oxazolidinyl]methyl acetamide
With the exception of using 9-fluorenyhmethyloxy
carbonyl chloride as a starting material, the same procedure
as in Example 67 was carried out to provide the title
compound.
<EXAMPLE 104>
116
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
Preparation of (S)-[N-3-(4-(2~-(4-(2-Pyrimidinyl)piperazin-1-
yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazblidinyl]methyl
acetamide
In dimethylacetamide was dissolved 20 mg of (S)-[N-3-
(4-(2-piperazin-1-yl)pyridin-5-yl)-3-fluorophenyl]-2-oxo-5-
oxasolidinyl]methyl acetamide which was then reacted with 38
nig of 2-bromopyridine in the presence of 63 ~1 of
diisopropylethylamine at 50 °C for 20 hours with stirring.
Purification with column chromatography provided the title
compound. 39 mg.
<EXAMPLE 105>
Preparation of (S)-[N-3-(4-(2-(4-Methoxycarbonylmethyl
piperazin-1-yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazol
idinyl]methyl acetamide
With the exception of using methoxycarbonylmethyl
chloride as a starting material, the same procedure as in
Example.67 was carried out to provide the title compound.
<EXAMPLE 106>
Preparation of (S)-[N-3-(4-(2-Fluoromethylpyridin-4-yl)-3-
fluorophenyl)-2-oxo-5-oxazolidinyl]methyl acetamide
117
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
In methylene chloride was dissolved 68 mg of (S)-[N-3-
(4-(2-hydroxymethylpyridin-4-yl)-3-fluorophenyl)-2-oxo-5-
oxazolidinyl]methyl acetamide which was then reacted with
0.03 ml of diethylaminosulfurtrifluoride (DAST) in the
presence of 0.04 ml of triethylamine at 0 °C for 2 hours with
stirring. Water was added to. the reaction mixture, followed
by extraction with methylene chloride. The organic layer thus
separated was dehydrated, filtered, and concentrated under
vacuum. Through column chromatography, the concentrate was
purified to provide the title compound. 20 mg.
1H-NMR(CDC13) s8.45(d,lH), 5.25(dd,lH),_ 5.02(dd,lH),
4.93(m,lH), 4.02(t,lH), 4.17(t,lH), 3.87(m,lH), 3.63(m,2H),
2.04(s,3H)
<EXAMPLE 107>
Preparation of (S)-[N-3-(4-(2-Cyanomethylpyridin-4-yl)-3-
flnorophenyl)-2-oxo-5-oxasolidinyl]methyl acetamide
Starting with 2-cyanomethyl-4-bromopyridine, the title
compound was prepared in a manner similar to that, of Example
38.
iH-NMR(CDC13) 88.59(d,lH), 6.10(t,lH), 4.82(m,lH),
4.13(t,lH), 3.98(s,2H), 3.79(dd,lH), 3.83(dd,2H),. 3.&8(m,2H),
2.02(s,3H)
118
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
<EXAMPLE 108>
Preparation of (S)-[N-3-(4-(2-methylpyridin-4-yl)-3-fluoro
phenyl)-2-oxo-5-oxazolidinyl]methyl acetamide
Starting with 2-methyl-4-bromopyridine, the title
compound was prepared in a manner similar to that of Example
38.
1H-NMR(DMSO-d6) 68.54 (d,lH), 8.27(t,lH),. 4.78 (m,lH),
4.17(t,lH), 3.80(dd,lH), 3.42(t,2H), 2.54(s,3H), 1.83(s',3H)
<EXAMPLE 109>
Preparation of (S)-[N-3-(4-(2-(4-(2-Hydroxy)ethylpiperazin-1-
yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetamide
Starting with 2-hydroxyethylpiperazinyl-5-bromo
pyridine, the title compound was prepared in a manner similar
to that of Example 38.
<EXAMPLE 110>
Preparation of (S)-[N-3-(4-(2-(4-(2-Acetoxy)ethylpiperazin-1-
yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetamide
119
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
Starting with 2-acetoxyethylpiperazinyl-5-bromo
pyridine, the title compound was prepared in a manner similar
to that of Example 38.
<EXAMPLE 111>
Preparation of (S)-[N-3-(4-(2-(4-Methoxycarbonylpiperazin-1-
yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetamide
Starting with 4-methoxycarbonylpiperazinyl-5-bromo
pyridine, the title compound was prepared in a manner similar
to that of Example 38.
<EXAMPLE 112>
Preparation of (S)-[N-3-(4-(2-(4-(2-Methanesulfonyloxy)ethyl
piperazin-1-yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazol
idinyl]methyl acetamide
In tetrahydrofuran was dissolved 30 mg of the compound
prepared in Example 76 and the solution was dropwise added
with 15 ~ul of methanesulfonyl chloride and 30 ~,l of triethyl
amine at room temperature. Reaction was conducted for 1 hour
with stirring. Water was added to~ the reaction mixture,
followed by extraction with ethyl acetate. The organic layer
thus separated was dehydrated, filtered, and concentrated
120
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
under vacuum. Through,column chromatography,. the concentrate
was purified to provide the title compound.. 20 mg:
<EXAMPLE 113>
Preparation of (S)-[N-3-(4-(2-(3-Hydroxymethylimidazol-1-
yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetamide
Starting with 3-hydroxymethylimidazolyl-5-bromo
pyridine, the title compound was prepared in a manner similar
to that of Example 38.
iH-NMR(DMSO-d6) ~9.80(s,lH), 8.79(s.lH), 8.31(m,3H),
8.11(d,lH), 7.64(m,2H), 7.45(dd,lH), 4.77(m,lH), 4.59(s,2H),
4.18(t,lH), 3.81(dd,lH), 3.43(t,2H), 1.83(s,3H)
<EXAMPLE 114>
Preparation of (S)-[N-3-(4-(2-Aminoacetylaminopyridin-5-yl)-
3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl acetamide
In 100 ml of pyridine was dissolved 10.13 g of N-t-
butoxycarbonylglycine and the solution was added with 5 g of
2-amino-5--bromopyridine, 13.85 g of 1-(3-dimethylamino
propyl)-3-ethylcarbodiimide hydrochloride and 7.06 g of 4-
dimethylaminopyridine, individually at room temperature.
Stirring was conducted for 15 hours at the same temperature.
121
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
Water was added to the reaction mixture which. was then
extracted with ethyl acetate. The organic layer thus
separated was washed with brine, dehydrated,, filtered, and
concentrated under vacuum to give. 5.58 g of 2-(N-t-
butoxycarbonylglycinylamino)-5-bromopyridine. This compound
was dissolved, , along with 5.82 g of (S)-[N-3-(4-
trimethylstannyl-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetamide, in 70 ml of dimethylformamide and added with 4.9
ml of triethyl amine and 2.97 g of
dichlorobistriphenylphosphine palladium (II) at room
temperature. Reaction was performed at 100 °C for 4 hours
with stirring. Water was added to the reaction mixture,
followed by extraction with ethyl acetate. The organic layer
was washed with brine, dehydrated, filtered and concentrated
under vacuum. Recrystallization of the concentrate provided
5.13 g of (S)-[N-3-(4-(2-(N-t-
butoxycarbonylglycinylaminopyridin-5-yl)-3-fluorophenyl)-2-
oxo-5-oxazolidinyl)methyl acetamide. This product was reacted
with 1.65 ml of trimethylsilyl iodide in chloroform at room
temperature for 30 min under a nitrogen atmosphere with
stirring. Following the addition of chloroform, the organic
layer thus separated was washed with brine, dehydrated,
filtered, and concentrated in vacuo. The concentrate was
122
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
purified through column chromatography to, provide the title
compound. 550 mg.
1H-NMR(DMSO-d6) 58.49(s,lH), 8.23(m.2H), 8.00(m,lH),
7.64(m,2H), 7.40(dd,lH), 4.75(m,lH), 4.16(t,lH), 3.77(dd,lH),
3.42(t,2H), 3.32(s,2H), 1.83(s,3H)
<EXAMPLE 115>
Preparation of (S)-[N-3-(4-(2-(4-Cyanopiperazin-1-yl)pyridin
-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl acetamide
In methanol, 500 mg of (S)-[N-3-(4-(2-piperazin-1-
ylpyridin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetamide hydrochloride was reacted with 192 mg of
cyanobromide in the presence of 295 mg of sodium acetate at
room temperature for 3 hours with stirring. Chloroform was
added to the reaction mixture, and the organic layer thus
separated was washed with brine, dehydrated, filtered and
concentrated under vacuum. The concentrate was purified
through column chromatography to provide the title compound.
480 mg. Yield 90 0.
<EXAMPLE 116>
123
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
Preparation of (S)-[N-3-(4-(2-(4-Carboxamideoximepiperazin-1-
yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetamide
In ethanol was dissolved 250 mg of (S)-[N-3-(4-(2-(4-
cyanopiperazin-1-yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-
oxazolidinyl]methyl acetamide and the solution was added ~iith
79 mg of hydroxylamine hydrochloride and 2l1 mg of sodium
carbonate. Reaction was conducted for 3 hours with refluxing.
Following the addition of chloroform, the organic layer thus
separated was washed with brine, dehydrated, filtered and
concentrated in vacuo. The concentrate was subjected ~to
column chromatography to give the title compound. 150 mg.
Yield 39 0.
<EXAMPLE 117>
Preparation of (S)-[N-3-(4-(2-(4-Oxopiperidin-1-yl)pyridin-5-
yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl acetamide
In a mixture of acetone ( 3 ml ) and water ( 1 ml ) , 3 . 3 g
of (S)-[N-3-(4-(2-(1,4-dioxa-8-,azaspiro(4,5)decan-8-yl)pyri
din-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl acetaur
ide was reacted with 4 g of. p-toluenesulfonic. acid for 24
hours under reflux. Following the addition of ethyl.acetate,
the organic layer thus separated was washed with brine,
124
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
dehydrated, filtered and concentrated in vacuo. Purification
of the concentrate through column chromatography gave the
title compound. 1.2 g. Yield 40 %.
1H-NMR(CDC13) 58.35(s,lH), 7:73(m,lH); 7.53(dd,lH),
7.42(t,lH), 7.25(m,lH), 6.80(d,lH), 6.12(t,lH), 4.79(m,lH),
4.09(t,lH), 3.98(t,4H), 3.78(m,lH), 3.67(m,2H), 2.52(t,4H),
2.01(s,3H) ..
<EXAMPLE 118>
Preparation of (S)-[N-3-(4-(2-Azidoacetylaminopyridin-5-yl)-
3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl aaetamide
In 6.2 ml of methylene chloride was dissolved 500 mg of
(S)-[N-3-('4-(2-hydroxyacetylaminopyridin-5-yl)-3-fluoro
phenyl)-2-oxo-5-oxazolidinyl]methyl acetamide which was then
reacted with 0.144 ml of methanesulfonyl chloride in. the
presence of 0.35 ml of triethyl amine at 0 °C for 1 hour with
stirring. Following the addition of methylene chloride, the
organic layer thus separated was washed with brine,
dehydrated, filtered and concentrated under vacuum to give
0.47 g of (S)-[N-3-(4-(2-methanesulfonyloxyacetyl
aminopyridin-5-yl)-3-fluorophenyl)-2-oxo-5-
oxazolidinyl]methyl acetamide. This intermediate was
dissolved in 5 ml of dimethylformamide and added with 1.5 g
125
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
of sodium azide at room temperature. Thereafter, reaction was
conducted at 100 °C for 2 hours with stirring. Following the
addition of ethyl acetate, the' organic layer thus separated
was washed with brine, dehydrated,,filterecl, and concentrated
under vacuum. The concentrated. was' subjected to column
chromatography to produce the title compound. 180 mg. Yield
34%.
1H-NMR(DMSO-d6) 510.83(s,lH), 8.51(s,lH), 8.28(t,lH),
8.18(d,lH), 8.00(dd,lH), 7.64(m,2H), 7.40(dd,lH), 4.76(m,4H),
4.21(t,lH), 4.13(s,2H), 3.78(dd,lH), 3.42(t,2H), 1.83(s,3H)
«EXAMPLE 119»
Preparation of (S)-[N-3-(4-(2-(1,2,3,4,6,7-Hexahydro-5-oxo-
1,4-diazepan-1-yl)-pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-
oxazolidinyl]methyl aCetamide
In 20 ml of formic acid,. 1.2 g of (S),-[N-3-(4-(2-(4-
oxopiperidin-1-yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-
oxazolidinyl]methyl acetamide, prepared in Example 117, was
reacted with 1.6 g of hydroxylamino-o-sulfonic acid at 100 °C
for 8 hours with stirring: The reaction mixture was
neutralized with sodium hydroxide, followed by extraction
with methylene chloride. The organic layer was washed with
brine, dehydrated, filtered, and concentrated in vacuo.
126
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
Purification of the concentrate with, column chromatography
provided the title compound. 120 mg.
1H-NMR(DMSO-d6) s8.30(S,1H), 8.26(t,lH), 7.74(m,lH),
7.59(m,3H), 7.38(dd,lH), 6.80(d,lH), 4.76(m,lH), 4.16(t,lH),
3.77(m,6H), 3.47(t,2H), 3.19(m,2H), 1.83(s,3H)
<EXAMPLE 120>
Preparation of (S)-[N-3-(4-(2-N-('Dimethylaminomethylene)
aminopyridin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]
ethyl acetamide
In methanol, 50 mg .of (S)-[N-3-(4-(2-aminopyridin-5-
yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl acetamide was
reacted with 58 ml of N,N-dimethylaminodimethoxymethane at
room temperature for 24 hours under reflux. Methylene
chloride was added to the reaction mixture. The organic layer
thus separated was then washed with brine, dehydrated,
filtered, and concentrated under vacuum, followed by
purification with column chromatography to provide the title
compound. 52 mg. Yield 90%.
1H-NMR(CDC13) 58.46(s,lH), 8.39(s,lH), 7.73(m,lH),
7.53(dd,lH), 7.47(d,lH), 7.27(m,lH), 7.00(d,lH), 6.04(t,lH),
4.80(m,lH), 4.08(t,lH), 3.81(dd,lH), 3.61(m,2H), 3.10(s,6H),
2.02(s,3H)
127
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
<EXAMPLE 121>
Preparation of (S)-[N-3-(4-(2-(4-Hydroxyiminopiperidin-1-
yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetamide
In, ethanol, 600 mg of (S)-[N-3-(4-(2-(4-oxopiperidin-1-
yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetamide~, prepared in Example 117, was reacted with 200 mg
of hydroxylamine hydrochloride in the presence of 250 mg of
pyridine for 2 hours under reflux. Following the addition of
ethyl acetate, the organic layer thus separated was washed
with brine, dehydrated, filtered, and concentrated under
vacuum. Recrystallization of the concentrate (in
chloroformlmethanol/ethyl ether) provided the title compound.
600 mg. Yield 96%.
1H-NMR(DMSO-d6) s10.42(s,lH), 8.31(m,2H), 7.75(m,lH),
7.55(d,lH), 7.51(m,lH), 7.38(dd,lH), 6.95(d,lH), 4.79(m,IH),
4.14(t,lH), 3.75(m,5H), 3.41(t,2H), 2.49(t,2H), 2.36(t~2H),
1.82(s,3H)
<EXAMPLE 122>
128
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
Preparation of (S)-[N-3-(4-(2-(4-Methanesulfonyloxyimino
piperidinl-yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazoli
dinyl]methyl acetamide
In tetrahydrofuran, 50 mg of (S)-[N-3-(4-(2-(4-
hydroxyiminopiperidin-1-yl)pyridin-5-yl)-3-fluorophenyl)-2-
oxo-5-o~azolidinyl]methyl acetamide, prepared in Example 121,
was reacted with 14 mg of methanesulfonyl chloride in the
presence of 50 mg of triethyl amine at room temperature for
30 min with stirring. Following the addition of ethyl
acetate, the organic layer thus separated was washed with
brine, dehydrated, filtered and concentrated iri vacuo.. The
concentrate was subjected to column chromatography to produce
the title compound. 40 mg. Yield 65%.
<EXAMPLE 123>
Preparation of (S)-[N-3-(4-(2-(4-methyliminopiperidin-1-
yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetamide
In ethanol, 50 mg of (S)-[N-3-(4-(.2-(4-oxopiperidin-1-
yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetamide, prepared in Example 117, was reacted with l6 mg of
methylamine hydrochloride in the presence of 28 mg of
pyridine. The imination was conducted for 3 hours under
129
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
reflux. Addition of ethyl acetate to the. reaction mixture
separated an organic layer. This organic layer was washed
with brine, followed by conducting dehydration, filtration
and vacuum concentration in order. Column chromatography of
the concentrate provided the title compound of purity. 10 mg.
Yield 20 a.
<EXAMPLE 124>
Preparation of (S)-[N-3-(4-(2-(4-Methoxycarbonylhydrazino
piperidin-1-yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-
oxazolidinyl]methyl acetamide
In ethanol, 100 mg of (S)-[N-3-(4-(2-(4-oxopiperidin-7.-
yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetamide, prepared in Example 117, was reacted with 106 mg
of methoxycarbonylhydrazine for 3 hours under reflux.
Addition of ethyl acetate to the reaction mixture separated
an organic layer. This layer was washed with brine, followed
by dehydration, filtration and vacuum concentration in order.
The concentrate was subjected to column chromatography to
provide the title compound. 80 mg. Yield 70a.
1H-NMR(DMSO-d6) s9.94(s,lH), 8.27(m,2H), 7.78(d,lH),
7.64(m,2H), 7.38(dd,lH), 7.00(d,lH), 4.78(m,lH), 4.16(t,lH),
3.79(m,SH), 3.63(s,3H), 3.42(t,4H), 2.49(t,2H), 1.83(s,3H)
130
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
<EXAMPLE 125>
Preparation of (S)-[N-3-(4-(2-N-(L-Alanyl)aminopyridin-5-yl)-
3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl aaetamide
In 20 ml of pyridine was dissolved 2.19 g of N-t-
butoxycarbonyl-z-alanine and the solution was added with 1 g
of 2-amino-5-bromopyridine,. 2.77 g of 1-(3-dimethyl
aminopropyl)-3-ethylcarbodiimide hydrochloride and 1.41 g of
4-dimethylaminopyridine individually and stirred at room
temperature for 15 hours. Water was then added to the
reaction mixture, followed by extraction with ethyl acetate.
The organic layer thus' separated was washed with brine,
dehydrated, filtered, and concentrated in vacuo to give 0.713
g of 2-(N-t-butoxycarbonyl-L-alanylamino)-5-bromopyridine.
This compound was dissolved, along with 0.714 g of (S)-[N-3-
(4-trimethylstannyl-3-fluorophenyl)-2-oxo-5-
oxazolidinyl]methyl acetamide, in 20 ml of dimethylformamide.
Reaction was conducted at 100 °C for 4 hours in the presence
of 0.6 ml of triethyl amine with the catalytic aid of 0.36 g
of dichlorobistriphenylphosphine palladium (II) with stirring
after their addition at room temperature. Water was then
added to the reaction mixture, followed by the extraction
with ethyl acetate. The organic layer thus separated was
131
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
washed with brine, dehydrated, filtered and concentrated in
vacuo. Recrystallization of the concentrate gave 0.27 g of
(S)-[N-3-(4-(2-(N-t-buxotycarbonyl-L-alanylaminopyridin-5-
yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl)methyl acetamide.
This compound was reacted with 0.15 m1 of trimethylsilyl
iodide in chloroform at room temperature for 30 min under a
nitrogen atmosphere. Following the. addition of chloroform,
the organic layer thus separated was washed with brine,
dehydrated, filtered, and concentrated in vacuo. The
concentrate was subjected to column chromatography to produce
the title compound. 50 mg.
1H-NMR(DMSO-d6) s8.50(s,lH), 8.27(t,lH), 8.20(d,lH),
8.01(m,lH), 7.63(m,2H), 7.40(dd,lH), 4.78(m,lH), 4.16(t,lH),
3.78(dd,lH), 3.51(q,lH), 3.42(t,2H), 1.83(s,3H),,1.20(d,3H)
<EXAMPLE 126>
Preparation of (S)-[N-3-(4-(2-Acetylaminoacetylaminopyridin-
5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl~acetamide
In 10 ml of methylene chloride was dissolved 50 mg of
(S)-[N-3-(4-(2-aminoacetylaminopyridin-5-yl)-3-fluorophenyl)
-2-oxo-5-oxazolidinyl]methyl acetamide to which 0.018 ml of
acetic anhydride and 0.035 ml of triethyl amine were dropwise
added. Reaction was conducted at room temperature for 30 min
132
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
with stirring. Addition of methylene chloride separated an
organic layer. This layer was washed with brine,, followed by.
dehydration, filtration, and vacuum concentration. The
concentrate was purified by column chromatography to give the
title compound. 15 mg. Yield 270.
1H-NMR(DMSO-d6) s10.60(s,lH), 8.49(s.lH), 8.20(m,3H),
7.99(m,lH), 7.64(m,2H), 7.43(dd,lH), 4.78(m~,lH), 4.16(t,lH),
3.95(d,2H), 3.79(m,lH), 3.42(t,2H), 1.88(s,3H), 1.83(s,3H)
<EXAMPLE 127>
Preparation of (S)-[N-3-(4-(2-Dimethylaminoacetylamino
pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-oxa~olidinyl]methyl
acetamide
In 100 ml of pyridine was dissolved 5.96 g of N,N-
dimethylglycine and the solution was added with 5 g of 2-
amino-5-bromopyridine 5 g, 13.85 g of 1-(3-
dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride and
7.06 g of 4-dimethylaminopyridine individually at room
temperature. Reaction was carried out at room temperature for
15 hours with stirring. Water was then added to the reaction
mixture, followed by extraction with ethyl acetate. The
organic layer thus separated was washed with brine,
dehydrated, filtered and concentrated in vacuo to give.l.0 g
133
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
of 2-(N,N-dimethylaminoacetylamino)-5-bromopyridine. This
compound was dissolved, along with. 1.34 g of (S)-[N-3-(4-
trimethylstannyl-3-fluorophenyl)-2-oxo-5-oxazolidinyljmethyl
acetamide, in 14 ml of dimethylformamide and added with 0.68
ml of triethyl amine and '0.68 g of dichloro
bistriphenylphosphine palladium (II) individually. Reaction
was conducted at 100 °C for 4 hours with stirring. Water was
then added to the reaction mixture, followed by extraction
with ethyl acetate. The organic layer thus separated was
washed with brine, dehydrate, filtered, and concentrated .in
vacuo. The concentrate was subjected to column chromatography
to produce the title compound. 430 mg.
iH-NMR(DMSO-d6) s10.03(s,lH), 8.49(s,lH), 8.27(m,2H),
7.99(m,lH), 7.64(m,2H), 7.38(dd,lH), 4.78(m,lH), 4.16(t,lH),
3.79(dd,lH), 3.42(t,2H), 3.16(s,2H), 2.31(s,6H), 1.83(s,3H)
<EXAMPLE 128>
Preparation of (S,)-[N-3-(4-(2-Nicotinoylaminopyridin-5-yl)-3-
fluorophenyl)-2-oxo-5-oxazolidinyl]methyl acetamide
With the exception of using,, instead of ~ N,N-
dimethylglycine, nicotinic acid as a starting material, the
same procedure as in Example 127 was conducted to prepare the
title compound.
134
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
1H-NMR(DMSO-d6) 511.21(s,lH), 9.15(d,lH), 8.77(dd,lH),
8.59(s,lH), 8.38(m,lH), 8.28(m,lH), 8.02(m,lH), 7.67(m,lH),
7.59(m,3H), 7.43(m,lH), 4.76(m,lH), 4.17(t,lH), 3:81(dd,lH),
3.42(t,2H), 1.83(s,3H)
<EXAMPLE 129>
Preparation of (S)-[N-3-(4-(2-(1,2,4-Triazol-1-yl)pyridin-5-
yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl acetamide
In 20 ml of dimethylformamide, 1 g of 2,5-
dibromopyridin was reacted with 0.58 g of 1,2,4-triazole
sodium at 80 °C for 10 hours with stirring. Following the
addition of ethyl acetate, the organic layer thus separated
was washed with brine, dehydrated, filtered, and concentrated
in vacuo to give 880 mg of 2-(1,2,4-triazol-1-yl)-5-
bromopyridine. This compound was dissolved, along with 1.4 g
of (S)-[N-3-(4-trimethylstannyl-3-fluorophenyl)-2-oxo-5-
oxazolidinyl]methyl acetamide, in 50 ml of dimethylformamide
and then added with 1.2 ml of triethyl amine and 1.1 g of
dichlorobistriphenylphosphine palladium (II) at room
temperature. Reaction was conducted at 100 °C for 3 hours.
Water was then added to the reaction mixture, followed by
extraction with ethyl acetate. The organic layer thus
separated was washed with brine, dehydrated, filtered, and
135
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
concentrated in vacuo. Purification of the concentrate with
column chromatography provided the title compound: 320 mg.
Yield 23 0.
1H-NMR(DMSO-d6) s9.41(s,lH), 8.72(s,lH),. 8.33(s,lH),
8.25(m,2H), 7.96(d,lH), 7.72(m,2H), 7.47(dd,lH), 4..76(m,lH),
4.18(t,lH), 3.43(t,2H), 1.83(s,3H)
<EXAMPLE 130>
Preparation of (S)-[N-3-(4-(2-(4-Hydroxypiperidin-1-
yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetamide
In a mixture of ethanol and tetrahydrofuran, 300 mg of
(S)-[N-3-(4-(2-(4-oxopiperidin-1-yl)pyridin-5-yl)-3-
fluorophenyl)-2-oxo-5-oxazolidinyl]methylacetamide, prepared
in Example 82, was reacted with 106 mg,of sodium borohydride
at. room temperature for 1 hour with stirring. The organic
layer was concentrated in vacuo, followed by the
recrystallization of the concentrate in methanol, chloroform
and ethyl ether to provide the tit.le,compound. 270 mg. Yield
90%.
1H-NMR(DMSO-d6) 58.27(m,2H), 7.70(m,lH), 7.52(m,2H),
7.34(m,lH), 6.90(d,lH), 4.76(m,lH), 4.69(d,lH), 4.17(t,lH),
136
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
4~,07(~i,2H), 3.79(m,2H), 3.42(t,2H), 3.12(m,2H), 1.83(s,3H),
1..75(m,2H), 1.41(m,2H)
<EXAMPLE 131>
Preparation of (S)-[N-3-(4-(2-N,N-(Hydroxpacetyl)methylamino
pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetamide
In a mixture of methanol and chloroform, 470 mg of (S)-
[N-3-(4-(2-N,N-(acetoxyacetyl)methylaminopyridin-5-yl)-3-
fluorophenyl)-2-oxo-5-oxazolidinyl]methyl acetamide was
reacted with 1.5 m1 of a 1 N KOH solution at room temperature
for 15 min with stirring. After vacuum concentration,
addition of ethylacetate separated an organic layer. This
layer was dehydrated, filtered, and concentrated in vacuo.
Through column chromatography, the concentrate was purified
to the title compound. 64 mg.
1H-NMR(DMSO-d6) s8.61(s,lH), 8.26(t,lH), 8.06(m,lH),
7.62(m,3H), 7.47(dd,lH), 4.85(t,lH), 4.78(m,lH), 4.21(d,2H),
4.16{t,lH), 3.79(t,lH), 3.42(t,2H), 3.32(s.3H), 1.83(s,3H)
<EXAMPLE 132>
Preparation of (S)-[N-3-(4-(2-(4-Methylimidazol-1-yl)pyridin
-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl acetamide
137
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
Except that- 2-(4-methylimidazole)-5-bromopyridine was
used as a starting material, the same procedure as in Example
129 was conducted to prepare the title compound.
1H-NMR(DMSO-d6) 58.64(s,lH), 8.45(s,lH), 8.30(t,lH),
8.17(m,lH), 7.81(d,lH), 7.64(m,~3H), 7.38(dd,lH), 4.78(m,lH),
4.16(t,lH), 3.79(m,lH), 3.42(t,2H), 2.18(s,3H), 1.83(s,3H)
<EXAMPLE 133>
Preparation of (S)-[N-3-(4-(2-(2-Hydroxypropionyl)aminopyri
din-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl acet
amide
Staring with (S)-[N-3-(4-(2-(2-acetoxypropionyl)amino
pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-o~azolidinyl]methyl
acetamide, the title compound was prepared in a manner
similar to that of Example 121.
1H-NMR(DMSO-d6) s9.73(s,lH), 8.50(s,lH); 8.26(t,7.H),
8.16(d,lH), 8.03(d,lH), 7.63(m,2H), 7.40(dd,lH), 5.90(d,lH),
4.75(m,lH), 4.20(m,2H), 3.79(dd,lH), 3.43(t,2H), 1.82(s,3H),
1.31(d,3H)
<EXAMPLE 134>
138 w
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
Preparation of (S)-[N-3-(4-(2-(3-Amino-1,2,4-Triazol-1-yl)
pyridin-5-yl)-3-fluorophenyl)-2-oxo=5-oxazolidinyl]methyl
acetamide
Staring with 2-(3-amino-1,2,4-triazin.yl)-5-bromo
pyridine, the title compound was prepared in- a manner similar
to that of Example 129.
zH-NMR(DMSO-d6) 68.64(s,lH), 8.24(m,2H), 7.83(d,lH),
7.61(m,5H), 7:43(dd,lH), 4.77(m,lH), 4.17(t,lH), 3.76(dd,lH),
3.42(t,2H), 1.82(s,3H)
<EXAMPLE 135>
Preparation of (S)-[N-3-(4-(2-(4-Ethoxycarbonylimidazol-1-
yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetamide
The title compound was prepared in a manner similar to
that of Example 129, except ~ that 2-(4-
ethoxycarbonylimidazolyl)-5-bromo pyridine was used as a
starting material.
<EXAMPLE 136>
Preparation of (S)-[N-3-(4-(2-(Tetrazol-1-yl)-5-pyridinyl)-3-
fluorophenyl)-2-oxo-5-oxazolidinyl]methyl acetamide
139
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
In 8.8 ml of dimethylformamide was dissolved 734 mg of
(S)-[N-3-(4-trimethylstannyl-3-fluorophenyl)-2-oxo-5-oxazol
idinyl]methyl acetamide, prepared in Preparation, Example 8,
which was then reacted with 600 mg of 2-(1-tetrazolyl)-5-
bromo pyridine, prepared in Preparation Example 13; in the
presence of 0.49 ml of triethyl amine with the catalytic aid
of 372 mg of dichlorobistriphenylphosphine palladium (II) at
100 °C for 4 hours with stirring. Water was then added to the
reaction mixture, followed by extraction with ethyl acetate.
The organic layer thus separated was washed with brine,
dehydrated, filtered and concentrated in vacuo. The
concentrate was purified through column chromatography to
provide the title compound. 110 mg.
1H-NMR(DMSO-d6) s 10.22(s,lH), 8.83(s,lH), 8.39(dd,lH),
8.30(t,lH), 8.15{d,lH), 7.76{m,2H), 7.47(dd,lH) 4..78(m,lH),
4.16(t,lH), 3.80(dd,lH), 3.43(t,2H), 1.83(s,3H)
<EXAMPLE 137>
Preparation of (S)-[N-3-(4-(2-(5-Methyl-(1,3,4)-Oxadiazol-2-
yl)-pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetamide.
In 10 ml of 1-methyl-2-pyrrolidone was dissolved 1 g of
(S)-[N-3-(4-trimethylstannyl-3-fluorophenyl)-2-oxo-5-oxaz
140
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
olidinyl]methyl acetamide, prepared in Preparation Example 8,
and the solution was added at room temperature with 600 mg of
2-(1,3,4-oxadiazol)-5-bromo pyridine, 320 mg of lithium
chloride, and 100 mg of dichlorobistriphenyl phosphine
palladium (II) individually, followed by stirring at 100 °C
for 4 hours. Water was then added to the reaction. mixture,
then extracted with ethyl acetate. The organic layer thus
separated was washed with brine, dehydrated, filtered and
concentrated in vacuo. Through column chromatography, the
concentrate was purified to the title compound. 300 mg.
1H-NMR(DMSO-d6) S 9.99(s.lH), 8.73(s,lH), 8.26(t,lH),
7.95(m,2H), 7.64(m,2H), 7.47(dd,lH), 4.78(m,lH), 4.16(t,lH),
3.80(dd,lH), 3.43(t,2H), 1.83(s,3H)
<EXAMPLE 138>
Preparation of (S)-[N-3-(4-(2-(5-Methyl-(1,2,4)-oxadiazol-3-
yl)pyridin-5=yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetamide
Starting with 2.8 g of 2-[5-methyl-(1;2,4)-oxadiazol-3-
yl]-5-bromo pyridine, the title compound was prepared in a
manner similar to that of Example 137. 280 mg.
141
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
1H-NMR(CDC13) 6 8.85(s,lH), 8.09(d,l.H), 7.97(m,lH),
7.58(dd,lH), 7.45(t,lH), 7.26(dd,lH), 6.50(t,lH), 4.81(m,lH),
4.10(t,lH), 3.84(dd,lH), 3.68(m,2H), 2.67(s,3H), 2:01(s,3H)
<EXAMPLE 139>
Preparation of (S)-[N-3-(4-(2-(1-Methyl-5-tetrazol-yl)-
pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetamide
Starting with 110 mg of 2-(1-methyl-5-tetrazoly)-5-
bromo pyridine, the title compound was prepared in a manner
similar to that of Example 137. 60 mg.
1H-NMR(CDC13) ~8.89(s,lH), 8.29(d,lH), 8.00(m,lH),
7.61(dd,lH), 7.46(t,lH), 7.26(dd,lH), 6.12(t,lH), 4.80(m,lH),
4.45(s,3H), 4.07(t,lH), 3.83(dd,lH), 3.67(m,2H), 2.02(s,3H)
<EXAMPLE 140>
Preparation of (S)-[N-3-(4-(2-(2-Methyl-5-tetrazolyl)-pyri
din-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetamide
Starting with 220 mg of 2-(2-methyl-5-tetrazolyl)-5-
bromo pyridine (220 mg), the title compound was prepared in a
manner similar to that of Example 137 . 180 mg.
142
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
1H-NMR(CDC13) s8.85(s,lH), 8.34(d,lH); ~8.00(m,lH),
7.56(dd,lH), 7.40(t,lH), 7.26(dd,lH), 4.76(m,lH), 4.49(s,3H),
4.07(t,lH), 3.79(dd,lH), 3.59(m,2H), 1.96(s,3H)
<EXAMPLE 141>
Preparation of (S)-[N-3-(4-,(2-(4-Ethoxycarbonyl-(1,2,3)-
triazol-1-yl)-5-pyr,idinyl)-3-fluorophenyl)-2-oxo-5-oxazol
idinyl]methyl acetamide
Starting with 200 mg of 2-[4-ethoxycarbonyl-(1,2,3)-
triazol-1-yl]-5-bromo pyridine, the title compound was
prepared in a manner similar to that of Example 137. 60 mg.
~H-NMR(DMSO-d6) s9.02(s,lH), 8.59(s,lH), 8.16(dd,lH),
8.02(dd,lH), 7.51(dd,lH), 7.35(t,lH), 7.29(dd~,lH),
6.63(t,lH), 4.78(m,lH), 4.42(tr,2H) 4.16(t,lH), 3.80(dd,lH),
3.43(t,2H), 1.83(s,3H), 1.37(t,3H)
<EXAMPLE 142>
Preparation of (S)-[N-3-(4-(2-.(3-Pyrrolinyl)-5-pyridinyl)-3-
fluorophenyl)-2-oxo-5-oxazolidinyl]methyl acetamide
Starting with 200 mg, of 2-(3-pyrrolinyl)-5-bromo
pyridine, the title compound was prepared in a manner similar
to that of Example 137.
143
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
1H-NMR(CDC13) &8.27(brm,2H), 7.53(m,2H), 7.40(m,lH),
6.49(dd,lH), 6.03(s,lH), 4.76(m,lH), 4.07(t,lH), 3.79(dd,lH),
3.59(m,2H), 3.40(m,2H), 1.96(m,2H), 1.92(s,3H)
<EXAMPLE 143>
Preparation of (S)-[N-3-(4-(2-(2-Oxo-1,3-oxazolidin-3-yl)-5-
pyridinyl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetamide
Starting with 150 mg of 2-(2-oxo-3-oxazolidinyl)-5-
bromo pyridine, the title compound was prepared in a manner
similar to that of Example 137. 14 mg.
1H-NMR(CDC13) 68.37(s,lH), 8.19(d,lH), 7.80(m,lH),
7.44(m,2H), 7.34(t,lH), 7.16(dd,lH), 4.67(m,lH), 4.41(m,lH),
4.23(m,lH), 3.91(t,lH), 3.74(dd,lH), 3.50(m,2H), 1.87(s,3H)
<EXAMPLE 144>
Preparation of (S)-[N-3-(4-(2-(5-Oxazolyl)-5-pyridinyl)-3-
fluorophenyl)-2-oxo-5-oxazolidinyl]methyl acetamide
Starting with 204 , mg of 2- ( 5-o~azolyl ) -5-bromo
pyridine, the title compound was prepared in a manner similar
to that of Example 137. 130 mg.
144
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
1H-NMR(DMSO-d6) 58.82(s,lH), 8.57(s,lH), 8.27(m,lH),
8.10(m,lH), 7.88(s,lH), 7.85(s,lH), 7.68(m,2H), 7.44(dd,lH),
4.76(m,lH), 4.17(t,lH), 3.79(dd,lH), 3.43(t,2H), 1.83(s,3H)
<EXAMPLE 145>
Preparation of (S)-[N-3-(4-(2-((1,2,4)-Oxadiazol-3-yl)-5-
pyridinyl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetamide
Except that 700 mg of. 2-[(1,2,4)-oxadiazol-3-yl]-5-
bromo pyridine was used as a starting material, the title
compound was prepared in a manner similar to that of Example
137. 300 mg.
1H-NMR(CDC13) 58.82(t,lH), 7.99(m,lH), 7.75(dd,lH),
7.61(dd,lH), 7.30(t,2H), 7.28(dd,lH), 4.76(m,lH), 4.06(t,lH),
3.80(dd,lH), 3.58(m,2H), 1.96(s,3H)
<EXAMPLE 146>
Preparation of (S)-[N-3-(4-(2-((1,2,3)-Triazol-1-yl)-5-
pyridinyl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetamide
Except that 120 mg of 2-[(1,2,4)-triazol-1-yl]-5-bromo
pyridine was used as a starting material, the title compound
145
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
was prepared in a manner similar to that of Example 137. 90
mg:
1H-NMR(DMSO-d6) s8.90(d,lH), 8.78(s,lH), 8.29(m,3H),
8.02(d,lH), 7.70(m,2H), 7.46(dd,lH), 4.76(m,lH), 4.17(t,lH),
3.79(dd,lH), 3.43(t,2H), 1.83(s,3H) .
<EXAMPLE 147>
Preparation of (S)-[N-3-(4-(2-(3-Methyl'-2-oxo-(1,3,4)-
triazol-1-yl)-5-pyridinyl)-3-fluorophenyl~)-2-oxo-5-
oxazolidinyl]methyl acetamide.
Except that 290 mg of 2-[3-methyl-2-oxo-(1,3,4)-
triazol-1-yl)-5-bromo pyridine was used as a starting
material, the title compound was prepared in a manner similar
to that of Example 137. 160 mg.
1H-NMR(DMSO-d6) s8.68(s,lH), 8.66(s,lH), 8.27(m,3H),
7.64(m,2H), 7.46(dd,lH), 4.75(m,lH), 4.17(t,lH), 3.78(dd,lH),
3.44(t,2H), 3.41(s,3H), 1.83(s,3H)
<EXAMPLE 148>
Preparation of (S)-[N-3-(4-(2-(2-oXO-(1,3)-Imidazolid~in-1-
yl)-5-pyridinyl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetamide
146
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
Except that 150 mg of 2-[2-oxo-3-t-butyloxy carbonyl-
(1,3)-imidazolidin-1-yl]-5-bromo pyridine was used as a
starting material, the same procedure as in Example 137 was
carried out to prepare the title compound. 25 mg.
1H-NMR(CDC13) s8.29(s,lH), 8.21(dd,lH), 7.66(m,lH),
7.52--7.39(m,2H), 7.27(d,lH), 7.12(dd,lH), 4.67(m,lH), 4.07-
3;.88(m,2H), 3.70(dd,lH), 3.50-3.27(mt,4H), 1.87(s,3H)
<EXAMPLE 149>
Preparation of (S)-[N-3-(4-(2-(4-Hydroxy-piperidin-1-yl)-5-
piridinyl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetamide
Starting with 1.9 g of 2-(4-hydroxypiperidin-1-yl)-5-
bromo pyridine, the title compound was prepared in a manner
similar to that of Example 137. 400 mg.
1H-NMR(DMSO-d6) 88.27(s.lH), 8.24-8.22(t,lH),
7.67(dd,lH), 7.52(dd,lH), 7.47(dd,lH), 6.91(d,lH),
4.75(m,lH), 4.69(d,lH), 4.16(d,lH), 4.07(m,2H), 3.72(m,2H),
3.43(t,2H), 3.12(m,2H),1.83(s,3H), 1.75(m,2H), 1.34(m,2H)
<EXAMPLE 150>
147
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
Preparation of (S)-[N-3-(4-((2-oxo-(2,3)-Dihydro-(1,3;4)-
triazol-1-yl)-5-pyridinyl)-3-fluorophenyl)-2-oxo-5-
oxazolidinyl]methyl acetamide
Except that 500 mg of 2-[3-t-butoxycarbonyl-2-oxo-
(2,3)-dihydro-1,3,4-triazol-1-yl]-5-bromo pyridine, the title
compound was prepared in a manner similar to that of Example
137. 100 mg.
~H-NMR(DMSO-d6) s8.60(dd,lH), 8.21(m,2H), 7.68(d,lH),
7.62-7.44(dd,lH), 4.76(m,lH), (t,lH), 3.79(dd,lH),
3.59(m,2H), 3.15(m,2H), 1.96(s,3H)
<EXAMPLE 151>
Preparation of (S)-[N-3-(4-(2-(5-Hydroxymethyl-(1,2,4)-
oxadiazol-3-yl)-5-pyridinyl)-3-fluorophenyl)-2-oxo-5-oxazol
idinyl]methyl acetamide
(Step 1) Preparation of (S)-[N-3-(4-(2-cyano-5-pyridinyh)-3-
fluorophenyl)-2-oxo-5-oxazolidinyl]methyl acetamide
In 85 ml of 1-methyl-2-pyrrolidone was dissolved 10.7 g
of (S)-[N-3-(4-trimethylstannyl-3-fluorophenyl)-2-oxo-5-
oxazolidinyl]methyl acetamide, prepared in Preparation
Example 8, and the solution was added at room temperature
with 4.7 g of 2-cyano-5-bromo pyridine, 3.27 g of lithium
148
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
chloride, and 0.9 g of dichlorobistriphenylphosphine
palladium (II) individually. Reaction was conducted at 120 °C
for 4 hours with stirring. After completion of the reaction,
the same post-treatment as in above examples was effected to
give the title compound. 4.67 mg.
1H-NMR(DMSO-d6) 88.95(s.lH), 8.26-8.22(dd,2H),
8.15(d,lH), 7.7&(m,2H), 7.47(dd,lH), 4.78(m,lH), 4.16(t,lH),
3.80(dd,lH), 3.43(t,2H), 1.83(s,3H)
(Step 2): Preparation of (S)-[N-3-(4-(2-i~iino-N-
hydroxyaminomethyl-5-pyridinyl)-3-fluorophenyl)-2-oxo-5-
oxazolidinyl]methyl acetamide
In 100 ml of ethanol, 7 g of (S)-[N-3-(2-cyano-5-pyridinyl)-
3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl acetamide was
reacted at room temperature for 2 hours with 3.4 g of hydroxy
amine in the presence of 5.0 g of sodium hydrogen carbonate
under reflux. After completion of the imination, an ordinary
post-treatment was conducted to give the title compound. 6 g.
1H-NMR(DMSO-d6) 6 9.99(s.lH), 8.73(s,lH),: 8.26(t;lH)~,
7.95(m,2H), 7.64(m,2H), 7.47(dd,lH), .4.78(m,lH), 4.16(t,lH),
3.80(dd,lH), 3.43(t,2H); 1.83(s,3H)
149
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
(Step 3): Preparation of~ (S)-[N-3-(4-(2-(5-hydroxyrilethyl-
(1,2,4)-oxadiazol-3-yl)-5-pyridinyl)-3-fluorophenyl)-2-oxo-5-
oxazolidinyl]methyl acetamide
In 20 ml of acetone, 2 g of (S)-[N-3-(4-(2-imino-N-
hydroxyaminomethyl-5-pyridinyl)-3-fluorophenyl)-2-oxo-5-
oxazolidinyl]methyl acetamide was reacted for 6 hours with
0.7 ml of acetoxyacetyl chloride in the presence of 1.1 g of
potassium carbonate under reflux. After, completion of the
reaction, a typical post-treatment was conducted. The
resulting residue was dissolved in 20 ml of pyridine and
refluxed for 7 hours. Afterwards, the reaction mixture was
concentrated in vacuo and added with a citric acid solution,
followed by extraction with ethyl acetate. The organic layer
thus separated was washed with brine, dehydrated, filtered
and concentrated in vacuo. The concentrate was dissolved in
methanol and reacted with 588 mg of potassium carbonate at
room temperature for 2 hours. After the reaction was
completed, the reaction mixture was added with water and
extracted with chloroform. Subsequently, the organic layer
was dehydrated, filtered, and concentrated in vauo. The
concentrate was subjected to column chromatography to give
the title compound. 600 mg,
150
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
1H NMR(CDC13) s8.85(s,lH), 8.06(d,lH), 8.00(dd,lH),
7.86(t,lH), 7.45(dd,lH), 7.40(t,lH), 7.22(dd,lH), 4.80(s,lH)
4.76(m,lH), 4.07(t,lH), 3.79(dd,lH), 3.59(m,2H), 1.96(s,3H)
<EXAMPLE 152>
Preparation of (S)-[N-3-(4-(2-(5-Tetrazolyl)-5-pyridinyl)-3-
fluorophenyl)-2-oxo-5-oxazolidinyl]methyl aaetamide
Tn 15 ml of dimethylformamide was dissolved 1 g of (S)-
[N-3-(4-(2-cyano-5-pyridinyl)-3-fluorophenyl)-2-oxo-5-
oxazolidinyl]methyl acetamide, prepared.in .Example 151 and
the solution was added at room temperature with 1.10 g of
sodium azide and 0.91 g of ammonium chloride, followed by ..
stirring at 120 °C for 2 hours. After begin cooled to room
temperature, the reaction mixture was added with 4 ml of ice
water and 4 ml of ethyl acetate, along with 2 g of sodium
nitrate, and controlled to pH 2 with a 6 N HCl solution.
Following stirring at room temperature 1 hour, the reaction
mixture was extracted with ethyl acetate. The organic layer
thus separated was dehydrated, filtered, and concentrated to
give a solid which was. then recrystallized in ethyl ether to
provide the title compound. 0.8 g..
151
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
1H-NMR(DMSO-d6) 88.97(s,lH), 8.29(~m,3H), 7.72(t,lH),
7.65(dd,lH), 7.47(dd,IH), 4.78(m,lH), 4.18(t,lH),
3.81(dd,lH), 3.44(dd,2H), 1.83(s,3H)
<EXAMPLE 153>
Preparation of (S)-[N-3-(4-(2-(5-Methoxymethyl-(1,2,4)-
oxadiazol-3-yl)-5-pyridinyl)-3-fluorophenyl)-2-oxo-5-oxazol
idinyl]methyl acetamide
In 5 ml of pyridine was dissolved 300 mg of the
intermediate (S)-[N-3-(4-(2-imino-N-hydroxyaminomethyl-5-
pyridinyl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetamide(300 mg), prepared in Example 151, which was then
reacted with 450 ml of methoxyacetyl chloride for' 1 hour
under reflux. After completion of the reaction, the reaction
mixture was concentrate under vacuum. Water was then added to
the concentrate, followed by extraction with ethyl acetate.
The organic layer thus separated was washed with brine,
dehydrated, filtered, and concentrated under vacuum.
Purification of the concentrate through column chromatography
provided the title compound. 200 mg.
iH-NMR(CDC13). s8.86(s,lH), 8.22(d,lH), 8.00(dd,lH),
7.64(m,lH), 7.46(t,lH), 7.25(dd,lH), 6.16(t,lH), 4.81(s,lH),
152
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
4.75(m;lH), 4.17(t,lH), 3.78(dd,lH), 3.44(t,.2H), 3.55(s,3H),
2.01(s,3H)
<EXAMPLE 154>
Preparation of (S)-[N-3-(4-(2-(5-Trichloromethyl-(1,2,4)-
oxadiazol-3-yl)-5-pyridinyl)-3-fluorophenyl)-2-oxo-5-
oxazolidinyl]methyl acetamide
In 20 ml of trichloroacetic acid was dissolved 600 mg
of the intermediate (,S)-[N-3-(4-(2-imino-N-hydroxyamino
methyl-5-pyridinyl)-3-fluorophenyl)-2-oxo-5-
oxazolidinyl]methyl acetamide and the solution was added with
34 ml of trichloroacetyl chloride at 85 °C. Reaction was
conducted at 95 °C for 3 hours. ~ Water was then added to the
reaction mixture, followed by extraction with ethyl acetate.
The organic layers thus separated was washed with brine,
dehydrated, filtered, and concentrated in vacuo. Purification
of the concentrate through column chromatography provided the
title compound. 600 mg.
1H-NMR(CDC13) s7.99(m,lH), 7:75(dd,lH)~, 7.61(dd,lH),
7.30(t,2H), 7.2$(dd,lH), 4.76(m,lH), 4.06(t;lH), 3.80(dd,lH),
3.58(m,2H), 1.96(s,3H)
<EXAMPLE 155>
153
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
Preparation of (S)-[N-3-(4-(2-(5-dimethylamino-(1,2,4)-
oxadiazol-3-yl)-5-pyridinyl)-3-fluorophenyl)-2-oxo-5-oxazol
idinyl]methyl acetamide
In 5 ml of dimethylformamide was dissolved 80 mg of
(S)-[N-3-(4-(2-(5-trichloromethyl-(1,2,4)-oxadiazol-3-yl)-5-
pyridinyl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetamide, prepared in Example 154, which was then reacted at.
room temperature for 4 hours with 2 ml of dimethylamine.
Water was then added to the reaction mixture, followed by
extraction with ethyl acetate. The organic layer thus
separated was washed with brine, dehydrated, filtered, and
concentrated under vacuum. The concentrate was subjected to.
column chromatography to provide the title compound. 40 mg.
1H-NMR(CDC13) s8.85(s,lH), 8.34(d,lH), 8.00(m,lH),
7.56(dd,lH), 7.40(t,lH), 7.26(dd,lH), 4.76(m,lH), 4.07(t,lH),
3.79(dd,lH), 3.59(m,2H), 3.15(s,6H), 1.96(s,3H)
<EXAMPLE 156>
Preparation of (S)-[N-3-(4-(2-(5-Amino-(1,2,4)-oxadiazol-3-
yl)-5-pyridinyl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetamide
In 5 ml of methanol was dissolved 500 mg:of (S)-[N-3-
(4-(2-(5-trichloromethyl-(1,2,4)-oxadiazol-3-yl)-5-
154
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
pyridinyl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetamide, prepared in Example 154, which was then reacted at
room temperature for 24 hours with 273. mg of cyanogens
bromide under reflux. The reaction was stopped by the
addition of water, followed by extraction with ethyl acetate.
The organic layer thus separated was washed with brine,
dehydrated, filtered, and concentrated in vacuo. The
concentrate was subjected to column chromatography to. provide
the title compound. l3 mg.
1H-NMR(CDC13) 58.87(brm,lH), 7.92(m,2H), 7.41(m,2H),
4.76(m,lH), 4.07(t,lH), 3.79(dd,lH), 3.59(m,2H), 3.40(m,2H),
1.96(m,2H)
<EXAMPLE 157>
Preparation of (S)-[N-3-(4-(2-(4-Acetylamino-piperidin-1-yl)-
5-pyridinyl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetamide
In 5 ml of methylene chloride was dissolved 400 mg of (S)-[N-
3-(4-(2-(4-hydroxy-piperidin-1-yl)-5-pyridinyl)-3-fluoro
.phenyl)-2-oxo-5-oxazolidinyl]methyl acetamide, prepared in
Example 149, and the solution was added with at 0 °C with 530
ml of triethyl amine, 150 ml of .methansulfonyl chloride.
Reaction was conducted at room temperature. Subsequently,
155
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
water was added to the reaction mixture to stop the reaction,
followed by extraction with ethyl acetate. The. organic layer
thus separated was washed with brine, dehydrated, filtered,
concentrated in vacuo, and dried. ~In 5 ml of
dimethylformamide, 450 mg of the residue was reacted~with~200 '.
mg of sodium azide at 90 °C for 3 hours. After water was
added to stop the reaction, the reaction mixture was
extracted with ethyl acetate. The organic thus separated was
washed with brine, dehydrated, filtered, concentrated under
vacuum, and dried. Without additional purification, 300 mg of
the residue was dissolved in 4 ml of tetrahydrofuran and
reacted with 200 mg of triphenylphosphine in the presence of
a small quantity of water for 3 hours under reflux. Water was
then added, followed by extraction with ethyl acetate. The
organic layer thus separated. was dehydrated, filtered,
concentrated under vacuum, and dried to give 250 mg of (S)-
[N-3-(4-(2-(4-amino-piperidine-1-yl)-5-pyridinyl)-3-
fluorophenyl)-2-oxo-5-oxazolidinyl]methyl acetamide. To 100
mg of this compound, 5 ml of methylene chloride was added,
followed by the addition of 48 ml of triethylamine and 36 ml
of..acetic anhydride at 0 °C. Reaction was conducted at room
temperature for 1 hour. After water was added to stop the
reaction, the reaction mixture was extracted with ethyl
156
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
acetate. The organic layer thus separated was washed with
brine, dehydrated, filtered, and concentrated under vacuum.
Through column Chromatography,, the concentrate was purified
to the title compound. 80 mg.
iH-NMR(CDC13) 57.69(dd,lH), 7.52(dd,2H), 7..40(dd;~lH),
6.98(dd,lH), 4.76(m,lH), 4.07(t,lH), 3.79(dd,lH), 3.59(m,2H),
3.15(m,2H), 2.88(t,2H) 1.99(m,2H), 1.94(s,3H), 1.96(s,3H),
1.52(m,2H)
<EXAMPLE 158>
Preparation of (S)-[N-3-(4-(2-(4-Acetyloxymethylcarbonyl
amino-1-piperidinyl)-5-pyridinyl.)-3-fluorophenyl)-2-oxo-5-
oxazolidinyl]methyl acetamide
In 5 m1 of tetrahydrofuran was dissolved 300 mg of the
intermediate (S)-[N-3-(4-(2-(4-amino-piperidin-1-yl)-5-pyri
dinyl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl acet
amide, prepared in Example 157, and the solution was added
with 0 °C with 300 ml of triethyl amine and 115 ml of
acetoxyacetyl chloride. Reaction was conducted. at room
temperature for 1 hour. Water was then added to stop the
reaction, followed by extraction with ethyl 'acetate. The
organic layer thus separated was washed with brine.,
dehydrated, filtered, and concentrated in vacuo. The
157
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
concentrate was purified through column chromatography to
provide the title compound. 150 mg.
1H-NMR(DMSO-d6) 67.69(dd,lH), 7.52(dd,2H); 7.40(dd,lH),
6.98(dd,lH), 4.76(m,lH), 4.73(s,2H), 4.07(t,lH), 3:79(dd,lH),
3.59(m,2H), 3.15(m,2H), 2.88(t,2H), 2.16(s,3H), 1.99(m,2H),
1.96(s,3H), 1.52(m,2H)
<EXAMPLE 159>
Preparation of (S)-[N-3-(4-(2-(4-Hydroxymethylcarbonylamino-
piperidin-1-yl)-5-pyridinyl)-3-fluorophenyl)-2-oxo-5-oxazol
idinyl]methyl acetamide
In 2 ml of methanol was dissolved 150 mg of (S)-[N-3-
(4-(2-(4-acetyloxymethylcarbonylamino-1-piperidinyl)-5-
pyridinyl)-3-fluorophenyl)-2-oxo-5-oxa~olidinyl]methyl
acetamide, prepared in Example 158, which was reacted with
200 mg of potassium carbonate at -room temperature for 2
hours. After completion of the reaction, an ordinary post-
treatment was conducted to provide the title compound. 100
mg.
zH-NMR(DMSO-d6) 6 7.69(dd,lH), 7.49(dd,2H), 7.40(dd,lH),
6.97(dd,lH), 4.76(m,lH), 4.75(s,2H), 4.08(t,lH), 3.74(dd,lH),
3.59(m,2H), 3:15(m,2H), 2.88(t,2H), 1.99(m,2H), 1.96(s,3H),
1.52(m,2H)
158
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
<EXAMPLE 160>
Preparation of (S)-[N-3-(4-(2-((3,4)-Dihydroxy-pyrrolidin-1-
yl)-5-pyridinyl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl
acetamide
In 2 ml of a mixture of water/acetone/acetonitrile
(1:1:1) was dissolved 100 mg of (S)-[N-3-(4-(2-(3-
pyrrolinyl)-5-pyridinyl)-3-fluoronyl)-2-oxo-5-
oxazolidinyl]methyl acetamide, which was reacted with 10 mg
of osmiumtetraoxide at room temperature for 10 hours. After
completion of the reaction, an ordinary post-treatment was
conducted to provide the title compound. 30 mg.
1H-NMR(DMSO-d6) 58.23(m,2H), 7.65(dd,lH), 7.47(mdd,lH),
7.40(dd,lH), 4.90(m,lH), 4.73(t,lH) 4.13(t,lH), 3.79(dd,lH),
3.59(m,2H), 3.20(m,2H), 3.15(m,2H), 1.96(s,3H)
EXPERIMENTAL EXAMPLE
Assay for in vitro Antibacterial Activity
Using an agar dilution method, compounds of the present
invention were assayed for inhibitory activity against
various microorganisms, including methicilin . resistant
Staphylococcus aureus (MRSA), vancomycin resistant
Enterococci (VRE), H. Influenzae, Ethanmbutol resistant
159
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
Mycobacterium tuberculosis (ATCC 35837), and vancomycin
resistant Mycobacterium tuberculosis (ATCC~ 35837). For
comparison, U-100766 (Zyvox) of formula 3, which gained the
approval of the FDA (Food and Drug Administration) of U. S.
A., Cycloserine, and Rifampin were also tested
(Chemotheraphy, 29(1), 76,(1981)). In this regard, the level
of antibacterial activity was expressed as minimal inhibitory
concentration (MIC, ~,/ml), and the results are given in Table
l, below.
TABLE 1
Antibacterial
Activity
(MIC50,
~,g/ml)
Cpd. .InfluentATCC ATCC
MRSA1 VREZ
ae3 358374 272945
U-100766 3.13 1.56 25 1.56 1.56
Cycloserine - - - ~ 6.25 6.25
Rifampin - - - 0.2 0.2
Exmp. 129 0.39 0.2 6.25 0.2 0.1
Exmp. 136 0.78 0.2 12.5 0.1 0.1
Exmp. 137 0.39 0.2 3.13 0.1 0.1
Exmp. 138 0.78 0.39 3.13 0.1 0.1
Exmp. 139 0.78 0.2 3.13 0.1 0.1
Exmp. 140 0.78 0.2 12.5 O.I 0.1
Exmp. 143 0.78 0.2 1.56 0.1 0.1
Exmp. 152 >25 >25 >25 >25 >25
1MRSA: methicillin resistant Staphylococcus aureus
160
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
~VRE: vancomycin resistant Enterococci
3H . Inf luenzae
4ATCC 35837: Ethanmbutol resistant Mycobacterium tuberculosis
SATCC 27294: Vancomycine Mycobacterium tuberculosis
As apparent from the data of Table d, the compounds of
the present invention have more potent inhibitory activity
against Staphylococcus and Enterococci, both resistant to
conventional antibiotics, compared to U-100766 (zyvox), which
gained the approval of the FDA of U.S.A. In particular,
compounds having the tetrazole-substituted pyridine ring show
various potentials of antibacterial activity, depending on
the substitution position of the tetrazole moiety and the
substituents attached to the tetrazole moiety (Compounds of
Example Nos. 136, 137, 140 and 152. Additionally, most of the
compounds. of the present invention are found to be superior
in inhibitory activity against the tuberculosis germs
compared to Cycloserine and Rifampin.
INDUSTIRAL APPLICABTLITY
As described hereinbefore, the oxazolidinone compounds
of formula 1 have potent antibacterial activity against a
broad spectrum of bacteria and their antibacterial activity
16l
CA 02411859 2002-12-04
WO 01/94342 PCT/KRO1/00821
is maintained high in vivo. Exerting potent antibacterial
activity versus various human and animal pathogens, including
Gram-positive bacteria such as Staphylococi, Enterococci and
Streptococi, anaerobic microorganisms such,as Bacteroides and
Clostridia, and acid-resistant microorganisms such as
Mycobacterium, the compounds of the present invention are
therefore useful as antibiotics.
The present invention ha.s been described. in an
illustrative manner, and it is to be understood that the
terminology used is intended to be in the nature of
description rather than of limitation. Many modifications and
variations of the present invention are possible in light of
the above teachings. Therefore, it is to be understood that
within the scope of the appended claims, the invention may be
practiced otherwise than as specifically described.
162
